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Background: There is currently insufficient evidence for the clinical effectiveness and cost-effectiveness of
psychological therapies for post-stroke depression.
Objective: To evaluate the feasibility of undertaking a definitive trial to evaluate the clinical effectiveness
and cost-effectiveness of behavioural activation (BA) compared with usual stroke care for treating
post-stroke depression.
Design: Parallel-group, feasibility, multicentre, randomised controlled trial with nested qualitative research
and a health economic evaluation.
Setting: Acute and community stroke services in three sites in England.
Participants: Community-dwelling adults 3 months to 5 years post stroke who are depressed, as
determined by the Patient Health Questionnaire-9 (PHQ-9) or the Visual Analogue Mood Scales ‘Sad’ item.
Exclusions: patients who are blind and/or deaf, have dementia, are unable to communicate in English, do
not have mental capacity to consent, are receiving treatment for depression at the time of stroke onset or
are currently receiving psychological intervention.
Randomisation and blinding: Participants were randomised (1 : 1 ratio) to BA or usual stroke care.
Randomisation was conducted using a computer-generated list with random permuted blocks of varying
sizes, stratified by site. Participants and therapists were aware of the allocation, but outcome assessors
were blind.
Interventions: The intervention arm received up to 15 sessions of BA over 4 months. BA aims to improve
mood by increasing people’s level of enjoyable or valued activities. The control arm received usual care only.
Main outcome measures: Primary feasibility outcomes concerned feasibility of recruitment to the main
trial, acceptability of research procedures and measures, appropriateness of baseline and outcome measures,
retention of participants and potential value of conducting the definitive trial. Secondary feasibility outcomes
concerned the delivery of the intervention. The primary clinical outcome 6 months post randomisation was
the PHQ-9. Secondary clinical outcomes were Stroke Aphasic Depression Questionnaire – Hospital version,
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Nottingham Leisure Questionnaire, Nottingham Extended Activities of Daily Living, Carer Strain Index,
EuroQol-5 Dimensions, five-level version and health-care resource use questionnaire.
Results: Forty-eight participants were recruited in 27 centre-months of recruitment, at a recruitment
rate of 1.8 participants per centre per month. The 25 participants randomised to receive BA attended a
mean of 8.5 therapy sessions [standard deviation (SD) 4.4 therapy sessions]; 23 participants were allocated
to usual care. Outcome assessments were completed by 39 (81%) participants (BA, n = 18; usual care,
n = 21). Mean PHQ-9 scores at 6-month follow-up were 10.1 points (SD 6.9 points) and 14.4 points
(SD 5.1 points) in the BA and control groups, respectively, a difference of –3.8 (95% confidence interval
–6.9 to –0.6) after adjusting for baseline PHQ-9 score and centre, representing a reduction in depression in
the BA arm. Therapy was delivered as intended. BA was acceptable to participants, carers and therapists.
Value-of-information analysis indicates that the benefits of conducting a definitive trial would be likely
to outweigh the costs. It is estimated that a sample size of between 580 and 623 participants would be
needed for a definitive trial.
Limitations: Target recruitment was not achieved, although we identified methods to improve recruitment.
Conclusions: The Behavioural Activation Therapy for Depression after Stroke trial was feasible with regard
to the majority of outcomes. The outstanding issue is whether or not a sufficient number of participants
could be recruited within a reasonable time frame for a definitive trial. Future work is required to identify
whether or not there are sufficient sites that are able to deliver the services required for a definitive trial.
Trial registration: Current Controlled Trials ISRCTN12715175.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 23, No. 47. See the NIHR Journals Library website
for further project information.
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Plain English summary
Approximately one-third of stroke patients experience depression, which can have negative effects onrecovery and quality of life (QoL). Currently, we do not have sufficient evidence to indicate which
psychological interventions are effective and affordable to the NHS for treating post-stroke depression.
We aimed to determine whether or not it is feasible to conduct a future large-scale study to evaluate a
psychological intervention, called behavioural activation (BA) therapy, for treating post-stroke depression.
BA aims to improve mood by identifying what stroke patients enjoy doing and helping them to undertake
these activities. BA can be used with all stroke patients with depression, including people with cognitive or
communication difficulties.
We recruited 48 post-stroke patients who had suffered a stroke between 3 months and 5 years previously.
People with dementia or significant aphasia were excluded. Participants were divided into two groups at
random. About half of the participants received BA over a 4-month period and the other half did not.
Participants received all other available care. After 6 months, participants completed questionnaires about
their mood, activity level and QoL. We also interviewed 16 participants and 10 carers about their views on
the actual research process and therapy.
Although we were able to recruit participants to the study, we recruited fewer than the original target
of 72 participants owing to delays in starting recruitment. However, we have identified ways to improve
participant recruitment in a future study. We found that it was feasible to deliver BA, and the therapy
was found to be acceptable to participants, carers and therapists. The results indicate that the benefits of
conducting a large-scale future study would outweigh the costs. However, the main consideration will be
whether or not we could identify enough stroke services able to run the study for a long enough period to
recruit the large number of participants required.
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Scientific summary
Background
About one-third of people become depressed after stroke. It is important that depression is treated as it
can negatively effect recovery, quality of life and carer strain. There is currently insufficient evidence for the
clinical effectiveness and cost-effectiveness of psychological therapies for post-stroke depression. One-third
of stroke survivors have aphasia and up to 75% of stroke survivors have problems with memory, thinking
or understanding (cognitive problems). People with communication or cognitive problems are often
excluded from studies evaluating psychological interventions. We wanted to evaluate a psychological
intervention that can be delivered to the wide range of stroke survivors.
Behavioural activation (BA) therapy may be an appropriate treatment for post-stroke depression. BA aims
to improve mood by increasing the time people spend doing activities that they enjoy. Importantly, it can
be used with stroke survivors with depression, including those with communication or cognitive difficulties.
We previously completed a randomised controlled trial (RCT) with 105 stroke survivors with aphasia and
low mood and found that those who received BA had improved mood 6 months later. However, this
previous study included only people with aphasia, did not explore participants’ and carers’ views on the
intervention and did not evaluate whether or not BA was cost-effective. Therefore, we conducted a
feasibility study of BA with stroke survivors with depression to evaluate whether or not it would be
possible to proceed to a definitive multicentre trial and, if so, how we could do this. The Behavioural
Activation Therapy for Depression after Stroke (BEADS) trial was funded in response to a National
Institute for Health Research (NIHR)-commissioned call.
Objectives
To evaluate the feasibility of undertaking a definitive trial to evaluate the clinical effectiveness and
cost-effectiveness of BA compared with usual stroke care for treating people with post-stroke depression.
The primary objective was to determine the feasibility of proceeding to a definitive trial. The secondary
objective was to determine the feasibility of delivering BA to people with post-stroke depression.
Design
The BEADS trial was a parallel-group, feasibility, multicentre RCT with nested qualitative research and
economic evaluation. Randomisation was web based and stratified by centre using a computer-generated,
pseudo-random list with random permuted blocks of varying sizes. The researcher completing the outcome
assessments was blinded to allocation.
Setting
Recruitment was from acute and community stroke services in three sites in England. The intervention was
delivered on an individual basis in participants’ homes.
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Participants
Participants were adults (aged ≥ 18 years) between 3 months and 5 years post stroke, living in community
settings (including nursing homes) and identified as depressed, defined as scoring ≥ 10 points on the
Patient Health Questionnaire-9 (PHQ-9) or ≥ 50/100 points on the Visual Analogue Mood Scales (VAMS)
‘Sad’ item. People were excluded if they had a visual or hearing impairment that would have an impact on
their capacity to take part in the intervention, had a diagnosis of dementia prior to stroke, were unable to
communicate in English, had communication difficulties that would have had an impact on their ability to
take part in the intervention, did not have capacity to consent, were receiving medical or psychological
treatment for depression at the time of stroke onset or were currently receiving psychological intervention.
Interventions
Participants were randomised (1 : 1 ratio) to BA therapy or usual stroke care. Those allocated to the
intervention could receive a maximum of 15 sessions of BA over 4 months in addition to their usual care.
BA was delivered by an assistant psychologist (AP) or psychological well-being practitioner over 4 months.
BA aims to increase activity, particularly the frequency of pleasant or enjoyable events, in order to improve
mood. A BEADS therapy manual was developed and BA therapy techniques included activity monitoring,
activity scheduling and graded tasks. The number of therapy sessions varied depending on the needs of
the individual and their progress in therapy. The therapists received training in the intervention and
additionally in communicating with stroke patients with cognitive and/or communication difficulties.
The control group (usual care) followed their current care pathway and received all other services routinely
available to them as local practice.
Main outcome measures
Feasibility outcomes
The primary end points were based on:
l feasibility of recruitment to the main trial
l acceptability of the research procedures and measures
l appropriateness of the baseline and outcome measures for assessing impact
l retention of participants at outcome
l potential value of conducting the definitive trial, based on value-of-information analysis.
The secondary end points, related to the feasibility of the BA therapy intervention, were based on:
l acceptability of BA therapy to participants, carers and therapists
l feasibility of delivering the intervention by APs or an Improving Access to Psychological Therapies (IAPT)
therapist under supervision of an experienced mental health practitioner
l documentation of ‘usual care’ using a health-care resource use questionnaire
l treatment fidelity of the BA therapy
l feasibility of delivery of BA therapy within current services and within a definitive trial
l estimation of sample size for a definitive trial.
Clinical outcomes
The primary clinical outcome measure at 6 months after randomisation was the PHQ-9.
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Secondary clinical outcome measures at 6 months after randomisation were the Stroke Aphasic Depression
Questionnaire – Hospital version (SADQ-H), the Nottingham Leisure Questionnaire (NLQ), the Nottingham
Extended Activities of Daily Living (NEADL), the Carer Strain Index (CSI), the EuroQoL-5 Dimensions,
five-level version (EQ-5D-5L) (standard version and a version for people with cognitive problems) and the
health-care resource use questionnaire. Outcome measures were sent by post for those participants
without aphasia; telephone calls and a home visit were offered to those for whom outcomes were not
returned by post. Outcomes were completed in person for those with aphasia.
Views on the acceptability of the trial design, procedures and the BA intervention were assessed using
semistructured interviews with a subset of participants and carers from each arm, and with all three study
therapists. Participants and carers were selected for interview using a purposive, maximum variation
sampling strategy. Interviews were audio recorded, transcribed verbatim and analysed using the
framework approach.
Fidelity was assessed by describing the content of treatment. Therapists completed a time sampling
record form at the end of each session to record the time spent on different components of the therapy.
A sample of therapy sessions were also video recorded and coded using a therapy record form.
For the health economic analysis, a value-of-information analysis was completed. Costs and utilities were
estimated using the EQ-5D-5L and resource use questionnaires, combined with standard costs and
valuation sources.
Results
Feasibility outcomes
A total of 48 participants were recruited at three centres in 27 centre-months of recruitment; this gave a
rate of 1.8 participants recruited per centre per month. Recruitment varied by site. The highest proportions
of participants were recruited through hospital databases (42.9%) and outpatients (26.5%).
Participants had a mean age of 65.6 years [standard deviation (SD) 13.6 years] and most participants were
men (60.4%). Most participants were between 3 months and 1 year post stroke (62.5%). The mean PHQ-9
score at baseline was 16.8 points (SD 4.7 points).
In total, 25 participants were randomised to receive BA and 23 randomised to the usual-care arm. Those
who received BA attended a mean of 8.5 (SD 4.4) therapy sessions (range 0–14). Sessions lasted for a
mean of 57 minutes (SD 13 minutes, range 10–125 minutes). Delivery of the intervention was good,
with high attendance (90%). The main reasons that sessions were missed were a change in the
participant’s availability (n = 14, 61%), illness (n = 4, 17%) and a change in the therapist’s availability
(n = 3, 13%). Two participants (9%) withdrew from treatment.
Outcome assessments were completed by 39 (81%) participants (18 BA, 21 usual care). Most participants
(63%) returned the follow-up questionnaire by post and 39% of these received at least one reminder
contact to complete the assessment. The 6-month follow-up rate was around 80% in most of the
outcome questionnaires.
According to the therapy recording forms, some of the time during sessions was spent covering between-
session tasks (18.3%). The second most frequent component was activities (18.1%). This included activity
monitoring (6.5%), identifying enjoyable activities (6.0%) and activity scheduling (4.8%), with relatively
little time spent on practising skills or tasks (0.8%). The least amount of time was spent on communication
and cognitive difficulties (0.8%). The use of graded tasks (2.1%) and problem-solving (3.8%) was relatively
infrequent. Ten therapy sessions were video recorded across eight participants. Most components of
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the manual that were intended to be delivered were evident in all sessions and the video recordings
highlighted aspects not otherwise recorded.
Sixteen participants and 10 carers from the intervention and control arms and all three study therapists
were interviewed. BA was found to be acceptable to participants, carers and therapists and those involved
were generally positive about their experiences.
Participants felt that the most helpful aspects of therapy were identifying new and meaningful activities,
reflection during the sessions, having weekly sessions and having the chance to talk with someone. Some
participants who received the therapy suggested that follow-up sessions would help to maintain the gains
made. Some control participants also found participation in the study helpful as it provided opportunities
to talk about their experiences. However, others were uncertain why they had been randomised to usual
care. The outcome measures were generally felt to be appropriate in content and length.
Therapists found the manual and training helpful but also suggested having a summary of each session
and an interactive notebook or workbook for participants. The biggest challenge reported was the
variation in patient presentation, although the therapy and manual allowed sessions to be tailored to
individuals’ needs. The therapists reported different experiences of recruiting participants, reflecting local
site differences.
Clinical outcomes
The mean PHQ-9 scores at 6 months post randomisation were 10.1 points (SD 6.9 points) and 14.4 points
(SD 5.1 points) in the BA and control groups, respectively, a difference of –3.8 points [95% confidence
interval (CI) –6.9 to –0.6 points] after adjusting for baseline and centre, representing a reduction in
depression in the BA arm.
On the secondary outcomes, the intervention had a positive effect for participants on VAMS Sad and
the NLQ and for carers on the CSI, although these differences were only small. There was no difference
between intervention and control groups on the NEADL. Small negative effects were found for the
patient-reported EQ-5D-5L and SADQ-H.
Value-of-information analysis indicated that the benefits of conducting a definitive trial would be likely
to outweigh the costs owing to high levels of uncertainty around key parameters such as resource use,
response rates, utility scores and relapse rates within the economic model. Our preliminary analysis of the
cost-effectiveness of the intervention demonstrates the feasibility of conducting a definitive economic
evaluation alongside a definite trial. Our preliminary analysis suggests that the intervention may represent
a dominant treatment strategy (i.e. cost saving and quality-adjusted life-years gain) from a societal
perspective, but which may be of borderline cost-effectiveness from a NHS and Personal Social Services
(PSS) perspective.
We calculated a sample size for a definitive scale trial comparing BA with usual care in participants with
post-stroke depression. The primary end point used was PHQ-9 score at 6 months post randomisation.
We assumed that a target difference in PHQ-9 scores of between 3 and 5 points would be clinically and
practically important and a conservative estimate of SD between 7 and 11 points, giving a range of
standardised effect sizes of between 0.27 and 0.71. From this feasibility study, data were used to calculate
the intra-cluster correlation coefficient of 0.06 in the intervention arm based on clustering by site. The attrition
rate of 18.8% was rounded up to 20% and used to adjust the final sample size calculation. A sample size of
580 participants would be required to detect a difference of 4 points on the PHQ-9 scale with 90% power
and 5% significance. This would take approximately 24 months of recruitment in 16 sites assuming a rate of
1.5 participants per site per month, which is similar to the rate observed in the feasibility study (recruitment
rate of 1.8 participants per site per month). A sample size of 623 participants would be required to detect a
difference of 3 points on the PHQ-9 scale with 90% power and 5% significance.
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Conclusions
Feasibility was demonstrated across the majority of the selected outcomes and strategies for improvements
were identified. Depression seemed to improve in the group that received BA. It was feasible to deliver
BA to people with and without aphasia or with cognitive impairment, and the therapy was acceptable to
participants, carers and therapists. As the study was not powered for efficacy, it is not appropriate to draw
conclusions on the value of BA for treating post-stroke depression. Similarly, although cost-effectiveness
results are preliminary, value-of-information analysis suggests that conducting a definitive trial would
represent good value for money.
Both methods of checking the fidelity of the intervention were feasible. Both highlighted potential ways
that therapy deviated from the treatment described in the manual. However, the records kept by therapists
were simpler to use and more complete.
The distribution of time on the different components of therapy was as expected. However, there was little
documentation of graded tasks assignments and training in problem-solving. This may be because graded
tasks were often used as a between-session task and so were coded as such.
The main issue outstanding is whether or not there are sufficient sites willing and able to deliver the
services needed to sustain recruitment for a definitive trial.
If a definitive trial were to be undertaken, based on the findings from the BEADS trial, our
recommendations are:
l recruit through stroke services rather than using IAPT as a main site for recruitment
l provide at-site support or central monitoring of recruitment
l hold regular teleconferences for the site staff and principal investigators to improve engagement
and recruitment
l send out regular newsletters to participants informing them of the study’s progress to improve
engagement in the study and increase retention
l amend the therapy record form so that the content of the between-session task is recorded
l ensure that study staff and Clinical Research Network staff resourcing is allocated accordingly for the
most effective recruitment routes
l explore general practitioner databases and social media as other sources to recruit participants
l ensure that data on NHS, PSS and societal costs are captured
l ensure that sufficient data are collected to allow estimation of a relapse rate
l improve the collection of usual-care data
l consider including a booster session(s) to support maintenance of therapy gains
l consider providing a Quick Reference Guide for the therapists to use alongside the full treatment manual
l develop a fidelity checklist to be used to inform the training of therapists and the monitoring of the
videos of therapy sessions during the trial.
Trial registration
This trial is registered as ISRCTN12715175.
Funding
This project was funded by the Health Technology Assessment programme of the National Institute for
Health Research.
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Chapter 1 Introduction
Post-stroke depression
Stroke
Stroke is a condition in which interruption of the blood supply to the brain causes brain damage. This leads
to the impairment of motor, sensory and cognitive abilities. Cognitive impairments include disorders of
communication, such as aphasia, and problems with attention, memory, visuospatial abilities and executive
function. These cognitive impairments have a negative effect on recovery and long-term outcomes.1–3
Depression after stroke
Many stroke patients experience emotional consequences, including depression, anxiety, post-traumatic
stress, anger, apathy and frustration. Depression is the most commonly investigated emotional
consequence of stroke.4,5
Several recent reviews5–8 have reported that about one-third of stroke patients have depression at any
time point. Two of these reviews1,2 included a meta-analysis. Ayerbe et al.1 analysed data from 43 studies
published between 1983 and 2011. They reported an average prevalence of depression among stroke
survivors of 29% [95% confidence interval (CI) 25% to 32%] of stroke survivors with depression, with
a prevalence of 28% (95% CI 23% to 34%) within 1 month of stroke, 31% (95% CI 24% to 39%)
at 1–6 months, 33% (95% CI 23% to 43%) at 6 months to 1 year and 25% (95% CI 19% to 32%)
at > 1 year. Hackett and Pickles2 conducted a similar review and identified 61 studies. They obtained a
pooled prevalence of depression among stroke survivors 31% (95% CI 28% to 35%) at any time, up to
5 years after stroke. Hackett et al.3 also highlighted that this figure was not significantly different from the
proportion in their earlier review (33%, 95% CI 29% to 36%; difference of 2%, 95% CI < 1% to 3%),
suggesting that the management of the problem had not substantially improved over the previous 10 years.
Factors associated with depression after stroke
Effective treatment of depression is important because depression is associated with worse rehabilitation
outcomes4–7 and increased disability.1 Stroke survivors who are depressed may engage less in rehabilitation,
which, in turn, can lead to decreased functional recovery.4 Depression is also associated with increased
mortality.1,8,9 Not only does depression affect stroke survivors themselves but it also has an effect on their
carers.10 It has cost implications for the NHS because it is associated with increased health-care utilisation.9
Most studies have assessed depression and its potential outcomes at the same time point, making it
unclear whether depression is a cause or consequence of the outcome variable. Ayerbe et al.1 reviewed
only those studies in which depression was assessed at an earlier time point than the outcome and found
that disability, lower quality of life (QoL) and mortality may be outcomes of depression in stroke survivors.
In a more recent review, Towfighi et al.11 concluded that the most consistent predictors of post-stroke
depression are physical disability, stroke severity, history of depression and cognitive impairment. They
also reported that post-stroke depression is associated with higher rates of health-care use after stroke.
Therefore, in addition to improving mood, effective treatment of post-stroke depression is important as
this has the potential to improve functional outcomes and QoL and reduce health-care costs.
Many studies of depression after stroke are based on clinical interviews or questionnaires to assess
depression but these may not be appropriate for those with communication problems. About one-third
of stroke survivors have aphasia,12,13 which may affect all communication modalities, namely speaking,
understanding, reading and writing. Studies that have used measures of depression appropriate for those
with communication problems have reported that stroke survivors with aphasia may be particularly
susceptible to post-stroke depression.14,15
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Current service provision
Psychological treatments for depression after stroke
Previous research16 indicates that a high proportion of depressed stroke patients are likely to be taking
antidepressants and so suggests that antidepressants have not resolved the mood problem. Previous
research also suggests that few stroke survivors receive ongoing psychological treatment.17 The
Communication and Low Mood (CALM) trial of behavioural activation (BA) for low mood in people with
aphasia17 found that, at 3-month follow-up, only 14% of participants who had been identified as having
low mood after stroke had received mental health treatment in the past 3 months (from a mental health
nurse, counsellor, psychologist, or psychiatrist). Although Improving Access to Psychological Therapies
(IAPT) has extended its remit to include people with physical health problems,18,19 the current uptake by
stroke survivors is unknown.
Among the several psychological approaches to the treatment of depression, cognitive–behavioural
therapy (CBT) is the most widely used psychological treatment for depression in clinical practice20 and
may be appropriate for those with stroke.21,22 There is evidence from single case design studies that some
patients with post-stroke depression improve following CBT.23,24 However, a randomised controlled trial25
(RCT) of CBT for post-stroke depression found no significant difference between those participants who
received CBT, an attention placebo or usual care. One of the possible reasons for the lack of efficacy was
that psychological treatments need to be tailored for people with aphasia and cognitive impairment.22,25
A systematic review26 of the modifications to CBT that were required for people with cognitive impairments
caused by acquired brain injury reported promoting an understanding of how specific changes to
cognition, affect and behaviour occur as a result of brain injury and the use of memory aids.27 However,
a randomised trial of augmented CBT, in which CBT was adapted to suit those with stroke, also found no
evidence of benefit in comparison with a cognitive training control group. In addition, a trial28 of CBT at
different time points after stroke found no overall effect of CBT in comparison with usual care, although
there was some evidence that CBT improved mood in those who were recruited > 9 months after stroke.
Therefore, there is currently little evidence to support the provision of CBT after stroke.
Effectiveness of psychological interventions for depression after stroke
Other psychological interventions that may be appropriate for those with depression after stroke include
counselling, motivational interviewing and problem-solving training. Some of these have been provided
early after stroke in an attempt to prevent the development of depression,29–35 whereas others have been
provided later to those who have developed depression.36,37
There is currently limited evidence for the clinical effectiveness and cost-effectiveness of these psychological
therapies for treating post-stroke depression.38 Towfighi et al.11 identified seven trials (n = 775 participants)
of psychological interventions for depression after stroke and concluded that these trials suggest that brief
psychosocial interventions may be useful and effective in the treatment of post-stroke depression. Two of
these trials36,37 evaluated a brief psychosocial behavioural intervention, but details of the content of the
intervention are limited. Motivational interviewing31,35 has also been shown to reduce post-stroke depression
but studies recruited participants early after stroke and excluded those with severe communication or
cognitive problems, so these findings may not be applicable to the broad range of stroke survivors with
post-stroke depression.
Behavioural activation
A psychological intervention that may be suitable for stroke survivors is BA therapy. BA is based on the
behavioural model of depression, in which depression is believed to result from a lack of response-contingent
positive reinforcement.39 Positive reinforcement is dependent on the person’s actions,40 and reduction in
activity can lead to loss of reinforcement. Low positive reinforcement can arise from several sources:
a deficiency in the individual’s skills (e.g. lack of social skills), limited availability of potential reinforcers in the
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environment and a decreased ability to enjoy pleasant events. The individual may engage in few activities
that generate reinforcement. These antecedents contribute to a low rate of positive reinforcement, and so
there are reduced feelings of mastery and esteem in success, which can lead to feelings of depression.
As individuals become depressed they reduce participation in activities and hobbies, decreasing the level
of reinforcement further and so leading to a vicious cycle.41 It is proposed that depression is, therefore,
maintained by a cycle of depressed mood, decreased activity and avoidance.42
A stroke can result in a loss or restriction of rewarding activities and interactions (such as everyday activities,
hobbies and social interactions) and this loss may lead to depression. The symptoms of depression (such as
reduced motivation and lack of energy), in addition to the consequences of stroke, can mean that some
behaviours or activities become more difficult and lose the positive reinforcement that they used to provide.
BA aims to increase activity level, particularly the frequency of valued activities, and decrease avoidance
behaviours in order to improve mood. In addition to its focus on reduced positive reinforcement leading
to depression, BA is also concerned with addressing avoidance behaviours that contribute to depression.
Depressed people may use avoidance as a coping strategy.43 For example, someone who feels low in mood
may withdraw from social contacts because they find this activity challenging and causing them discomfort.
Avoiding this activity provides short-term relief and is negatively reinforced, thereby increasing the likelihood
that they will repeat this avoidance again in the future.
Behavioural activation is effective at treating depression in adults in primary-care settings44–46 and in older
adults.47 It has been found to have comparable effectiveness to CBT in treating depression.48 In a randomised
controlled non-inferiority trial, Richards et al.49 found that BA had comparable effects to CBT for people with
depression in primary care and could be delivered by mental health workers with less intensive and less costly
training than that required to deliver CBT and was, thus, also more cost-effective.
Behavioural activation is considered a straightforward approach and, as such, is suitable for those with
reduced cognitive or communication ability. Stroke patients have cognitive impairment and some have
communication problems, which makes BA an appropriate treatment. A multicentre RCT, the CALM trial,17
evaluated BA delivered by an assistant psychologist (AP) for treating low mood in stroke patients with
aphasia. This trial17 found that mood was significantly better at 6-month follow-up in those who received
BA than in those who received usual clinical care. In addition, reduced resource use suggested potential
cost-effectiveness.50
The transferability of BA to hard-to-reach populations, such as those with aphasia and severe cognitive
problems,51–54 adds to its potential as a psychological intervention for depression after stroke. Given that
the CALM trial17 demonstrated that it was possible to deliver BA to stroke survivors with aphasia and that
studies of BA in people with dementia indicate that it is suitable for those with cognitive impairment,54
there is significant potential for using BA for treating depression in stroke survivors with mild to moderate
communication and cognitive impairment.
Rationale and objectives
The Behavioural Activation Therapy for Depression after Stroke (BEADS) trial was designed and conducted in
response to a commissioned call from the National Institute for Health Research (NIHR) Health Technology
Assessment (HTA) programme to answer the research question ‘How feasible is a study to investigate the
clinical and cost-effectiveness of a psychological intervention for people with post-stroke depression?’.
The BEADS trial was a multicentre trial designed to test the feasibility and clinical outcomes of BA for
treating post-stroke depression, as well as its acceptability to patients, carers and therapists. We also
collected data on the feasibility of delivering the BA intervention in the NHS as part of routine clinical
practice. This feasibility work was essential in informing a proposal for a definitive (Phase III) multicentre
RCT evaluating the clinical effectiveness and cost-effectiveness of BA for treating post-stroke depression.
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However, as a feasibility study, the BEADS trial was not powered to explore any factors that may modify
the effects of treatment.
Primary objective
The primary objective was to determine the feasibility of proceeding to a definitive trial.
Secondary objective
The secondary objective was to determine the feasibility of delivering BA to people with post-stroke depression.
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Chapter 2 Methods
The feasibility trial
This feasibility trial is reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT)
statement55 and the pilot and feasibility trials extension.56 The full protocol has been published.57
Trial design
This study used a parallel-group, feasibility, multicentre RCT design with nested qualitative research and
economic evaluation to compare BA therapy with usual stroke care for patients with post-stroke depression.
Participants were allocated to BA or usual stroke care at a ratio of 1 : 1.
Ethics approval
Ethics approval was granted on 29 January 2015 by the National Research Ethics Service (NRES) Committee
East Midlands – Leicester (reference number 15/EM/0014).
Important changes to the methods after feasibility trial commencement
Changes made to the essential documentation during the trial and following ethics approval on
29 January 2015 can be found in Appendix 1.
Early in the recruitment phase substantial amendment 2 [Protocol v2.1, Research Ethics Committee (REC)
approved 8 July 2015] provided additional options in the recruitment process. This allowed the therapists
to contact patients directly by telephone following initial consent to be contacted. This streamlined the
recruitment process by providing the opportunity for the therapist to explain more about the research and
arrange a home visit to complete screening measures. This amendment also broadened the recruitment
routes to include potential participants on acute outpatient caseloads.
In substantial amendment 3 (Protocol v2.2, REC approved 7 September 2015), an additional exclusion
criterion were added to exclude patients who were currently receiving psychological intervention. Five out
of the 49 participants were recruited prior to this exclusion criterion being added. Furthermore, it was
specified that participants in the intervention group could be withdrawn from the intervention if it was
subsequently agreed that the patient needed immediate clinical psychology input. This amendment also
clarified that participation in the study would not compromise access to other services (i.e. psychological
input) that were part of usual care.
Minor amendments were also made including changes in study personnel and contact details. In addition,
another secondary end point was added to estimate the sample size for a definitive trial and clarification
that two or fewer missing items within the Patient Health Questionnaire-9 (PHQ-9)58 could be imputed
if required.
Participants and eligibility criteria
Recruitment of participants
Participants were identified from hospital and community stroke databases at three stroke services, as well
as the corresponding acute hospital stroke wards, and from voluntary support groups. Participants were
approached by letter or by clinicians in community and acute stroke teams, or by voluntary group leaders.
Self-referrals were facilitated by advertising the study in newsletters of relevant charities and societies.
Posters were displayed in local voluntary sector groups, libraries and local community centres so that
potential participants unknown to local hospital and community stroke teams could self-present to the
local research team. The methods of identifying potential participants were kept broad to allow assessment
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of the optimum recruitment strategy for the definitive study. This also enabled recruitment of a
representative cross-section of the population.
Participants were recruited from three centres (see Settings and locations where the data were collected).
The process for recruitment varied depending on where the participant was recruited from.
Hospital stroke database and community stroke team database
At each site, the clinical teams sent invitation letters to those on the hospital or community stroke
databases of discharged patients. Patients were sent a postal pack containing a covering letter, a
participant information sheet, a reply slip, the PHQ-9, the Visual Analogue Mood Scales (VAMS) ‘Sad’ item
and a prepaid envelope. Patients who were interested in taking part returned the reply slip and completed
PHQ-9 and VAMS ‘Sad’ item to the therapist. Return of completed questionnaires was taken as implied
consent to be contacted by the therapist (i.e. for potential recruitment into the trial). Those patients who
did not reply were contacted by telephone by the clinical team to remind them about the study. The
PHQ-9 and VAMS ‘Sad’ item were used to assess whether or not participants met the inclusion criterion
of having depression. Participants who returned the reply slip with the completed PHQ-9 and VAMS ‘Sad’
item were contacted by the therapist if they were identified as depressed (scoring ≥ 10 points on PHQ-9 or
≥ 50 points on the VAMS ‘Sad’ item). Those who were identified as not being depressed (i.e. scores of
< 10 points on the PHQ-9 or < 50 points on the VAMS ‘Sad’ item) were thanked for their interest and
informed that they were not eligible.
Therapists contacted patients who were classified as depressed to arrange a visit. The purpose of the visit
was to check that the participant met the remainder of the inclusion criteria, to explain the study and to
formally invite eligible patients to take part, obtain signed consent and complete baseline assessments. If a
patient returned the reply slip to express interest in the study but did not return the completed PHQ-9 and
VAMS ‘Sad’ item, the therapist offered to visit and support the patient to complete these assessments.
Patients currently on acute hospital stroke wards
At each site, research nurses visited hospital stroke wards to provide information about the research to
potential participants and seek their permission to be contacted by the research team and, therefore,
permission for their contact details to be passed on to the research team. A screening form was used to
collect key demographic and contact information from all consented participants, who were then contacted
by the local therapist 3 months from the date of consent to be contacted. Before making contact, the local
research nurse or general practitioner (GP) was contacted to check whether or not the patient was still alive.
Patients were then contacted by telephone to tell them more about the research and arrange a home visit,
during which they completed the PHQ-9 and VAMS ‘Sad’ item. Those patients who were identified as not
being depressed were thanked for their interest and were informed that they were not eligible. For patients
who were classified as depressed, the therapist either (1) arranged a subsequent home visit or (2) continued
with recruitment as per the steps in Hospital stroke database and community stroke team database.
Alternatively, instead of a home visit or telephone call, the patient could be sent a pack containing a covering
letter, a participant information sheet, a reply slip, the PHQ-9, the VAMS ‘Sad’ item and a prepaid envelope
addressed to the therapist for that site. The same steps outlined in Hospital stroke database and community
stroke team database were then followed.
Patients currently on the active caseload of community and acute stroke teams
The BEADS trial was presented to the community and acute stroke teams at each of the study sites.
The clinical care teams were asked to explain the study to potential participants at the end of therapy,
outpatient appointments or between appointments by telephone. If patients were interested in taking part,
the clinician asked permission for their contact details to be passed on to the research therapist. Following
this, the therapist then sent a pack to the patients and followed the steps outlined in Hospital stroke
database and community stroke team database or arranged a home visit and followed the steps in Patients
currently on acute hospital stroke wards.
METHODS
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Voluntary sector (stroke and aphasia groups)
The therapists sought permission to attend stroke and aphasia groups in each site to explain the study to
members. Those who were interested in taking part were invited to provide their contact details to the
therapist, who then either arranged a home visit and followed the steps in Patients currently on acute
hospital stroke wards or sent the patient a pack and followed the steps in Hospital stroke database and
community stroke team database.
Potential participants were told that entry into the trial was entirely voluntary and that their treatment and
care would not be affected by their decision. It was also explained that they could withdraw at any time,
but attempts were made to avoid this happening. Participants were told that, if they withdrew, their data
could not be erased and could be used in the final analyses.
Recruitment of carers and therapists
For those participants with carers, the carer was also invited to take part. Carer participants were eligible if
they provided informal care to the trial participant. Family members, spouses and friends were all eligible
to participate as carers. The study therapists (staff participants) were invited to take part in the qualitative
interviews at the end of the study.
The presence of a carer was established by the therapist during the initial telephone call to arrange the
first home visit. When the carer was present during the home visit, study therapists provided them with a
copy of the participant information sheet to review and gave a verbal explanation of study participation.
When appropriate and relevant, written informed consent was taken from carer participants during
this first home visit. When the carer was not present during the home visit, a copy of the participant
information sheet was provided for the carer and the study therapist followed this up with a telephone
call to discuss the study in more depth. When the carer was interested in participating, an additional home
visit was undertaken to organise written informed consent from them.
Staff participants were consented by the study therapist; research and staff participants were consented
by the interviewer for the qualitative interview and by the trial manager for video recording (fidelity
assessment). It was explained that participation was voluntary and that they could withdraw at any time.
At consent for recruitment into the trial, all participants opted in or opted out of receiving invitations for their
treatment sessions to be video recorded as part of the fidelity assessment. Participants who declined video
recording were offered the option of audio recording instead. Participants were not excluded from the study
if they did not want their treatment sessions to be video or audio recorded. We documented the proportion
of participants who agreed to be video (or audio) recorded.
Eligibility criteria
Inclusion criteria
The criteria were designed to identify those who would be suitable for the intervention were it to be
offered within clinical practice. Participants were included in the study if they:
l had a diagnosis of stroke
l were aged ≥ 18 years
l were living in community settings, including home or nursing home
l were a minimum of 3 months and a maximum of 5 years post stroke
l were identified as depressed, defined as –
¢ a score of ≥ 10 points on the PHQ-958 (two or fewer missing items within the questionnaire may
be imputed)
¢ a score of at least 50 out of 100 points on the VAMS ‘Sad’ item.59
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Exclusion criteria
Participants were excluded if they:
l had a diagnosis of dementia, based on self-report or carer report, prior to their stroke
l reported receiving medical or psychological treatment for depression at the time at which they had
their stroke
l were currently receiving a psychological intervention
l had communication difficulties that would have an impact on their capacity to take part in the
intervention, based on assessment with the Consent Support Tool60 (CST) for people with aphasia
l had visual or hearing impairments that would have an impact on their capacity to take part in the
intervention based on their therapist’s opinion at baseline assessment
l were unable to communicate in English prior to the stroke
l did not have mental capacity to consent to take part in the trial.
All reasons for patient exclusion were recorded.
Consent process
During training by a speech and language therapist experienced in mental capacity assessment, all
recruiting researchers were taught techniques to identify whether or not a potential participant was able to
understand key information provided about the project and to retain and weigh this information, as well
as methods to assist participants to express their decision, adhering to the four key aspects of mental
capacity outlined in the Mental Capacity Act 2005.61
Written informed consent was obtained from all participants who were are able to give it. Those who
lacked the mental capacity to provide consent were excluded from the trial. The therapists explained
the details of the trial and provided a participant information sheet, ensuring that the participant had
sufficient time to consider participating or not. For patients who were physically unable to sign the form
(e.g. weakness in dominant hand attributable to stroke), consent could be given using a mark or line in the
presence of an independent witness (who had no involvement in the trial), who would then corroborate
this by signing the consent form.
A significant proportion of the stroke population have some degree of cognitive or language impairment
(aphasia). The level of support required to enable a person with aphasia to provide informed consent is
dependent on the severity and profile of the aphasia. In order to provide information in a format consistent
with each individual’s language ability, the CST could be used. The CST provides a means of determining
comprehension levels of people with aphasia, or cognitive difficulties, in order to provide information in
a format that is likely to be most accessible to the person with aphasia to support their understanding.
This tool also helps to identify methods that support the individual to express their decision. The therapist
requested verbal consent from the potential participant to carry out part A of the CST (10 minutes). The
result indicated how appropriate it was to provide the accessible information sheet. If the CST indicated that
the potential participant understood fewer than two key written or spoken words in a sentence, they would
be likely to find it difficult to understand all the information required to provide informed consent. These
participants were thanked for their time but were not eligible for the study as, despite the intervention using
techniques to support the inclusion of those people with reduced language or cognition, the intervention
did rely on achieving understanding with support and actively participating in therapeutic communication.
The accessible information sheet was provided to those who understood at least two key written and
spoken words. This follows standard aphasia-friendly principles, with one idea presented per page in short
simple sentences in large font. Key words are in bold and each idea is represented by a pictorial image to
support understanding of what the study is about. The therapists were trained to support understanding
further by reading parts of the information aloud and using supportive gestures/actions (as described
for information level 3 of the CST and consistent with the types of support offered in the intervention
under study).
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Once the potential participant was given the information and had sufficient time to ask questions and
discuss with family or friends, the therapist checked that the individual had capacity to provide informed
consent. This was performed by checking that they understood the information, could remember what
the study was about and could clearly express their decision in the way in which they usually communicate
(speaking, writing, using a communication aid). The CST provides information on ways people with
aphasia might choose to express their intentions.
When the CST was not needed, owing to adequate understanding and verbal expression in conversation,
the researchers were still taught to check that the trial information provided had been understood by each
individual by asking yes/no questions about the content of the information and the potential consequences
of their involvement to confirm the patient’s ability to weigh the information.
Participants with capacity to provide informed consent who used the accessible information provision were
provided with an aphasia-friendly consent form and asked to initial all boxes before signing. When stroke
symptoms prevented initialling of boxes or providing written consent, the patient could use a mark or line
and a relative/friend was asked to witness the fact that the participant was consenting to the study and to
sign and date the consent form to confirm this on behalf of the participant.
As participants may become distressed during the study and, therefore, may be advised to consult their
GPs, consent to notify the GP was sought from all participants. Participants’ GPs were notified by letter
that their patient was taking part in the research and were sent a copy of the participant information sheet
for information.
Expected duration of participant participation
Study participants were expected to participate in the study for approximately 6 months.
Settings and locations where the data were collected
The University of Nottingham sponsored the trial. Co-ordination of the trial was undertaken by the
Sheffield Clinical Trials Research Unit (CTRU). Participants were identified and recruited from hospital
and community stroke services at Sheffield Health & Social Care NHS Foundation Trust, Derby Teaching
Hospitals NHS Foundation Trust and Let’s Talk Wellbeing at Nottinghamshire Healthcare NHS Foundation
Trust. Screening and identification of potential participants was supported by Clinical Research Network
(CRN) staff based at Sheffield Teaching Hospitals NHS Foundation Trust, Derbyshire Community Health
Services NHS Foundation Trust and at Sherwood Forest Hospitals NHS Foundation Trust. Baseline data
were collected and BA therapy was delivered by the therapists in participants’ own homes. Six-month
follow-up data were collected in participants’ own homes, for those with aphasia, by blinded outcome
assessors. For those without aphasia, data were collected by post unless help was requested.
Interventions
Intervention: behavioural activation therapy
Behavioural activation therapy is a structured and individualised treatment that aims to increase people’s
level of activity, particularly the frequency of valued activities (pleasant or enjoyable events), and decrease
avoidance behaviours, in order to improve mood. Participants randomised to receive BA were treated
at their place of residence by a research therapist. The research therapists were APs at two sites and a
psychological well-being practitioner (PWP) at one site. APs are psychology graduates who support the
work of a clinical psychologist and work under the supervision of a clinical psychologist. Many APs aspire
to train to become clinical psychologists. The level of expertise and experience of an AP can vary, but they
would need to meet the person and job specification for the band at which they would be employed
(NHS bands 4 or 5). PWPs have completed an accredited training course to enable them to deliver
low-intensity CBT-based interventions to people with mental health conditions.
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The two APs in the study were psychology graduates. They had no previous formal training in psychotherapy
and had not previously worked in a stroke service. They were newly appointed to working as an AP in the
stroke service at their site; their background and level of experience was comparable to the APs who
delivered BA to people with aphasia in our previous CALM study.17
Participants were offered a maximum of 15 sessions of BA over 4 months, with an expected average of
10 sessions. Therapy sessions were delivered face to face on an individual basis and lasted for about 1 hour.
The intensity and duration of therapy were based on a study25 of CBT with stroke patients and were
informed by the CALM study,17 in which participants received an average of nine 1-hour sessions over 3
months. Experience and criticism of the CBT trial25 was that the 3-month duration of therapy was too short.
The trial62 of BA for treating depression in primary care provided 12 sessions over 3 months, but this was not
in a stroke sample and patients with communication or cognitive difficulties may require a longer duration of
therapy. Therefore, the duration of therapy was 4 months because the CALM study17 showed that it was
difficult to complete sessions in 3 months owing to non-availability of the participants and short-term
illnesses. Four months also allowed flexibility to provide therapy visits to support maintenance, as might be
provided in clinical practice. However, the number of therapy sessions varied depending on the needs of the
individual and their progress in therapy. The intensity of treatment was negotiated between the therapist and
the participant, based on their progress in achieving their therapy goals, so as to reflect usual clinical practice.
A BA treatment manual was developed for the previous CALM trial17 based on the behavioural component
of CBT for depression in stroke patients,23,25 behavioural therapy with older people41 and guidelines on
conducting therapy with people who have aphasia.21,41,51 For the BEADS trial, this therapy manual was
further revised to include BA with stroke patients who do not have aphasia, and provided examples and
practical guidance relevant to all stroke patients. In revising the manual from the CALM trial,17 we drew
on the CBT therapy manuals of Lincoln et al.23 and Laidlaw (Ken Laidlaw, University of Edinburgh, 2004
personal communication), BA manuals of Martell et al.,40 Lejuez et al.63 and Mitchell (Pamela Mitchell,
University of Washington School of Nursing, 2002, personal communication), BA strategies used in
low-intensity CBT64 and guidelines on adapting CBT for people with stroke.22,51
The therapy manual contained session content for 10 sessions, using the same behavioural approaches as
the CALM study.17 Participants could receive up to 15 sessions to allow for the fact that, for some people,
it may take longer to cover therapy content. Additional guidelines were provided for identifying strategies
to support people with aphasia and materials were recommended to enable guidelines on conducting
therapy to be followed.
Goals set during treatment to increase enjoyable activities were tailored to the individual. BA also included
‘homework’ tasks to be completed between sessions to practise exercises and increase activity levels.
Behavioural treatment strategies focused on maximising mood-elevating activities. The process of BA
involved identifying how the person currently spends their time, identifying activities that they enjoyed
doing (this included resuming previous activities, increasing current activity levels or introducing new
activities) and setting goals to increase the number of enjoyable activities.
Behavioural therapy techniques included:
l Activity monitoring – therapists identified how participants spent their time to assess current activity
level, determined what activities they enjoyed and when activities could be carried out. Participants
were given an activity diary or timetable to complete as a homework task. The complexity of the diary
varied depending on the cognitive and communication abilities of the patient. The activity diaries
were available in a range of formats, including word cards, picture cards and photographs.
l Activity scheduling – participants were encouraged to plan realistic activities and goals to complete
each day. This was intended to increase the likelihood that activities were being carried out. The
number of activities was gradually increased in order to increase the amount of positive reinforcement
received. Activities were set on the basis of the abilities and goals of the individual.
METHODS
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l Graded task assignment – tasks were broken down into smaller, manageable, steps to facilitate
practising tasks that participants found difficult. This was intended to increase the frequency of
self-reward and reduce the chances of failure and avoidance of tasks. For example, someone who
wanted to go shopping, were encouraged to start by going to a familiar local shop where they knew
people already; this was then extended to going to a larger shop, further away.
l Problem solving – this included focusing on difficulties a participant may have with completing activities
and using behavioural techniques (such as a graded task) for improving success at these tasks. Common
problems in carrying out activities or tasks were identified and then a problem-solving approach was used
to identify and practise possible solutions.
After each session, therapists completed the therapy recording form. This included the duration and
location of the therapy session and whether or not there was another person present. The time taken to
travel to the visit was recorded. The therapy recording form also included an estimate of how much time
(in 10-minute units) had been spent on each component of therapy. The components of therapy were
based on the content of BA approaches in the manual.
The therapist also completed the therapy session log. This included the planned number of treatment
sessions, the number of treatment sessions completed and the reasons that sessions were missed.
Ensuring intervention fidelity
The therapists attended a 2-day workshop led by a NHS consultant clinical psychologist and the chief
investigator. The workshop covered the rationale of BA therapy for treating depression, application of
behavioural techniques for treating post-stroke depression and explanation of the therapy manual. The
workshop included fictional case examples and role-play exercises. The workshop also included training from a
speech and language therapist on communicating with stroke patients with cognitive and/or communication
difficulties. Communication resources were developed during the CALM study17 (such as picture cards and
activity schedules) and were provided for each of the therapists. To support between-session activities,
worksheets/information-appropriate sheets were developed for varying levels of cognitive difficulties or aphasia.
It was important that the therapists delivered the intervention consistently, in accordance with the therapy
manual. Weekly clinical supervision for the therapists was provided by a local clinical psychologist at each
site. In addition, therapists delivering the intervention had a monthly teleconference to discuss the content
of the intervention, share examples of practice and raise any difficulties with the chief investigator and
NHS consultant clinical psychologist.
A sample of therapy sessions were video recorded (see Fidelity assessment for further details).
Control group: usual care
The availability of psychological support in the three sites varied. The content of usual care was decided
locally by the clinical team, as per local services. In the three sites, most stroke survivors are admitted to
hospital, usually to a stroke unit. On discharge, they may receive input from an early supported discharge
team or from a community stroke/rehabilitation team.
Participants in the usual-care group followed the current care pathway. Participants received all other services
routinely available to them as local practice but had no contact with the trial therapist. This usual-care control
group provided a record of usual care to inform the design of the definitive trial.
Concomitant treatment
Those receiving medical or psychological treatment for depression at the time of stroke onset were
excluded as we were interested in those who developed depression following stroke (as per exclusion
criteria in Participants and eligibility criteria). Those who were currently receiving antidepressants were
included so that we could record how commonly this occurs. Receipt of antidepressant medication or
other psychological intervention for depression was recorded in the case report form (CRF).
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Compliance
Compliance with BA was regarded as an outcome measure not a covariate and was measured by
recording whether or not participants allocated to the BA intervention attended scheduled therapy
sessions. The completion rates of follow-up questionnaires were also recorded.
Feasibility criterion
Primary outcome
The primary outcome measures related to the feasibility of (1) proceeding to a definitive trial and
(2) delivering the BA therapy intervention with participants with post-stroke depression.
The primary end points were based on:
(a) feasibility of recruitment
(b) acceptability of the research procedures and measures
(c) appropriateness of the baseline and outcome measures for assessing impact
(d) retention of participants at outcome
(e) potential value of conducting the definitive trial, based on value-of-information analysis.
Other feasibility outcomes
The secondary end points were related to the feasibility of the BA therapy intervention, based on:
(a) acceptability of BA therapy to participants, carers and therapists
(b) feasibility of delivering the intervention by APs or therapists under supervision of an experienced
mental health practitioner
(c) documentation of ‘usual care’ using a health-care resource use questionnaire
(d) treatment fidelity of the BA therapy
(e) feasibility of delivery of BA therapy within current services and within a definitive trial
(f) estimating the sample size for a definitive trial.
Clinical outcomes
Primary outcomes
The primary clinical outcome measure at 6 months was the PHQ-9.58 For participants with moderate to severe
language problems who were unable to complete the PHQ-9, the VAMS ‘Sad’ item59 was used – this is a
single-item, visual analogue mood measure. The number of participants unable to complete the PHQ-9 was
recorded, and the VAMS ‘Sad’ item was completed with all participants so that the relationship between the
measures could be explored. This was a pragmatic approach, based on self-completion at baseline.
Secondary outcomes
The secondary clinical outcomes were the questionnaire measures used to assess the potential secondary
outcomes at 6 months following BA therapy. These related to the feasibility primary end points (b) and (c).
The following measures were used to assess clinical outcomes at 6 months:
l Stroke Aphasic Depression Questionnaire – Hospital version (SADQ-H) (observer-rated depression)65
l Nottingham Leisure Questionnaire (NLQ) (leisure activities)66
l Nottingham Extended Activities of Daily Living (NEADL) (functional outcome)67
l Carer Strain Index (CSI) (carer-rated level of strain)68
l EuroQoL-5 Dimensions, five-level version (EQ-5D-5L) [health-related quality of life (HRQoL)] standard
version69 and a version for people with cognitive problems70 for participants and carers
l health-care resource use questionnaire.
METHODS
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Participant withdrawal
Participants had the right to withdraw from the study at any time. The reasons for leaving the study,
when given, were recorded on a CRF. Participants who withdrew were still invited to complete the 6-month
outcome assessments unless they had specified that they wished to have no further involvement in the trial.
Individuals removed from active participation in the intervention were not replaced. Reason for withdrawal
from the intervention, if known, was recorded.
Participants were withdrawn from the trial either at their own request or at the discretion of the chief
investigator. The investigator could withdraw a participant in the interest of the participant (e.g. if
continuation in the trial was considered to be causing undue stress) or because of a deviation from the
protocol (e.g. when, following review, it transpired that a participant was incorrectly deemed eligible at
the time of consent). Participants could discontinue their allocated intervention or withdraw from the study
for the following reasons:
l withdrawal of consent
l changes to their health status preventing their continued participation
l failure to adhere to protocol requirements.
If, during the trial, a patient allocated to the BEADS intervention subsequently required clinical psychology
input (as per the protocol of the local service), the BEADS therapist (AP/PWP) discussed this with the clinical
psychologist or clinical lead and the patient and all agreed what was best for the participant. If it was
agreed that the patient needed immediate clinical psychology input then they were withdrawn from
the BEADS intervention and they saw the clinical psychologist, or were referred to alternative provision.
Therefore, the patient was withdrawn from the intervention but not the overall trial and, thus, outcome
data were still collected from them. We recorded the number of participants who were withdrawn from
the BEADS intervention because of a conflict in using clinical services.
Changes to trial outcomes after the trial commenced, with reasons
An additional secondary end point, to estimate the sample size for a definitive trial, was added to the
protocol after the trial commenced, as an inconsistency was identified between the statistical analysis
plan (SAP) and the protocol.
Sample size
As this was a feasibility study, it was not powered for efficacy and no formal interim analyses of efficacy were
conducted; the sample size was adequate to estimate the uncertain critical parameters [standard deviation
(SD) for continuous outcomes; consent rates, event rates and attrition rates for binary outcomes] needed to
inform the design of the definitive RCT with sufficient precision. The sample size of 60 participants allowed
SDs for continuous outcomes, such as the PHQ-9 and VAMS ‘Sad’ item, to be estimated to within precision
of approximately ± 19% of its true value (with 95% confidence). Allowing for 15% attrition by 6 months
post-randomisation follow-up, 72 participants needed to be recruited. To achieve the target sample size of
72 over the 12-month recruitment period, with three centres, we needed to randomise two participants per
centre per month.
In addition to this, we estimated that we would recruit a total of 65 carers and three therapists to the
study. The carer estimate was based on the CALM study,17 in which approximately 90% of people with
stroke had an informal carer present who completed the study outcome assessments.
Further information on both the quantitative and the health economic analyses is provided in the SAP.
This covers both the procedures for missing, unused and spurious data and definitions of populations for
which data were analysed.
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Explanation of any interim analyses and stopping guidelines
The overall study could have been stopped because of safety concerns or issues with study conduct at the
discretion of the sponsor. There were no formal statistical criteria for stopping the trial early. Decisions to
stop the trial early on grounds of safety or futility would have been made by the Trial Steering Committee
(TSC) on the basis of advice from the Data Monitoring and Ethics Committee (DMEC). No early stopping
was planned, but the study could have been terminated early if, in the view of the TSC, no useful
information was likely to be obtained by continuing. The criteria for assessing this were primarily the
feasibility outcomes listed in Feasibility criterion. The TSC could also have recommended the closure of a
centre but that the trial as a whole continued, on the same grounds. Unblinded adverse event (AE) data
were reviewed by the DMEC, who could have recommended to the TSC that the trial was stopped if, in
their opinion, there was evidence of harm in the intervention group. As this was a feasibility trial, it would
not have stopped early for efficacy.
Method used to generate the random allocation sequence
Randomisation was conducted using a computer-generated list with random permuted blocks of varying
sizes, created and hosted by the Sheffield CTRU in accordance with their standard operating procedures
and was held on a secure server. Once a participant had consented to the study, the therapist logged into
the remote, secure, internet-based randomisation system and entered basic demographic information.
The allocation for that participant was then revealed to the researcher.
Type of randomisation and details of any restriction (such as blocking and block size)
Block randomisation with randomly varying block sizes of two, four and six was used so that the sequence
of allocation could not be predicted. The block sizes were determined by the trial statistician and block size
was not revealed to any other member of the study team. Participants were allocated to BA or usual stroke
care at a ratio of 1 : 1. Randomisation was stratified by site.
Allocation concealment mechanism
Access to the allocation sequence was restricted to those with authorisation. The sequence of treatment
allocations was concealed until interventions had been assigned and recruitment, data collection and
analyses were complete.
Neither the participants nor the therapists were blind to which treatment the participants were receiving.
The outcome assessors were blind to the treatment received and there was no requirement for them
to know the treatment allocation at any stage. As a result, a procedure for breaking the code was not
necessary.
Blinding
Participants were randomised at baseline (after consent and baseline assessments) in equal proportions to
BA or usual stroke care. It was not pragmatically possible for the participant or therapist to be blind to the
group allocation, but the researchers completing the 6-month outcome assessments were blinded and had
no involvement in any other aspects of the trial. The researchers were asked to record whether or not they
thought they were unblinded and were also asked to guess the group allocation. We followed guidelines71,72
to minimise unblinding during RCTs of rehabilitation.
The trial statisticians remained blind until data freeze, at which point data checks were carried out on
unblinded data.
Statistical methods
As the trial was a pragmatic, parallel-group RCT, data were reported and presented in accordance with the
CONSORT 2010 Statement.55 All statistical analyses were performed in R version 3.3.1 (The R Foundation
for Statistical Computing, Vienna, Austria).73 As a feasibility study, the main analysis was descriptive and
focused on CI estimation and not formal hypothesis testing.
METHODS
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Analysis populations
The intention-to-treat (ITT) population includes all participants for whom consent was obtained and who
were randomised to treatment, regardless of whether they received the intervention. This is the primary
analysis set and end points were summarised for the ITT population unless otherwise stated.
Baseline characteristics
Baseline characteristics were participants’ demographics (age, sex and ethnicity), patient- and carer-reported
outcomes [PHQ-9, VAMS ‘Sad’ item, EQ-5D-5L, NEADL, NLQ, Stroke Aphasic Depression Questionnaire
(SADQ), CSI and EQ-5D-5L carer], stroke history (time since last stroke, lateralisation of stroke, stroke type,
side of weakness, previous stroke and depression treatment) and stroke outcomes [Montreal Cognitive
Assessment (MoCA), Frenchay Aphasia Screening Test (FAST) and Modified Rankin Scale].
For continuous variables, the number of observations, mean and SD or median and interquartile range (IQR),
and minimum and maximum observations were presented by treatment group and site. For categorical
variables, the number and percentage of observations in each category were presented.
Imbalance between treatment arms was not tested statistically but was reported descriptively.
Feasibility outcomes
The numbers of participants screened, eligible and randomised per month per centre and overall were
presented with relevant percentages. Attrition was examined by presenting the number of participants
who dropped out by treatment arm, site and time since last stroke. The reasons for attrition, where given,
were also presented for each participant.
The time of key events including screening, randomisation, baseline and follow-up was plotted by
participant to check that these were carried out as planned.
The number and percentage of participants randomised to the BA arm and who received at least two,
five, eight and 10 therapy sessions were presented. The mean, SD, median and IQR number of planned
sessions that were missed were presented.
A summary of missing patient- and carer-reported outcome measures was also presented. In addition to
this, we reported the timing of the post-randomisation follow-up assessment.
As part of the feasibility analysis, the effect size for the 6-month PHQ-9 outcome (the probable primary
end point for the definitive study), that is the difference in mean scores between the BA and control
groups, was estimated, along with its associated 95% CI estimate,74 using a mixed-effects model; site was
included as a random effect and baseline PHQ-9 as a covariate to check that the likely effect was within a
clinically relevant range as confirmation that it was worth progressing with the definitive trial.
The following sensitivity analyses were presented alongside the ITT analysis:
l multiple imputation of missing primary outcome data
l unadjusted analysis.
Although this was not prespecified, to examine the effect of the treatment, we also examined the change
in PHQ-9 depression categories (Table 1).
Individual PHQ-9 score and depression category at baseline and follow-up were plotted by treatment arm.
To assess the level of agreement between PHQ-9 and VAMS ‘Sad’ item, scatterplots were generated using
baseline and 6-month follow-up data. Pearson’s correlation coefficient was also calculated using baseline
and 6-month follow-up data.
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Sample size calculations for a definitive trial
We calculated a sample size for a definitive trial comparing BA with usual care in participants with
post-stroke depression. The primary end point used was PHQ-9 at 6 months post randomisation. The
sample size was based on a range of differences in PHQ-9 of between 3 and 5 points75 and a range of
conservative estimates of SD of 7–11 points, giving a range of standardised effect sizes between 0.27
and 0.71, allowing us to determine the most appropriate option. Feasibility data were used to calculate
the intraclass correlation coefficient (ICC) in the intervention arm based on clustering by site. Furthermore,
the feasibility trial attrition rate was used to adjust the final sample size calculation.
Clinical outcomes
Primary outcomes
The primary clinical outcome measure at 6 months was the PHQ-9.58 We planned that those participants
with moderate to severe language problems who were unable to complete the PHQ-9 would instead
complete the VAMS ‘Sad’ item59 – this was a single-item, visual analogue mood measure. However, we did
not have any participants with moderate to severe language problems who did not complete the PHQ-9.
A comparison of PHQ-9 to VAMS ‘Sad’ item was carried out as described above to inform a potential
definitive trial.
To assess the quality of the primary outcome, the follow-up window, defined as the period between screening
and 6-month follow-up assessment, was calculated for each participant. A mean and SD of follow-up time in
days were calculated. Timing of key events (screening, consent, randomisation, withdrawal and follow-up)
were plotted with number of days on the x-axis and screening number on the y-axis.
The secondary outcomes at 6 months post randomisation were analysed using a multiple linear regression
model on the ITT population adjusting for baseline measure and centre to examine the difference between
treatment arms. Mean differences and their 95% CIs were presented.
Missing spurious and unused data
The numbers of missing scores for each of the primary and secondary outcomes at baseline and 6 months
post randomisation were presented by treatment arm. Furthermore, the number and percentage of
missing items were presented for each of these questionnaires.
Multiple imputation was carried out using the Multivariate Imputation by Chained Equations ‘mice’ package
in R statistical software.76 Missing 6-month post-randomisation PHQ-9 scores were imputed using chained
equations and 30 multiply imputed data sets. The multiple imputation model included sex, age, treatment
group, PHQ-9 score at baseline and/or 6 months, EQ-5D-5L at baseline and 6 months and SADQ at baseline
and 6 months as predictors.
TABLE 1 Patient Health Questionnaire-9 depression categories
PHQ-9 score (points) Depression category
0–4 Minimal depression
5–9 Mild depression
10–14 Moderate depression
15–19 Moderately severe depression
20–27 Severe depression
METHODS
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Safety outcomes
The number of AEs and serious adverse events (SAEs) was recorded and presented by treatment arm.
These events were further categorised by the type of AE (fall, worsening health, etc.) and whether or
not they resulted in a hospital stay.
Patient and public involvement
The BEADS trial received input from the patient and public involvement (PPI) group (including one patient
with significant aphasia) on aspects of the design and methods development as well as study oversight.
Two patients and one carer attended five scheduled meetings to discuss feedback on how the study was
being conducted, including ideas about recruitment, study documents, ensuring the well-being of the
patients and carers, and supporting the therapists. The meetings were attended by the PPI group members,
the trial manager and the chief investigator. Meetings took place prior to receiving ethics approval when
study materials were being developed, during recruitment and intervention delivery, and after the study to
discuss the study results. The meetings each had an agenda that was agreed by the group. A summary of
the discussions was written up by the trial manager and chief investigator and was circulated to the group
for them to add any points and to ensure that it was an accurate summary of the meeting. Suggestions
were put into practice with the creation of a short study summary card and a spiral-bound version of the
aphasia-friendly participant information sheet. At the suggestion of the patient and carer representatives,
the therapists were invited to join the PPI meetings. In these meetings, the PPI group members were able to
ask the therapists questions and give suggestions. PPI group members asked the therapists if they found their
job difficult and whether or not there were any challenges with delivering the intervention. The therapists
explained that they were well supported and that they enjoyed their role. The PPI group members felt that
this was crucial to the success of the study. Another question asked by the PPI group was whether the
therapists felt that having the carer being present during therapy was helpful or not. The therapists explained
that the carer provided support to the patient. One of the therapists said that they made sure they addressed
any discussion or questions to the participant directly, so that they could choose when they wanted their
carer to answer on their behalf.
Fidelity assessment
To ensure the fidelity of the intervention, the content of treatment was described and analysed against
the manual.
Therapy sessions were video recorded to ensure that the treatment was being delivered in accordance with
the manual and to be potentially used for future training. The plan was to select participants and sessions
iteratively, using purposive sampling to represent the range of severity of depression (mild, moderate,
severe from baseline scores) and across the phases of therapy (beginning, middle and end). We planned to
video record up to 24 therapy sessions (based on recruiting the target sample size). It was anticipated that
more sessions would be recorded in the middle phase of therapy because this covered more of the therapy
sessions and is when the majority of the BA intervention occurs.
The video recordings were transferred to a secure encrypted device, deleted from the video recorder prior
to transportation and stored in a secure area on the University of Nottingham server.
Practices for video recording drew on guidance on minimising intrusiveness of the recording.77,78 Coding
of video recordings was carried out by an independent researcher using a time sampling procedure.
Recordings were made on the minute, every minute, throughout the recording. On each observation,
the activity of the therapist and participants was given the appropriate activity code.
The assessors analysing the video recordings applied a customised therapy record form designed to capture
a variety of key elements spanning all aspects of the intervention. The recordings included activities that
were expected in all sessions and those that were session specific. They also included content derived from
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the treatment manual and other content. The other content included activities that were likely to occur
but were not specified in the manual, such as social chat and making travel arrangements. A sample of
recordings was checked by another observer and discrepancies were resolved by discussion.
The video-recording categories are shown in Appendix 2.
Data from coding sheets were entered into Statistical Product and Service Solutions (SPSS) version 22
(SPSS Inc., Chicago, IL, USA) for analysis.
Health economic methods
Background
The health economic analysis had two key components that related to the primary end points of the trial:
1. assessing the feasibility of collecting data that may be used in a health economic analysis
2. conducting an economic evaluation and a value-of-information analysis in order to provide information
on the potential value of conducting the definitive trial.
Overview
For the feasibility analysis, the number of participants who had complete data for each of the key measures
is reported for each time point by treatment group and overall. For patient and carer questionnaires, the item
response rate at each visit (baseline and 6 months) is reported. Response rate was measured as a fraction of
the total number of items. This provides an analysis of the feasibility of collecting data required to complete a
health economic analysis. For the health economics analysis, the data of most relevance are those from the:
l EQ-5D-5L – standard version (completed by participants who are able)
l EQ-5D-5L – aphasia-accessible version (completed by all participants)
l EQ-5D-5L – completed by the carers of participants for themselves
l EQ-5D-5L – completed by the carers of participants on behalf of the participant
l resource use questionnaire.
For the economic evaluation, a series of cost-effectiveness analyses were conducted:
l within-trial analysis from a NHS and Personal Social Services (PSS) perspective
l within-trial analysis from a societal perspective
l model-based analysis from a NHS and PSS perspective
l model-based analysis from a societal perspective.
Owing to the importance of carers for people with post-stroke depression, it was important to include
analyses undertaken with a societal perspective to supplement the NHS and PSS analyses.
The within-trial analyses were undertaken both with and without multiple imputation, which was used
to estimate values for missing data. Patient-level costs and outcomes were assessed over the full length of
the feasibility study and this was supplemented with the construction of a simple economic model to
examine the longer-term cost-effectiveness of treatment and priorities for future research. Costs and
utilities were estimated for individual patients using data collected at baseline and follow-up, based on
responses to EQ-5D-5L and resource use questionnaires, combined with standard cost and valuation
sources.79,80 Differences between costs and quality-adjusted life-years (QALYs) in the two groups were
described and the incremental cost-effectiveness ratio (ICER) was calculated.
METHODS
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The main aim of the BEADS trial was to assess the feasibility of conducting a future definitive RCT to
investigate the clinical and cost-effectiveness of BA therapy for people with post-stroke depression.
Therefore, our analysis cannot provide conclusive cost-effectiveness results. However, early cost-effectiveness
modelling remains of value because it provides insight into the likely cost-effectiveness of the intervention
and demonstrates the value of pursuing further research, particularly when value-of-information analyses are
included.81,82 The value-of-information framework allows the maximum value of further research to be
estimated, taking into account the uncertainty in the parameters included in the economic model.83,84 We
estimated the expected value of perfect information (EVPI), representing the maximum value of further
research on all uncertain parameters in the economic model, and also estimated the expected value of
perfect partial information (EVPPI), representing the maximum value of obtaining more information on each
specific parameter (or group of parameters) included in the model.
Resource use
Costs were estimated for each participant, including intervention costs (based on staff time and number of
sessions) and health-care resource use. Questionnaires were tested as a method for collecting resource use
data. The resource use questionnaire included questions about a participant’s use of health services over
the previous 3 months, representing the final 3 months of the follow-up period. As data were required
for the entire 6-month follow-up period, we assumed that costs for the first 3 months were the same as
for the final 3 months. In the questionnaire, resources were split by services, such as inpatient, outpatient,
primary care and community services, and, where necessary, included average appointment length.
Participants were also asked to record dosages of medication relating to depression, and information about
carer time and employment. This information was used to calculate total medical costs and societal costs.
Unit costs
Resource use data were combined with unit cost data from the latest versions of the Personal Social
Services Research Unit (PSSRU) unit cost publication,85 NHS reference costs79 and the British National
Formulary86 in order to calculate costs for inclusion in the economic analysis. When appropriate values
were not available from the latest version of the PSSRU unit costs publication, earlier versions were
consulted87–89 and prices were inflated using the hospital and community health services index.85
The unit costs used to estimate the costs associated with the resource use observed in the trial are
presented in Appendix 3.
Outcomes
Participants who did not have moderate or severe language problems were asked to complete the
standard version of the EQ-5D-5L as well as an amended (and as yet unvalidated) accessible version (based
on pictures).57 Participants who had moderate to severe language problems were asked to complete the
accessible version of the EQ-5D-5L. In addition, for participants who had carers, the carer was asked to
complete a standard EQ-5D-5L by proxy. This allowed us to test alternative methods for collecting data
from which to calculate QALYs.
Analysis
Within-trial analysis
Utility scores, based on EQ-5D-5L responses, were calculated for participants at baseline and follow-up.
Differences in costs and QALYs between the two groups were estimated over the 6-month trial period
using seemingly unrelated regression (SUR). SUR allows for correlation between costs and utility data.90–92
The SUR model was specified to adjust for baseline EQ-5D-5L as suggested by Manca et al.93 and also
adjusted for baseline (pre-randomisation) costs. The regression was run for participants with no missing
data (complete cases) and also for all participants including imputed values for costs and utilities.
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For missing EQ-5D-5L data, multiple imputation was used as described in Analysis populations. Predictive
mean matching was used to impute the missing data for costs using a chained regression.94 Thirty
imputations were generated for each missing value and the mean of these was used in the final imputed
data set analysis. Differences between costs and QALYs were summarised using the ICER and CIs were
algebraically determined by using the variance–covariance matrix.
A supplementary societal perspective analysis involved costing carer time associated with each participant
(collected using the resource use questionnaire) using the human capital approach.95 The resource use
questionnaire also collected data on employment changes and private care costs, which were incorporated
in the societal analysis.
Model-based analysis
The trial-based analysis was supplemented with an analysis using a simple decision-analytic model, used to
estimate the cost-effectiveness of the intervention over the lifetime of participants. This was populated
using the trial data combined with unit costs and mortality rates as well as assumptions regarding the
maintenance of the treatment effect over time. The base-case analysis was undertaken from a NHS and
PSS perspective, but a supplementary societal analysis was also undertaken.
The structure of the model (Figure 1) was based on that used to estimate the cost-effectiveness of
computerised aphasia treatment compared with usual stimulation in the CACTUS study.70 A simple three-state
Markov model was used to extrapolate the data from the trial to a simulated cohort over a lifetime horizon.
Participants entered the model in the no response state. Each month, they could remain in this state or
transition to the good response state or death. Once in the good response state, participants could remain
in this state or move back to the no response state or to death.
Transition probabilities were primarily based on the trial data. The primary clinical outcome measure
was the PHQ-9; therefore, we based our definition of ‘good response’ on PHQ-9 scores. Specifically,
participants moved from the ‘no response’ state to the ‘good response’ state if they achieved a 4.78-point
decrease in PHQ-9 score from baseline to follow-up. This definition of a response was chosen based on
the minimum important clinical difference of PHQ-9 reported by Löwe et al.75 In the model, we assumed
that the intervention would be given over 4 months, as in the trial, and a response (if achieved) would
occur after 3 months. As the trial had only one follow-up time point, it was not possible to estimate a
relapse rate for a good response. Hence, in the base case, it was assumed that the relapse rate was zero.
A sensitivity analysis was carried out to estimate the effect on cost-effectiveness of changing the relapse
rate; in this analysis, it was assumed that participants in the ‘good response’ state could move back to the
‘no response’ state after 6 months.
Transitions from the ‘no response’ and ‘good response’ states to death were based on evidence on
long-term survival following stroke,96 combined with background mortality rates from the Office for
National Statistics,97 reflecting the approach taken in a previous economic evaluation of an intervention for
people with aphasia.70 The same mortality rate was used for the ‘no response’ and ‘good response’ states.
No
response
Good
response
Dead
FIGURE 1 Markov model.
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The HRQoL utility scores applied to each health state were reduced over time on the basis of multipliers
estimated by Ara and Brazier.98 QALYs were estimated for each cycle of the model by combining utility
scores with life-years, allowing the total QALYs associated with each treatment strategy to be calculated.
Costs and QALYs were discounted at a rate of 3.5% each year, in line with recommendations made by
the National Institute for Health and Care Excellence (NICE).99
Distributions were placed around each of the uncertain parameters included in the model for use in
probabilistic sensitivity analysis (PSA), which allowed the estimation of cost-effectiveness acceptability
curves (CEACs) and a value-of-information analysis. Gamma distributions were used for costs, log-normal
distributions for utilities, and beta distributions for probabilities, with dispersions based on numbers
observed in the trial. The PSA was supplemented with deterministic scenario analysis on the relapse
rate as this was not observed directly in the trial.
The EVPI and EVPPI analyses were undertaken assuming a cost-effectiveness threshold of £20,000 per
QALY gained (based on NICE decision rules99) over a 10-year period (assuming that it might take 10 years
before a new treatment for these patients is developed), using a 3.5% discount rate. The Sheffield
Accelerated Value of Information tool100 was used to estimate the EVPI and EVPPI.
The qualitative research
A series of qualitative interviews with a sample of participants and carers (from both the intervention and
the control arms of the study), as well as all three therapists, were completed by an independent researcher
to provide a description of the acceptability of the design and procedures used in the trial and the BA
intervention. We interviewed 16 participants and 10 carers. The participant and carer interviews were
completed in the interviewees’ homes (or an agreed convenient, private location) and the therapist
interviews were completed in private locations, as agreed with the researcher. Participants and carers were
interviewed after 6-month outcome assessments had been completed. Therapists were interviewed after
they had completed all therapy sessions for the study. The interviews took between 10 and 55 minutes.
All participants were provided with information concerning the purpose of the study, issues relating to
confidentiality and anonymity of the data, and their rights as a participant. All participants provided
informed consent to participate in the interview, which was also audio recorded on an encrypted digital
recorder and transferred to a secure area on the University of Nottingham server. The researcher transcribed
all of the interviews; the transcripts did not include any personal identifiers and the recordings were deleted
on completion of the transcription.
Interviewer characteristics
Three women and one man conducted the interviews with patient and carer participants. They were
Doctor of Philosophy (PhD) students and research assistants who were registered allied health professionals
(one was a speech and language therapist) or working towards gaining professional registration as an
allied health professional (psychologist). They had experience of working with people with neurological
conditions and had been trained to conduct interviews with patients and carers, including those with
reduced language and cognitive ability. Dr Gogem Topcu, who has expertise in health psychology and
research into long-term conditions, conducted the therapist interviews. She is an experienced qualitative
researcher who has adopted a realist pragmatic approach to research; she had no previous experience of
conducting BA therapy.
Relationship with participants
The interviewers’ role was to guide and facilitate the interview, rather than impose how the interview
proceeded. The interviewers had no involvement in the delivery or provision of care for the participants
and participants were aware of this. The person who interviewed the therapists did not have any prior
relationship with the therapists. The interview analysts did not have a personal view on the benefits or
limitations of the intervention or about participants’ experience of taking part in the study.
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Theoretical and thematic framework
A framework approach was adopted, which is a hierarchical, matrix-based method for ordering and
synthesising qualitative data.101,102 This approach enables in-depth exploration of the data while
simultaneously maintaining an effective and transparent audit trail.101,103 Adopting this approach
consolidated the rigour of the analysis and the credibility of the findings.
The thematic framework was constructed iteratively from the interview objectives and existing literature
(e.g. previous trials of BA) as well as the issues the participants raised during the interviews. We followed
Ritchie and Spencer’s102 approach in arriving at the final thematic framework, which began with familiarisation
of the transcripts and audio recordings of the interviews to gain an overview of the data, noting salient points
and recurrent ideas. The thematic framework was further consolidated by amalgamating the notes taken
during the familiarisation process and the a priori issues covered in the interview schedule and extant literature.
However, we did keep an open mind to incorporate material that did not fit within our predefined structure,
and iteratively checked whether or not additional themes were warranted or whether or not some predefined
themes needed to be minimised in terms of importance or relevance, based on the interview (see Appendix 4
for a worked example of an audit trail of how a framework was developed and amended).
Participant selection
We used a purposive, maximum-variation sampling strategy to select participants and their carers for
the interview phase. We attempted to recruit a heterogeneous sample based on their demographic and
stroke characteristics. The selection strategy was designed to balance the sample of participants in the
following categories:
l recruitment site
l treatment arm
l sex of participant
l level of depression (mild, moderate or severe)
l aphasia status
l recruitment (early or late to the study).
As there was a large number of stratification factors, we prioritised selecting participants by site and
treatment arm, and then by the other factors. The sample size was guided by our previous experiences
of soliciting feedback about trials from stroke survivors and patients with neurological conditions (e.g.
das Nair and Lincoln104), whereby we felt that we were able to achieve sufficient detail related to each
construct under investigation, and the categories had ‘conceptual depth’.105 We were also guided by the
limits placed by the recruitment process of the main trial and our framework analysis method. Our primary
criterion for conceptual depth related to the question, ‘Do we have sufficient data for each key question
that represents rich, nuanced, wide ranging experiences, that resonate with (agree or depart from) the
extant literature?’ (cf. Nelson106). Therefore, we did not seek to achieve ‘data saturation’ per se. The trial
therapists from each participating site were invited to take part in interviews about their experiences of
working on the trial and delivering the intervention.
Data collection
The interviewers had sufficient knowledge of the interview schedule to loosely follow the questions in line
with interests and views offered by the participant. Although a predetermined and structured schedule
was used to conduct the interviews, the interviews were flexible, allowing the emergence of issues relevant
and important to interviewees that were not in the initial schedule. This allowed participants to say what
they felt was important to them, while maintaining a basic framework of inquiry at the same time.
Prompts were used throughout interviews to provide cues when participants had difficulties, to clarify
questions and encourage responding.
METHODS
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The interview schedule included general questions for all participants and carers concerning their
experiences of participating in the study, and specific questions to those who had received the intervention
and those who were in the control group (see Appendices 5 and 6). An accessible version of the interview
questions was also developed for participants with aphasia. The interview schedule for therapists included
questions relating to therapists’ experiences of delivering the therapy, views on the trial procedures and
practical aspects of delivering the therapy (see Appendix 7). Interviews were transcribed verbatim.
The transcripts did not include any personal identifiers and the recordings were deleted on completion
of the transcription.
Data analysis
Data analysis was undertaken by Gogem Topcu using the framework approach,101,102 for which the data
were mapped onto the constructed thematic framework. If required, the framework was amended to
include new concepts or themes introduced during the interviews. To map the data onto the theoretical
framework, we relied on indexing various sections of the data to specific thematic constructs. This, again,
was an iterative process, requiring Gogem Topcu to go back to previously analysed transcripts to check
whether or not the newly emerged construct was also evident there. After mapping all the data, a matrix
was generated in which the data were charted to summarise each main theme. This matrix was then
used in the interpretation of the data in addition to the notes made during the coding process. The
interpretation process, like the other processes, was iterative and relied on consultation between Gogem
Topcu and Roshan das Nair regarding the viability and relevance of a theme, to interrogate theoretical
constructs, and to unpack nuances within the data.
To ensure rigour and credibility of the findings, Roshan das Nair reviewed the generated matrix and
checked the quotations for their relevance to the themes. Disagreements were resolved by discussion.
We provided information regarding the context in which the interviews were conducted, some pertinent
descriptions of the interviewers and interviewees, and some verbatim quotations from our participants,
to ensure transparency. To ensure quality of study reporting, we used the COnsolidated criteria for
REporting Qualitative research (COREQ) checklist (see Appendix 8).
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Chapter 3 Results of the feasibility trial
Implementation of the intervention and trial
Implementation summary
The trial was due to start recruitment at the beginning of May 2015 but, owing to delays in set-up,
recruitment did not start until 27 May 2015 in site 3, 20 August 2015 in site 1 and 3 September 2015 in
site 2. This resulted in a total of 27 recruitment months available rather than the planned 36 months.
Recruitment ended as planned on 30 April 2016. Follow-up was completed in November 2016. There
were a number of issues in regard to recruitment, data collection and delivery of the interventions, which
are discussed below.
In order to maintain anonymity, the sites will be referred to as ‘site 1’, ‘site 2’ and ‘site 3’ rather than by
their geographical name.
Recruitment and participant flow
Recruitment to the trial
The study set out to assess feasibility of recruitment by utilising a number of different recruitment routes
including hospital database, community database, stroke ward, community caseload, voluntary group,
self-referral and outpatients. The CONSORT flow diagram (Figure 2) shows the flow of participants through
the trial. See Chapter 2, Feasibility criterion, for the primary end points referred to in the analysis section.
Table 2 displays a summary of recruitment flow by screening route and Table 3 shows the number identified
by the different screening routes for each site. The number randomised signifies the success of each route;
however, it is necessary to discuss each method in turn to understand its individual efficiency fully. Overall,
we randomised 49 participants to the trial in 27 centre-months of recruitment (one participant was
randomised in error and was not included in analysis, and one participant withdrew consent 5 days after
randomisation and was included in analysis). Recruitment by centre can be seen in Table 4 and numbers
recruited by the recruitment route can be seen in Table 5.
Table 6 shows that 28 out of a possible 33 carers were recruited to the study. These carers were evenly
spread across treatment arms and centres. Table 7 shows the reasons why a small number of carers (n = 5)
refused to consent to the trial.
Hospital database
The highest number of participants was recruited through the hospital database. Therefore, this could be
considered the most efficient method as it required only minimal staff time. However, uptake seemed to
be even more effective if a potential participant was approached by a clinician and given the opportunity
to discuss the study and ask questions. It is worth noting that the success of this route varied between the
sites. In site 1, the hospital database was the most effective route of recruitment. However, the therapist
in site 1 was based in the hospital setting and worked closely to support the CRN nurse to identify and
recruit participants. By comparison, the therapists at the other two sites were frequently based at different
hospitals from the CRN nurse and, therefore, worked less closely with the latter.
Stroke ward
Based on the values in Table 3, the stroke ward seemed to be the least effective recruitment route.
Although research nurses had the opportunity to approach inpatients on the stroke ward to discuss the
study, participants did not become eligible to take part until 3 months after their stroke. The protocol
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Number screened
(n = 756)
No response
(n = 349)
Ineligible at screening
(n = 69)
Did not complete questionnaires
(n = 87)
Eligible but did not want to continue
(n = 7)
Eligibility assessment arranged but not conducted
(n = 6)
Did not consent
(n = 0)
Not approached
(n = 312)
Not interested
(n = 44)
Contact details not taken
(n = 3)
Deceased
(n = 2)
Visit cancelled
(n = 5)
Sent pack or home visit arranged
(n = 574)
Pack returned/visit complete
(n = 225)
Eligible at screening
(n = 69)
Asked for consent
(n = 49)
Baseline
(n = 49)
Randomised
(n = 49)a
Allocated to intervention
(n = 26)a,b
Received intervention
(n = 20)
Did not receive intervention
(n = 6)a,b
Assessed for eligibility
(n = 56)
PHQ-9 score of > 10 points or
VAMS  SAD score of > 50 points
6-month follow-up
(n = 18)
Lost to follow-up
(n = 5)
Withdrew consent
(n = 2)
Investigator decision
(n = 1)
Assessed for primary end point (a)
(n = 26)
Assessed for primary end point (b)
(n = 26)
Assessed for primary end point (c)
(n = 18)
Assessed for primary end point (d)
(n = 18)
Assessed for primary end point (e)
(n = 18)
Allocated to control
(n = 23)
Received usual care
(n = 23)
Did not receive usual care
(n = 0)
6-month follow-up
(n = 21)
Lost to follow-up
(n = 1)
Investigator decision
(n = 1)
Assessed for primary end point (a)
(n = 23)
Assessed for primary end point (b)
(n = 23)
Assessed for primary end point (c)
(n = 21)
Assessed for primary end point (d)
(n = 21)
Assessed for primary end point (e)
(n = 21)
Not eligible
(n = 7)
• Not between 3 months and 5 years post stroke, n = 1
• Not depressed, n = 1
• Received treatment for depression, n = 4
• Communication and visual difficulties, n = 1
ControlIntervention
FIGURE 2 Study CONSORT flow diagram. a, One participant was randomised in error (found to be ineligible within
days of being randomised), this participant was excluded from analyses; b, one participant withdrew consent 5 days
after randomisation, this participant was included in analyses.
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TABLE 2 Summary recruitment flow, by screening route
Identified
Screening route, n (%)
Hospital database
(N= 444)
Community database
(N= 8)
Stroke ward
(N= 183)
Community caseload
(N= 80)
Voluntary group
(N= 9)
Self-referral
(N= 4)
Outpatients
(N= 28)
Pack sent/home visit arranged 444 (100.0) 8 (100.0) 64 (35.0) 24 (30.0) 9 (100.0) 3 (75.0) 22 (78.6)
Pack received/home visit conducted 156 (35.1) 2 (25.0) 12 (6.6) 22 (27.5) 9 (100.0) 3 (75.0) 21 (75.0)
Questionnaires completed 74 (16.7) 1 (12.5) 11 (6.0) 20 (25.0) 9 (100.0) 3 (75.0) 20 (71.4)
Initial eligibility met 29 (6.5) 1 (12.5) 3 (1.6) 13 (16.3) 4 (44.4) 3 (75.0) 16 (57.1)
Eligibility appointment conducted 25 (5.6) 1 (12.5) 2 (1.1) 10 (12.5) 3 (33.3) 3 (75.0) 13 (46.4)
Eligible 21 (4.7) 1 (12.5) 1 (0.5) 8 (10.0) 2 (22.2) 3 (75.0) 13 (46.4)
Consent obtained 21 (4.7) 1 (12.5) 1 (0.5) 8 (10.0) 2 (22.2) 3 (75.0) 13 (46.4)
Randomised 21 (4.7) 1 (12.5) 1 (0.5) 8 (10.0) 2 (22.2) 3 (75.0) 13 (46.4)
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indicated that the therapists should perform a mortality check prior to contacting patients at 3 months
post stroke. However, this follow-up might not always have taken place. Furthermore, in this early stage,
some stroke patients were focused more on dealing with practical issues, such as walking and talking,
rather than with their mood.
Community database
Identifying patients through the community stroke databases was not used consistently across the three
sites. Community stroke services varied between trusts, and records were kept less consistently than in
secondary care. For a definitive study, it would be important to discuss the composition of community
services available to improve understanding of specific recruitment routes at the outset.
Community caseload
This route was used by the study therapists to identify current community patients. Approaching patients
by telephone or face to face was more effective than the community database route as it allowed the
patients an opportunity to discuss the study, although it was more time-consuming for staff.
Voluntary group
The protocol specified that the therapist could attend stroke and aphasia groups to explain the study and to
collect contact details of those interested, although this route was time-consuming and not successful in
recruiting many participants. However, if the protocol had been less prescriptive and allowed for the people
who run the voluntary groups to discuss the study and collect contact details on behalf of the therapists, it
may have been possible to make this route a more efficient method for a definitive study. Site 3 was the only
site that recruited through this route. The therapist in site 2 reported that recruitment from voluntary groups
was unfruitful as many members were not eligible, few had low mood and many were > 5 years post stroke.
Self-referral
According to Table 3, this route appears very effective; however, few participants were recruited this way.
This route could be more efficient if the study had been advertised more widely in the press and through
social media.
Outpatients
It could be suggested that this route was successful because patients were screened and identified by
clinical care teams in outpatient settings, allowing for the opportunity of face-to-face discussions with
patients about the study. This route was particularly successful at one site (site 3), with the principal
investigator (PI) and therapist being based in the community team and patients being referred post stroke.
TABLE 3 Number identified by screening routea
Route
Site, n (%)
1 2 3 Total
Community caseload 10 (2.6) 63 (22.7) 7 (7.9) 80 (10.6)
Community database 0 (0.0) 8 (2.9) 0 (0.0) 8 (1.1)
Hospital database 198 (50.8) 193 (69.7) 53 (59.6) 444 (58.7)
Outpatients 4 (1.0) 7 (2.5) 17 (19.1) 28 (3.7)
Self-referral 2 (0.5) 1 (0.4) 1 (1.1) 4 (0.5)
Stroke ward 176 (45.1) 5 (1.8) 2 (2.2) 183 (24.2)
Voluntary 0 (0.0) 0 (0.0) 9 (10.1) 9 (1.2)
a One participant from the hospital database was randomised in error.
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TABLE 4 Participants randomised, by centre and by montha
Site
Month (n)
Total
(n)July 2015 August 2015 September 2015 October 2015 November 2015 December 2015 January 2016 February 2016 March 2016 April 2016b
1 0 0 1 5 5 0 4 0 3 6 24
2 0 0 0 0 0 1 2 0 2 2 7
3 1 1 2 1 1 2 3 2 2 3 18
a Recruitment start dates: site 1 opened 20 August 2015, site 2 opened 3 September 2015 and site 3 opened 27 May 2015.
b One participant was randomised in error at site 2.
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This outpatients route was for community-based patients and not hospital outpatients. Outpatients
differed from community caseload as this is a longer-term service, identifying participants who were at a
longer time point post stroke.
Protocol non-compliances
Table 8 shows protocol non-compliances reported, by site and category. All of the issues identified as
non-compliances could be incorporated into site staff training for a future definitive trial.
We also reported a non-compliance relating to the inconsistency in using the CST during recruitment;
this is discussed in further detail in Challenges with recruitment and data collection.
In addition to the non-compliance reports, there was one instance of unblinding occurring at a 6-month
outcome visit in which a participant revealed their allocation to an outcome assessor.
TABLE 5 Number recruited by the recruitment route
Recruitment route
Site, n (%)
Total, n (%)1 2a 3
Community caseload 4 (16.7) 1 (14.3) 3 (16.7) 8 (16.3)
Community database 0 (0.0) 1 (14.3) 0 (0.0) 1 (2.0)
Hospital database 14 (58.3) 4 (57.1) 3 (16.7) 21 (42.9)
Outpatients 3 (12.5) 0 (0.0) 10 (55.6) 13 (26.5)
Self-referral 2 (8.3) 1 (14.3) 0 (0.0) 3 (6.1)
Stroke ward 1 (4.2) 0 (0.0) 0 (0.0) 1 (2.0)
Voluntary 0 (0.0) 0 (0.0) 2 (11.1) 2 (4.1)
a One participant from the hospital database was randomised in error.
TABLE 6 Number of carers recruited to BEADS trial, by treatment arm and site
Treatment arm Participants with carers, n (%) Carers recruited, n (%)
Overall 33 (68.8) 2 (84.8)
Treatment arm
Intervention 17 (68.0) 15 (88.2)
Control 16 (73.9) 13 (81.2)
TABLE 7 Reasons for non-consent given by carers
Reason for carer non-consent n (%)
Carer not present at time to give consent 3 (40)
Carer does not speak English 1 (20)
Carer does not have enough time and is not interested in participating in research 1 (20)
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Losses and exclusions after randomisation
Table 9 shows the number and percentage of participants who dropped out of the trial by treatment arm, site
and length of time since stroke. Attrition is defined here as the number of participants who did not complete
the primary outcome (PHQ-9) at 6 months post randomisation. (See Appendix 9 for an outline of the reasons,
where given, for dropout.) A total of nine participants dropped out of the trial during the 6-month follow-up
period. Of these nine participants, seven were in the intervention arm. All of the participants who dropped
out of the study had their most recent stroke between 3 and 12 months previously.
Participants lost to follow-up
Table 10 shows the method for completion of 6-month follow-up data. Reminders involved a telephone
call to the participant or carer. We aimed to test the feasibility of collecting 6-month outcome data by post
compared with in person using a blinded outcome assessor. For a definitive RCT, it may be necessary to
implement additional measures to further minimise loss to follow-up (e.g. reminder telephone calls rather
than the initial reminder letter to identify those who need a home visit to complete the questionnaires
sooner, sending regular newsletters to participants during the follow-up period to maintain engagement
with the study, and offering vouchers to participants to encourage return of postal questionnaires).
TABLE 8 Non-compliances reported in the trial
Non-compliances
Site (n)
Total (n)1 2 3
Delegation log 2 0 0 2
Eligibility 0 1 0 1
Intervention delivery 0 0 1 1
Failure to report SAE 0 1 0 1
TABLE 9 Attrition presented by treatment arm, site and time since stroke
Treatment arm, site and
time since stroke
Attrition, n (%)
Overall
attrition,
n (%)Number
Withdrew
consent
Intervention
withdrawal and
decision not to
follow-up
Investigator
decision:
patient too ill
Lost to
follow-upa
Overall 48 1 (11.0) 1 (11.0) 1 (11.0) 6 (67.0) 9 (18.8)
Treatment
Intervention 25 1 (11.1) 1 (11.1) 0 (0.0) 5 (55.6) 7 (28.0)
Control 23 0 (0.0) 0 (0.0) 1 (11.1) 1 (11.1) 2 (8.7)
Site
1 24 0 (0.0) 0 (0.0) 1 (11.1) 4 (44.4) 5 (20.8)
2 6 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
3 18 1 (11.1) 1 (11.1) 0 (0.0) 2 (22.2) 4 (22.2)
Time since strokeb
3 months to 1 year 30 1 (11.1) 1 (11.1) 6 (66.7) 1 (11.1) 9 (30.0)
1–2 years 12 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
2–4 years 6 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
a One participant completed follow-up but did not complete the PHQ-9. This participant did not have aphasia.
b The mean number of days since last stroke in participants who dropped out is 231.6 days (SD 76.1 days) with a
minimum of 108 days and a maximum of 343 days.
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Dates defining the periods of recruitment and follow-up
Data collected outside the data collection window
It was agreed that data would be accepted within 4 weeks before or after the 6-month time point.
However, data from four participants were collected outside this data collection window as collection was
delayed because of illness.
Delay in randomisation following initial eligibility measures
During the analysis, there were some delays between completion of the initial eligibility measures and
randomisation. In most cases, there was a delay of between 7 and 30 days between completing the initial
eligibility and randomisation, which was probably due to the availability of the therapist and the patient
in arranging a home visit (see Appendix 10). However, nine participants had a delay of > 30 days. Each
therapist could only deliver the therapy to a limited number of participants at one time and, therefore,
some participants had to wait for therapist availability. The PHQ-9 score collected at initial eligibility is
considered the baseline PHQ-9 and, therefore, because of these delays the time point between baseline
and 6-month PHQ-9 is not always the same. For a definitive trial, we would suggest setting a time frame
between collecting initial eligibility and full eligibility at baseline.
Baseline data
Demographic information, patient- and carer-reported outcomes and stroke-related outcome data for
randomised participants by treatment arm can be seen in Tables 11–14.
The PHQ-9 has a range of 0–27 points, with low scores indicating a low level of depression. VAMS ‘Sad’
item has a range of 0–100 points, with low scores indicating a low mood. EQ-5D-5L standard scores
can range from –0.281 to 0.951, with 0, 1 and negative values corresponding to death, full health and
health states worse than death, respectively. NLQ scores range from 0 to 60, with a low score indicating
a low level of leisure activity. NEADL scores range from 0 to 22, with low scores corresponding to lower
independence. SADQ scores range from 0 to 63 on the SADQ-H, with low scores indicating a low level of
depression. This questionnaire was completed by carers. CSI scores range from 0 to 13, with low scores
corresponding to a low level of strain on the carer.
TABLE 10 Number of participants who completed follow-up, by home visit and postal pack
Methods
Follow-up
Home visit Postal pack
Total, n (%) 17 (37.0) 29 (63.0)
Visit arranged/pack sent, n (%) 16 (94.1) 28 (96.6)
Visit conducted/pack returned, n (%) 14 (87.5) 24 (85.7)
At least one reminder contact, n (%) 1 (6.2) 11 (39.3)
Mean (SD) number of reminders 0.1 (0.2) 0.8 (1.5)
Reminder resulted in completed questionnaires, n (%) 1 (100.0) 8 (72.7)
Other method used, n (%) 0 (0.0) 2 (6.9)
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TABLE 11 Baseline demographics, by treatment arm
Demographic characteristics
Treatment arm
OverallIntervention Control
Age (years)
n 25 23 48
Mean (SD) 62.6 (14.5) 68.8 (12.1) 65.6 (13.6)
Median (IQR) 65 (53–72) 67 (60–75) 66 (55–75)
Minimum, maximum 31, 88 40, 97 31, 97
Sex, n (%)
Male 17 (68.0) 12 (52.2) 29 (60.4)
Female 8 (32.0) 11 (47.8) 19 (39.6)
Ethnicity, n (%)
White 25 (100.0) 22 (95.7) 47 (97.9)
Asian 0 (0.0) 1 (4.3) 1 (2.1)
TABLE 12 Baseline outcome measures, by treatment arm
Measures
Treatment arm
OverallIntervention Control
PHQ-9 score (points)
n 25 23 48
Mean (SD) 16.3 (4.7) 17.3 (4.8) 16.8 (4.7)
Minimum, maximum 10, 25 10, 27 10, 27
PHQ-9 category
n 25 23 48
Moderate (10–14 points), n (%) 12 (48.0) 7 (30.4) 19 (39.6)
Moderately severe (15–19 points),
n (%)
6 (24.0) 9 (39.1) 15 (31.3)
Severe (≥ 20 points), n (%) 7 (28.0) 7 (30.4) 14 (29.2)
VAMS ‘Sad’ item score (points)
n 25 22 47
Median (IQR) 51 (39–74) 52 (41–83) 51 (39–82)
Minimum, maximum 3, 100 0, 96 0, 100
SADQ score (points)
n 15 12 27
Mean (SD) 25.3 (7.6) 18.8 (8.1) 22.4 (8.4)
Minimum, maximum 8, 35 5, 29 5, 35
continued
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TABLE 13 Stroke characteristics, by treatment arm
Stroke characteristics
Treatment arm
OverallIntervention Control
Modified Rankin Scale score (points)
n 24 23 47
Mean (SD) 3.2 (0.9) 3.2 (0.9) 3.2 (0.9)
Minimum, maximum 2, 4 2, 5 2, 5
FAST score
n 24 23 47
Median (IQR) 27 (22–29.5) 27 (22–29) 27 (22–29)
Minimum, maximum (18, 30) (12, 30) (12, 30)
FAST category
n 24 23 47
Aphasia (below cut-off point) 10 (41.6) 11 (47.8) 21 (44.7)
MoCA score (points)
n 24 23 47
Median (IQR) 22 (17.5–25) 22 (17–26) 22 (17–25)
Minimum, maximum 11, 30 4, 29 4, 30
TABLE 12 Baseline outcome measures, by treatment arm (continued )
Measures
Treatment arm
OverallIntervention Control
NLQ score (points)
n 24 23 47
Mean (SD) 16.2 (6.0) 13.1 (5.4) 14.7 (5.9)
Minimum, maximum 4, 29 5, 24 4, 29
NEADL score (points)
n 24 23 47
Mean (SD) 12.3 (7.2) 11.7 (6.0) 12 (6.6)
Minimum, maximum 2, 22 0, 21 0, 22
CSI score (points)
n 13 11 24
Mean (SD) 7.2 (3.6) 6.5 (2.7) 6.9 (3.2)
Minimum, maximum 1, 13 3, 11 1, 13
EQ-5D-5L score (points)
n 24 23 47
Mean (SD) 0.5 (0.3) 0.5 (0.3) 0.5 (0.3)
Minimum, maximum 0.045, 0.924 –0.218, 0.951 –0.218, 0.951
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A total of 25 participants were randomised to the intervention arm and 23 were randomised to the control
arm. The mean age of participants was 65.6 years (SD 13.6 years) and most participants were men (60.4%).
Site 1 recruited 24 participants, site 3 recruited 18 participants and site 2 recruited seven participants.
Mean scores were consistent across treatment arms. In most participants the time since stroke was
3 months to 1 year (62.5%). The proportion of participants who had had a previous stroke was higher in
the control arm (47.8%) than in the intervention arm (24%).
The proportion of men who had had a previous stroke was higher in the intervention arm (72.2%) than in
the control arm (52.4%).
Tables 15 and 16 show the baseline demographics and baseline outcome measures for participants
included in the primary effectiveness analysis.
TABLE 14 Stroke history, by treatment arm
Stroke history
Treatment arm, n (%)
Total, n (%)Intervention Control
Time from stroke
< 3 months 0 (0) 0 (0.0) 0 (0.0)
3 months to 1 year 16 (64) 14 (60.9) 30 (62.5)
1–2 years 7 (28) 5 (21.7) 12 (25.0)
2–4 years 2 (8) 4 (17.4) 6 (12.5)
Lateralisation of stroke
Left 11 (44) 9 (39.1) 20 (41.7)
Right 12 (48) 10 (43.5) 22 (45.8)
Unknown 2 (8) 4 (17.4) 6 (12.5)
Stroke type
Ischaemic 19 (76) 18 (78.3) 37 (77.1)
Haemorrhagic 6 (24) 4 (17.4) 10 (20.8)
Side of weakness
Left 13 (52) 10 (43.5) 23 (47.9)
Right 10 (40) 7 (30.4) 17 (35.4)
Bilateral 0 (0) 2 (8.7) 2 (4.2)
Unknown 2 (8) 4 (17.4) 6 (12.5)
Previous stroke
Yes 6 (24) 11 (47.8) 17 (35.4)
No 19 (76) 12 (52.2) 31 (64.6)
Depression treatment
Yes 10 (40) 12 (52.2) 22 (45.8)
No 15 (60) 11 (47.8) 26 (54.2)
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TABLE 15 Baseline demographics of the participants collected at baseline and 6-months’ follow-up, by treatment
arm (n= 39)
Demographic characteristics
Treatment arm
OverallIntervention Control
Age (years)
n 18 21 39
Mean (SD) 63.4 (11.8) 67.9 (10.7) 65.8 (11.3)
Median (IQR) 62.5 (54–72) 67.0 (64–75) 66.0 (56–75)
Minimum, maximum 47, 85 40, 89 40, 89
Sex, n (%)
Male 13 (72.2) 11 (52.4) 24 (61.5)
Female 5 (27.8) 10 (47.6) 15 (38.5)
Ethnicity/nationality, n (%)
English/Welsh/Scottish/Northern Irish/British 18 (100.0) 20 (95.2) 38 (97.4)
Pakistani 0 (0.0) 1 (4.8) 1 (2.6)
TABLE 16 Baseline outcome measures of the participants collected at baseline and 6-months’ follow-up,
by treatment arm (n= 39)
Measures
Treatment arm
OverallIntervention Control
PHQ-9 score (points)
n 18 21 39
Mean (SD) 16.2 (4.9) 16.9 (4.6) 16.6 (4.7)
Minimum, maximum 10, 25 10, 27 10, 27
VAMS ‘Sad’ item score (points)
n 18 20 38
Median (IQR) 59.5 (39–82) 52.0 (35.5–82.5) 56.0 (39–82)
Minimum, maximum 3, 100 0, 96 0, 100
SADQ score (points)
n 11 11 22
Median (IQR) 25 (22–32) 19 (13–28) 22 (14–29)
Minimum, maximum 8, 35 5, 29 5, 35
NLQ score (points)
n 18 21 39
Median (IQR) 17.5 (10–20) 14.0 (10–17) 16.0 (10–19)
Minimum, maximum 7, 29 5, 24 5, 29
NEADL score (points)
n 18 21 39
Median (IQR) 12.5 (5–20) 11.0 (10–18) 12.0 (8–18)
Minimum, maximum 2, 21 2, 21 2, 21
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Clinical outcomes and estimation
Primary clinical outcomes
A total of 39 out of the 48 randomised participants had valid PHQ-9 outcomes at follow-up (18 participants
in the intervention arm and 21 participants in the control arm). Table 17 shows a summary of the results
of the primary effectiveness analysis. Following adjustment for baseline and centre, we observed a mean
difference in PHQ-9 of –3.8 points (95% CI –6.9 to –0.58 points) at 6 months post randomisation. This
represents a reduction in depression in the BA arm.
Multiple imputation by chained equation was used to impute this missing outcome data; this was a
sensitivity analysis that increased the sample size back up to 48 (25 in the intervention arm, 23 in the
control arm). Adjusting for baseline and centre, we observed a mean difference in PHQ-9 score of
–3.4 points (95% CI –7 to 0.094 points) at 6 months post randomisation. This is shown in Figure 3.
Adjusted models included baseline measure and centre as a random effect (n = 39 in unadjusted and
adjusted analysis, n = 48 in MI adjusted and unadjusted analysis).
TABLE 16 Baseline outcome measures of the participants collected at baseline and 6-months’ follow-up,
by treatment arm (n= 39) (continued )
Measures
Treatment arm
OverallIntervention Control
CSI score (points)
n 9 10 19
Median (IQR) 7.0 (5–8) 5.5 (4–9) 6.0 (4–9)
Minimum, maximum 1, 13 3, 11 1, 13
EQ-5D-5L score (points)
n 18 21 39
Median (IQR) 0.466 (0.3–0.7) 0.599 (0.4–0.7) 0.563 (0.4–0.7)
Minimum, maximum 0.045, 0.893 0.206, 0.951 0.045, 0.951
TABLE 17 Primary effectiveness analysis on PHQ-9, adjusted for baseline PHQ-9 and centre as a random effect
Adjustment
Treatment arm
Mean difference in
PHQ-9a (95% CI)
Intervention Control
n Median (IQR) Mean (SD) n Median (IQR) Mean (SD)
Unadjusted 18 6.5 (5–15) 10.1 (6.9) 21 14 (10–17) 14.4 (5.1) –4.3 (–8.0 to –0.5)
Adjusted –3.8 (–6.9 to –0.58)
MI unadjustedb 25 23 –3.9 (–7.7 to –0.0041)
MI adjustedb 25 23 –3.4 (–7.0 to 0.094)
MI, multiple imputation.
a A negative mean difference implies that the intervention group had lower scores.
b PHQ-9 score was imputed using chained equations and 30 multiply imputed data sets. The multiple imputation model
included sex, age, treatment group, PHQ-9 at baseline and/or 6 months, EQ-5D-5L at baseline and 6 months, and SADQ
at baseline and 6 months as predictors.
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Previous research has suggested that the minimum clinically important difference or change for the PHQ-9
is 4.78 points on the scale.75 The 95% CI for the mean difference in PHQ-9 scores between the groups
includes a difference of ≥ 5 points, suggesting that the likely treatment effect is within a clinically
relevant range.
Figure 4 shows that in more participants in the intervention arm than in the control arm the PHQ-9 category
was reduced (horizontal dashed lines) from baseline to follow-up. Horizontal dashed lines represent the
cut-off scores for depression categories. This information is also presented in Table 18. Most participants in
the intervention arm were in the ‘moderate depression’ category at baseline (n = 9), whereas participants
in the control arm are distributed across three depression categories: ‘moderate’ (n = 7), ‘moderately
severe’ (n = 8) and ‘severe’ (n = 6). Most of the participants in the intervention arm reduced their level
of depression by one (n = 7) or two categories (n = 7) at the 6-month follow-up compared with baseline.
Most participants in the control arm stayed in the same category (n = 9) or reduced by one category (n = 6).
Table 18 shows that a greater number of participants in the intervention arm than in the control arm
decreased by one or two categories.
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FIGURE 3 Results from unadjusted and adjusted primary analyses showing mean difference between intervention
and control at 6 months.
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FIGURE 4 Line plot showing individual participant change in PHQ-9 score from baseline to follow-up, by treatment
arm. (a) Control; and (b) intervention.
TABLE 18 Summary of changes in PHQ-9 category, by treatment arm
Changes in PHQ-9 category
Treatment arm, n (%)
Intervention Control
Increased by one category 2 (11.1) 3 (14.3)
No change in category 2 (11.1) 9 (42.9)
Decreased by one category 7 (38.9) 6 (28.6)
Decreased by two categories 7 (38.9) 2 (9.5)
Decreased by three categories 0 (0.0) 1 (4.8)
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Figure 5 shows the mean PHQ-9 score in the intervention and control arms at baseline (n = 48) and
6 months (n = 39). Despite the intervention arm having a lower mean score at baseline, the decrease in
PHQ-9 score overall was greater in the intervention arm. The dashed lines represent the cut-off points for
PHQ-9 depression categories and show that the mean score in the intervention arm has reduced by one
depression category.
Figure 6 shows the relationship between PHQ-9 and VAMS ‘Sad’ item at baseline and 6 months post
randomisation. Correlation was found to be moderate at both baseline and follow-up (r = 0.45 and
r = 0.57, respectively). The level of agreement would be considered too low for VAMS ‘Sad’ item to be
used to impute PHQ-9.107
Secondary clinical outcomes
Table 19 shows the analysis of patient-reported secondary outcomes. In terms of the patient-reported
secondary outcomes, most of the differences suggest that the intervention has a small positive effect.
Table 19 shows the adjusted mean differences and their relative 95% CIs for the patient-reported
outcomes including VAMS ‘Sad’ item, NLQ, NEADL and EQ-5D-5L. VAMS ‘Sad’ item and NLQ both
suggest that the intervention has a positive effect although the 95% CIs include a difference of zero.
The NEADL does not demonstrate any difference between intervention and control arms. EQ-5D-5L
score is lower in the intervention arm, which suggests a small negative effect.
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FIGURE 5 Mean PHQ-9 score at baseline and 6-month follow-up, by randomised group by treatment arm (n= 48).
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Table 20 shows the analysis of carer-reported secondary outcomes. CSI score was lower in the intervention
group, which represents a positive effect. EQ-5D-5L Carer score was lower in the intervention arm, which
suggests a small negative effect of the intervention. SADQ score showed very little difference between
groups. CIs are wider because of smaller numbers of carers than participants. CIs around the adjusted mean
differences for carer-reported outcomes are very wide because of low numbers of carers who completed the
6-month follow-up (n = 22).
Standardised mean differences and their CIs can be seen in Figure 7, where arrows on the y-axis indicate
the direction of a positive intervention effect. Arrows on the y-axis indicate the direction of a desired
effect. Outcomes have been standardised onto a 0–100 scale.
Decision on the primary end point and sample size for a definitive trial
Sample size calculations
We calculated a range of sample sizes for a definitive scale trial comparing BA with usual care in patients
with post-stroke depression. The primary end point used was PHQ-9 score at 6 months post randomisation.
PHQ-9 has a range of 0–27 points, with low scores meaning a low level of depression. We assumed that a
target difference in PHQ-9 scores of approximately 5 points75 would be clinically and practically important,
but also used lower estimates of 3 and 4 points so as to produce a range of scenarios. A range of estimates
of SD (7, 9 and 11 points) were used, roughly based on the SDs observed in the pilot, which are subject to
considerable uncertainty. These scenarios give a range of standardised effect sizes of 0.27–0.71. From the
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FIGURE 6 Scatterplot showing correlation between standardised PHQ-9 and VAMS ‘Sad’ item at baseline and
6-month follow-up (n= 48 at baseline and n= 39 at 6 months). (a) Baseline (r= 0.45) and (b) 6 months (r = 0.57).
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TABLE 19 Secondary effectiveness analysis on patient-reported outcomes, adjusted for baseline and centre
Outcomes
Treatment arm
Mean difference (95% CI)
Intervention Control
n Median (IQR) Mean (SD) n Median (IQR) Mean (SD)
VAMS ‘Sad’ item
Unadjusted 19 39.0 (10–64) 39.8 (28.5) 21 54.0 (34–69) 48.6 (24.7) –8.8 (–26.0 to 8.2)
Adjusted –8.6 (–25.0 to 7.7)
NLQ
Unadjusted 18 17.5 (14–26) 20.5 (9.1) 21 15.0 (12–20) 15.6 (5.5) 4.9 (0.087 to 9.7)
Adjusted 3.2 (–0.96 to 7.3)
NEADL
Unadjusted 18 12.0 (5–18) 12.0 (7.1) 19 11.0 (6–17) 11.6 (6.1) 0.37 (–4.0 to 4.8)
Adjusted –0.032 (–2.2 to 2.1)
EQ-5D-5L
Unadjusted 18 0.6 (0.33–0.71) 0.5 (0.3) 20 0.7 (0.47–0.82) 0.6 (0.2) –0.12 (–0.29 to 0.054)
Adjusted –0.04 (–0.17 to 0.092)
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TABLE 20 Secondary effectiveness analysis on carer-reported outcomes, adjusted for baseline and centre
Outcomes
Treatment arm
Mean difference (95% CI)
Intervention Control
n Median (IQR) Mean (SD) n Median (IQR) Mean (SD)
SADQ
Unadjusted 10 23.5 (20.0–27.0) 23.5 (8.7) 11 17.0 (13.0–25.0) 17.6 (7.4) 5.9 (–1.5 to 13.0)
Adjusted –0.55 (–6.5 to 5.4)
CSI
Unadjusted 9 4.0 (1.0–7.0) 5.1 (4.5) 10 7.5 (2.0–9.0) 6.0 (3.5) –0.89 (–4.8 to 3.0)
Adjusted –2.0 (–4.9 to 0.84)
EQ-5D-5L Carer
Unadjusted 12 0.8 (0.67–0.87) 0.7 (0.2) 10 0.8 (0.75–0.87) 0.8 (0.2) –0.062 (–0.23 to 0.11)
Adjusted –0.052 (–0.24 to 0.14)
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feasibility study, data were used to calculate the ICC of 0.06 in the intervention arm based on clustering by
site. We also assumed an average cluster size of around 20 participants per therapist/site. Furthermore, the
attrition rate of 18.8% was rounded up to 20% over 6 months and was used to adjust the final sample
size calculation.
A sample size of 580 participants would be required to detect a difference of 4 points (SD 9 points) on the
PHQ-9 scale with 90% power and 5% significance (see Table 21). It would take approximately 24 months
of recruitment in 16 centres, assuming a recruitment rate of 1.5 participants per centre per month, which
is similar to the rate of 1.8 participants per month observed in BEADS.
A sample size of 623 participants would be required to detect a difference of 3 points (SD 7 points) on the
PHQ-9 scale with 90% power and 5% significance (Table 21).
Delivery and receipt of the intervention
Table 22 shows the attendance at BA sessions in participants who were randomised to the intervention.
Attendance of participants to therapy sessions was high. The mean number of therapy sessions received in
the intervention arm was 8.1 (SD 3.4). In total, 92% of participants randomised to the intervention arm
received at least two sessions, 88% received at least five sessions, 64% received at least eight sessions and
40% received at least 10 sessions. The mean number of missed sessions was 0.9 (SD 1.3), with 52% of
participants missing at least one scheduled therapy session.
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FIGURE 7 Results from secondary analyses showing mean difference between intervention and control at 6 months,
adjusted for baseline and centre.
RESULTS OF THE FEASIBILITY TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
TABLE 21 Sample size estimation for a definite trial
Outcome Significance (%) Power (%)
Target difference
(points) SD (points)
Standardised
effect size ICC
Average
cluster size (n)
Sample size
per group (n)
Total sample size
(adjusted for 20% attrition) (n)
PHQ-9 5 90 5 7 0.71 0.06 20 93 233
PHQ-9 5 90 4 7 0.57 0.06 20 142 355
PHQ-9 5 90 3 7 0.43 0.06 20 249 623
PHQ-9 5 90 5 9 0.56 0.06 20 150 375
PHQ-9 5 90 4 9 0.44 0.06 20 232 580
PHQ-9 5 90 3 9 0.33 0.06 20 409 1023
PHQ-9 5 90 5 11 0.46 0.06 20 221 553
PHQ-9 5 90 4 11 0.36 0.06 20 343 858
PHQ-9 5 90 3 11 0.27 0.06 20 608 1520
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Site 3 had a higher rate of missed sessions, probably owing to a higher number of withdrawals. Figure 8
shows that participants who withdrew from the intervention attended a low number of sessions. There
were also three participants who attended eight or more sessions and were lost to follow-up.
The timing of therapy sessions was fairly regular, with sessions generally occurring weekly.
TABLE 22 Number of sessions attended by participants who were randomised to the intervention arm
Number of sessions
Site
Overall1 2 3
n 12 3 10 25
Total number of sessions completed 110 23 69 202
Mean (SD) number of sessions attended 9.2 (2.2) 7.7 (1.2) 6.9 (4.6) 8.1 (3.4)
Median (IQR) number of sessions attended 10 (2.25) 7 (1.00) 8.5 (7.75) 9 (3.00)
Number (%) of participants attending at least two sessions 12 (100) 3 (100) 8 (80) 23 (92)
Number (%) of participants attending at least five sessions 12 (100) 3 (100) 7 (70) 22 (88)
Number (%) of participants attending at least eight sessions 9 (75.0) 1 (33.3) 6 (60.0) 16 (64.0)
Number (%) of participants attending at least 10 sessions 7 (58.3) 0 (0.0) 3 (30.0) 10 (40.0)
Total number of planned sessions not completed 6 (5.0) 1 (4.0) 16 (19.0) 23 (10.2)
Mean (SD) number of sessions not completed 0.5 (0.9) 0.3 (0.6) 1.6 (1.5) 0.9 (1.3)
Median (IQR) number of sessions not completed 0 (1.0) 0 (0.5) 1 (1.0) 1 (1.0)
Number (%) participants missing at least one session 4 (33.3) 1 (33.3) 8 (80.0) 13 (52.0)
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FIGURE 8 Number of sessions attended by participants who were randomised to the intervention arm (n= 25).
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Number of missing values/incomplete cases
Missing data in the outcome measures and missing items within these outcomes are presented in Table 23.
Baseline completion rate was high in all outcomes. The 6-month follow-up rate was around 80% in most
outcomes. Two participants had two or fewer missing items for the PHQ-9 at 6 months post randomisation.
Imputation was used on these missing items as specified in the SAP.
Summary of risks and benefits
This trial was not an investigation of a medicinal product and entailed no invasive procedures. No participants
had any existing treatments withdrawn. There was a risk that participants may have experienced some
distress from being asked about their mood, but all researchers and therapists were trained to deal with these
situations. If, at any point during the baseline assessment, intervention or outcome assessment, the researcher
or therapist was concerned about a participant, for example they had severe distress or reported feeling
suicidal, then the necessary referrals were made. This process is explained in Adverse events and Challenges
with implementation.
Adverse events
For the purposes of this study, AEs were defined as suicidal intentions. Researchers asked participants
about any AEs at the 6-month follow-up. This information was collected on outcome questionnaires
or recorded in person for those participants who required help at a home visit. Any AEs that were
self-reported by participants in the intervention group during the delivery of the therapy sessions were
also recorded by the therapist on the CRF and database.
TABLE 23 Summary of non-missing scores and items within questionnaires
Measures Time Total, n (%)
Treatment arm, median
(minimum, maximum) Overall, median
(minimum,
maximum)Intervention Control
PHQ-9,a 9 items Baseline 48 (100.0) 9 (7, 9) 9 (8, 9) 9 (7, 9)
6 months 39 (81.2) 9 (0, 9) 9 (0, 9) 9 (0, 9)
VAMS ‘Sad’ item,b 1 item Baseline 47 (97.9) N/A N/A N/A
6 months 40 (83.3) N/A N/A N/A
EQ-5D Standard, 5 items Baseline 47 (97.9) 5 (5, 5) 5 (5, 5) 5 (5, 5)
6 months 38 (79.2) 5 (0, 5) 5 (0, 5) 5 (0, 5)
NLQ, 30 items Baseline 47 (97.9) 30 (30, 30) 30 (30, 30) 30 (30, 30)
6 months 39 (81.2) 30 (0, 30) 30 (0, 30) 30 (0, 30)
NEADL, 22 items Baseline 47 (97.9) 22 (22, 22) 22 (22, 22) 22 (22, 22)
6 months 37 (77.1) 22 (0, 22) 22 (0, 22) 22 (0, 22)
SADQ, 21 items Baseline 27 (96.4) 21 (21, 21) 21 (20, 21) 21 (20, 21)
6 months 21 (75.0) 21 (0, 21) 21 (0, 21) 21 (0, 21)
CSI, 13 items Baseline 24 (85.7) 13 (10, 13) 13 (12, 13) 13 (10, 13)
6 months 19 (67.9) 13 (0, 13) 13 (0, 13) 13 (0, 13)
N/A, not applicable.
a Two participants had two or fewer missing items for PHQ-9 at 6 months post randomisation. Imputation was used on
these missing items as specified in the SAP.
b VAMS ‘Sad’ item is a 1-item measure, so cannot have missing items.
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Adverse events have been summarised by treatment arm in Table 24. There were a total of 13 AEs
experienced by 10 participants.
Serious adverse events (SAEs) are presented in Table 25. There were three SAEs experienced by three
separate participants. None of these were related to the intervention.
Challenges with implementation
Challenges with the delivery of the intervention
Based on the experiences of delivery of the intervention, we have gained some important insights for a
definitive trial:
l The therapists delivering the intervention identified that participants in the early days post stroke had
more practical goals, such as walking and speaking, and were less concerned with their mood.
l It was difficult to find activities for participants with limited mobility.
l Getting participants to adapt their goals was challenging and one therapist felt that, at this stage,
a talking therapy to deal with acceptance would be more beneficial.
l One of the therapists had experience of delivering CBT in a previous role. Therefore, it may be important
to tailor therapist training for those who are inexperienced in delivering psychological therapies and those
who are experienced in delivering psychological therapy but not specifically BA therapy. This would ensure
that both experienced and inexperienced therapists deliver the therapy in accordance with the manual.
l This feasibility study recruited only participants who were mildly affected by aphasia and, therefore, did not
provide us with knowledge of delivering the intervention to those with aphasia and cognitive impairments.
TABLE 25 Summary of SAEs
BEADS ID Description Was the SAE intervention related? Outcome of SAE
C7/014 Admitted to A&E following suicide attempt No Ongoing
C6/004 Admitted to hospital following a heart attack No Improved
B4/016 Repair to hernia No Recovered
A&E, accident and emergency.
TABLE 24 Summary of AEs
AEs
Treatment arm
AllIntervention Control
Number (%) of participants who experienced more than one AE 4 (15.4) 6 (26.1) 10 (20.4)
Number of AEs 5 8 13
Type of AE, n (%)
Fall 0 (0.0) 2 (25.0) 2 (15.4)
Health worsened 1 (20.0) 3 (37.5) 4 (30.8)
New health condition 2 (40.0) 0 (0.0) 2 (15.4)
Suicidal intentions 2 (40.0) 3 (37.5) 5 (38.5)
Hospital stay, n (%)
No 1 (20.0) 8 (100.0) 9 (69.2)
Yes 4 (80.0) 0 (0.0) 4 (30.8)
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Challenges with recruitment and data collection
There were a number of issues experienced with recruitment that resulted in lower than planned
recruitment rates. However, the final sample recruited was sufficient for this feasibility study, which was
powered not for efficacy but to inform the design of the definitive RCT. The original recruitment target of
72 participants was based on three sites recruiting two participants per month over 12 months, giving a
total of 36 recruitment months. However, owing to delays in site set-up, none of the sites was able to
utilise the full 12-month recruitment period. Instead, a total of 27 recruitment months were available
across the three sites.
There were three main challenges for the delays in site set-up: (1) approval of excess treatment costs
(ETCs), (2) the knock-on effect on appointment of study therapists in the NHS (as advertisement of the
posts was contingent on ETCs) and (3) a change to the IAPT provider close to the time that the study was
due to open. Although we under-recruited slightly, this had little impact on determining the feasibility of
the trial. Recruitment challenges included the fact that the therapists had a dual role, which meant they
were recruiting participants in addition to delivering the intervention. This also meant that they were
limited to being able to recruit only as many participants as they could deliver the intervention to at
one time.
A second recruitment challenge was the inevitable competition in highly engaged clinical research centres
for the resources to recruit participants. The CRN research nurses at sites were able to assist in screening
participants from the hospital database and stroke wards. They issued invitation packs to participants they
identified as fitting the initial eligibility criteria, but this then required further time to follow up potential
participants to discuss the study after issuing the invitation packs.
The third recruitment challenge was the centres being in different settings and, therefore, encountering
different problems with recruitment. Recruitment was particularly successful where the therapist was based
in the hospital setting and so was able to work closely with the CRN nurse in recruiting from the hospital
database and stroke wards. In contrast, the bulk of recruitment in the case of the therapist based in a
community setting was gained through the outpatient, community caseload and voluntary group routes as
there was limited resourcing to recruit from the hospital database. The therapist based in the IAPT service
was heavily reliant on the participants identified from the hospital database and stroke ward by the CRN
nurses and so was constrained by the resourcing available. For a definitive RCT, it would be beneficial to
fund more research assistant/research nurse time to support recruitment.
Use of the Consent Support Tool
A total of 18 out of the 48 participants recruited had aphasia, which represents one-third of this cohort
of stroke survivors, as expected. The intervention was designed to be suitable for people with mild and
moderate aphasia, with adaptations being made to support reduced language ability. Only those with
aphasia severe enough to make participation in the intervention difficult, even with support, were excluded.
The CST was recommended to identify those who were not eligible because they did not have the mental
capacity to provide informed consent, and those whose aphasia was too severe to participate in the
intervention with support (those with two key written or spoken word comprehension or below). The CST
was also recommended to help identify which participants required accessible information and to identify
strategies to support the individual’s communication needs during the intervention. The CST was used
with only 5 of the 18 participants with aphasia. The FAST scores for these participants show that they had
mild/very mild aphasia, confirming that they were all eligible for the study. The therapists reported having a
conversation with potential participants and, if they seemed to be communicating well and understanding
what was being said to them, then they did not feel the need to use the CST.
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Problems with data collection
There was an occasional need to visit some participants twice to collect data outcome because of health
and tiredness. Although this was not common, it did have an impact on therapist time.
The main problems experienced were with outcome data collection. The postal method proved to be
challenging and it was necessary to chase some participants to return their questionnaires, which
resulted in four participants (8%) having their outcome data collected outside the data collection window.
This may have been because the patient group required more support to complete the questionnaires.
For a definitive trial, the response rate may be more prompt or improved by issuing regular newsletters
to participants to keep them engaged or by planning for visits to those who request them.
During the trial, the therapists were funded only until the end of therapy. However, at this stage, 6-month data
collection was still ongoing and, therefore, AEs could still be reported and study completion/discontinuation
forms required completion. For a definitive trial, it may be beneficial to extend contracts a couple of months
beyond the end of treatment completion. Furthermore, organising regular teleconferences with the PIs could
improve PI engagement throughout the trial.
Reporting of adverse events
The protocol specified that all AEs were to be assessed for seriousness, expectedness and causality. In
addition, the therapists and researchers completed a SAE form for additional events that were classed
as serious, including death, suicide, a life-threatening AE, inpatient hospitalisation (or prolongation of
existing hospitalisation), disability or incapacity. For other AEs, the researcher completed an AE form.
Further stroke-related events were not reported as SAEs because these were expected within this
population. However, it was later identified that it was not always possible to assess all AEs for their
relationship to the stroke and to the intervention. For example, a score of 3 points ‘nearly every day’
on question 9 of the PHQ-9, ‘Thoughts that you would be better off dead or of hurting yourself in some
way’ would trigger the suicide protocol and be reported as an AE. When this occurred, this was referred
back to the site for it to follow its local procedures to ensure the safety of the participant. They were also
asked to assess if the event was related to the stroke and to the intervention (where applicable). This
proved difficult for a number of reasons. First, based on a response to the questionnaire, it is not possible
to assess these criteria without asking the participant, which may seem inappropriate and insensitive.
Second, as participants were recruited from various routes, they were not always known to the immediate
team and, therefore, did not have an established rapport with the therapists. Third, study teams based in
community psychology services did not always have access to the patient’s hospital records specifically for
admissions to general hospital and, therefore, found it difficult to identify and report details of SAEs.
Summary of usual care
A summary of the provision received by participants in the study by treatment arm can be seen in Table 26.
The provision is consistent across treatment arms; however, one participant who was in the intervention arm
received significantly more services than other participants.
RESULTS OF THE FEASIBILITY TRIAL
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TABLE 26 Summary of other resources used in the previous 3 months at 6 months post randomisation, by treatment arm
Resources used
Treatment arm
Intervention Control
Total
Number of
contacts
≥ 1 (n) Mean (SD) Median (IQR)
Mean (SD)
duration
(minutes) Total
Number of
contacts
≥ 1 (n) Mean (SD) Median (IQR)
Mean (SD)
duration
(minutes)
Inpatient hospital services 1 1 0.038 (0.2) 0.0 (0–0) – 0 0 0.0 (0.0) 0.0 (0–0) –
Outpatient hospital services 35 3 1.3 (4.7) 0.0 (0–0) – 2 1 0.087 (0.42) 0.0 (0–0) –
A&E or day hospital attendance 9 4 0.35 (1.2) 0.0 (0–0) – 4 3 0.17 (0.49) 0.0 (0–0) –
Doctor or nurse contact 64 14 2.5 (3.2) 1.5 (0–5) 19.0 (26.0) 96 17 4.2 (4.9) 2.0 (0–8) 27.0 (38)
Occupational therapist 32 5 6.4 (5.1) 3.0 (3–12) 66.0 (33.0) 12 2 6.0 (5.7) 6.0 (2–10) 42.0 (25)
Physiotherapist 42 4 10.0 (9.5) 7.5 (4–17) 60.0 (0.0) 29 5 5.8 (4.9) 3.0 (3–10) 44.0 (16)
Speech and language therapist 1 1 1.0 (–) 1.0 (1–1) 60.0 (–) 13 4 3.2 (3.3) 2.0 (1–5.5) 45.0 (17)
Home help/care worker 522 3 170.0 (81.0) 180.0 (90–252) 68.0 (75.0) 540 3 180.0 (160.0) 90.0 (90–360) 32.0 (13)
NHS counsellor, psychologist or psychotherapist 8 1 0.31 (1.6) 0.0 (0–0) 3.5 (18.0) 6 1 0.26 (1.3) 0.0 (0–0) 2.2 (10)
Community nurse, social worker, case manager
or well-being practitioner
9 1 0.35 (1.8) 0.0 (0–0) 50.0 (17.0) 2 1 0.087 (0.42) 0.0 (0–0) – (–)
CBT therapist 13 3 4.3 (2.9) 6.0 (1–6) 1.5 (7.8) 0 0 – (–) – (–) 2.6 (13)
Day care centre 24 2 12.0 (0.0) 12.0 (12–12) 120.0 (85.0) 13 2 6.5 (7.8) 6.5 (1–12) 240.0 (–)
Private counsellor, psychologist, psychotherapist
or psychiatrist
24 1 0.92 (4.7) 0.0 (0–0) – 0 0 0.0 (0.0) 0.0 (0–0) –
A&E, accident and emergency.
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Chapter 4 Fidelity assessment results
The mean number of sessions attended was 8.5 (SD 4.4), with a range from 0 to 14 sessions. Overall,90% of scheduled sessions were attended. The main reason that sessions were missed was a change
in participants’ availability (n = 14, 61%), illness (n = 4, 17%) and change of therapists’ availability (n = 3,
13%). In addition, two participants (9%) withdrew from treatment.
Table 27 shows the proportion of time (in 10-minute units) spent on individual components of therapy,
as reported by therapists.
TABLE 27 Frequency of 10-minute units of time spent on the subcomponents of therapy
Main component Subcomponent of therapy
Number of
10-minute units Percentage
Explanation of treatment rationale 117.8 10.2
Explain research project 13.0 1.1
Explain BA 45.2 3.9
Set and agree session agenda 59.6 5.2
Assessment 104.5 9.0
Background information 14.0 1.2
Current problems or difficulties 46.0 4.0
Depression symptoms, mood 28.0 2.4
Effects of stroke 16.5 1.4
Communication and cognitive
difficulties
9.0 0.8
Establish communication skills and
difficulties
1.0 0.1
Developing communication resources 2.0 0.2
Practice communication skills 0.0 0.0
Identify strategies for coping with cognitive
difficulties
6.0 0.5
Goals 117.0 10.1
Set and agree goal 48.5 4.2
Review progress of goals 68.5 5.9
Activities 209.5 18.1
Activity monitoring 75.0 6.5
Identify enjoyable activities 69.5 6.0
Activity scheduling 56.0 4.8
Practise skills or task 9.0 0.8
Graded task 240 2.1
Explain graded task principle 10.5 0.9
Set and agree graded task 10.0 0.9
Carry out part of the task in therapy 3.5 0.3
continued
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Most time was spent on between-session tasks (18.3%), which included setting and agreeing new
between-session tasks (7.7%) and reviewing the previous between-session tasks (10.6%). The second
most frequent component was activities (18.1%). This included activity monitoring (6.5%), identifying
enjoyable activities (6.0%) and activity scheduling (4.8%), with relatively little time spent on practising skills
or tasks (0.8%). The least amount of time was spent on communication and cognitive difficulties (0.8%).
In addition, the use of graded tasks (2.1%) and problem-solving (3.8%) was relatively infrequent.
All participants received an explanation of the treatment rationale, assessment, discussion of between-
session tasks, summary and review. Two participants (8%) did not receive any goal-setting or activity
scheduling. Twelve (50%) did not receive graded task assignments and eight (33%) did not receive
training in problem-solving. This indicates that some core components of BA were missed for some
participants. The therapy relied heavily on between-session tasks and activities.
The proportion of components of therapy by session number is shown in Table 28. This shows that
explanation of the treatment occurred across most sessions and that assessment was mainly concentrated
in the first two. Goals, activities, graded task assignments and problem-solving were spread across most
sessions. In all sessions, most time was spent discussing between-session tasks and on summary and
review. Discussion of generalisation occurred mainly in later sessions.
We were unable to video as many therapy sessions as planned. The main difficulty was that there was only
one video camera for the study, to be shared between the three therapists who were geographically based
in three different sites. The therapists had to take turns using the video camera and had to record available
sessions depending on whether or not the participants they were treating at that time had consented to
be videoed.
TABLE 27 Frequency of 10-minute units of time spent on the subcomponents of therapy (continued )
Main component Subcomponent of therapy
Number of
10-minute units Percentage
Problem-solving 44.0 3.8
Identify problems or obstacles arising 24.0 2.1
Identify and plan solution(s) to a problem 20.0 1.7
Between-session tasks 212.4 18.3
Set and agree between-session tasks 89.0 7.7
Review between-session tasks 123.4 10.6
Summary and review 149.1 12.9
Recapping information 54.3 4.7
Discuss therapy ending 36.0 3.1
Summarise session 58.8 5.1
Generalisation 52.0 4.5
Summary of skills learned during therapy 31.5 2.7
Plan for future scenarios 20.5 1.8
Other 118.5 10.2
Discussion with carer 29.5 2.5
General conversation 52.0 4.5
Other (specify) 37.0 3.2
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TABLE 28 Proportion of components of therapy by session number
Component of therapy
Session number, n (%)
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Explanation of treatment rationale 60 (29) 21 (14) 16 (10) 17 (10) 17 (11) 13 (8) 15 (10) 8 (8) 8 (9) 4 (7) 3 (9) 1 (4) 0 (0) 1 (17)
Assessment 84 (40) 20 (13) 8 (5) 2 (1) 2 (1) 2 (1) 3 (2) 2 (2) 3 (3) 1 (2) 1 (3) 0 (0) 0 (0) 0 (0)
Communication and cognitive difficulties 3 (1) 0 (0) 2 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Goals 0 (0) 20 (13) 6 (4) 8 (5) 7 (5) 13 (8) 19 (13) 16 (15) 16 (18) 9 (15) 2 (6) 3 (13) 1 (17) 1 (17)
Activities 5 (2) 9 (6) 44 (26) 46 (28) 34 (22) 36 (23) 22 (15) 11 (10) 8 (9) 4 (7) 2 (6) 1 (4) 1 (17) 0 (0)
Graded task 0 (0) 2 (1) 3 (2) 5 (3) 6 (4) 9 (6) 1 (1) 2 (2) 0 (0) 1 (2) 2 (6) 2 (8) 0 (0) 0 (0)
Problem-solving 0 (0) 3 (2) 11 (7) 9 (6) 12 (8) 4 (3) 9 (6) 8 (8) 2 (2) 0 (0) 1 (3) 0 (0) 0 (0) 0 (0)
Between-session tasks 22 (11) 39 (25) 43 (26) 42 (26) 38 (25) 34 (22) 31 (21) 17 (16) 12 (13) 5 (8) 4 (12) 4 (17) 0 (0) 0 (0)
Summary and review 29 (14) 23 (15) 25 (15) 22 (14) 22 (14) 30 (19) 26 (17) 23 (22) 23 (26) 15 (25) 6 (18) 4 (17) 2 (33) 2 (33)
Generalisation 0 (0) 0 (0) 0 (0) 0 (0) 2 (1) 5 (3) 13 (9) 8 (8) 9 (10) 16 (26) 6 (18) 4 (17) 0 (0) 1 (17)
Other 6 (3) 18 (12) 10 (6) 10 (6) 11 (7) 9 (6) 9 (6) 10 (9) 8 (9) 5 (8) 6 (18) 5 (21) 2 (33) 1 (17)
Total 209 155 168 162 152 156 149 106 90 61 33 24 6 6
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Video recordings of treatment sessions were analysed for eight participants, who were aged 47–76 years
(mean 62.6 years, SD 10.8 years); six participants were men. PHQ scores ranged from 11 to 23 (mean
15.8, SD 4.6) and VAMS ‘Sad’ item scores ranged from 22 to 88 (mean 59.3, SD 29.5). Ten treatment
sessions were recorded from across the three sites. There were no recordings for sessions 1, 5, 8 and 9.
The frequency of components of therapy was calculated separately for those components of the manual
that were applicable on all sessions and those that were session specific (see Appendices 11 and 12 for
the results). Most components of the manual that were intended to be delivered on all sessions occurred.
However, there were four sessions in which no session summary was observed. In addition, the recording
of session 10 comprised almost exclusively social chat and included few of the components of treatment
that should apply to all sessions.
The components of treatment that were specific to individual sessions were observed in the appropriate
sessions. However, the recording of session 4 did not show any discussion on how enjoyable activities
improve mood, nor a list of enjoyable activities being created, and no identification of barriers to engaging
in identified activities. These were all components listed in the manual for session 4. In addition, the
recording of session 10 showed that the session comprised entirely questions and answers and did not
include a review of problems addressed during therapy, a summary of successful strategies and skills used,
a discussion of generalisation of skills to future situations or a reminder about the 6-month follow-up.
See Appendix 13 for a summary of the frequency of therapist and participant activities. Most therapist
activities occurred on most sessions. The only notable omission was the lack of reference to previous
sessions by the therapist. The participants’ activities were similar across sessions. However, there were
no observations of participants asking for information or asking questions.
Discussion of fidelity results
Overall, for the assessment of fidelity, the results of the therapy records indicate that most of the
components of therapy described in the manual were delivered to participants. Importantly, each session
included essential components of therapy and the distribution of time was as expected. This suggests that
outcomes reflect the effect of the intervention as described in the manual. However, there were some
components of therapy that were not recorded as being delivered to some participants. There was little
use of graded task assignments and training in problem-solving, even for those elements that form the
core components of BA. This may be a reflection of the coding used, as graded task assignments were
often used as between-session tasks. The record form may need to be modified to reflect the content of
the between-session tasks, as well as the content of therapy.
The video recordings also indicated that therapy was mainly delivered in accordance with the manual.
The main limitations of the video analysis are that recordings were incomplete and some sessions were
not covered. The results therefore demonstrate the extent to which video analysis could be reported in a
definitive trial. The recordings highlighted that the content of the sessions that were recorded did not
cover all aspects of therapy expected from the manual. However, the intervention was designed to be
delivered flexibly and it may be that the missed content was delivered in other sessions.
Both methods of checking the fidelity of the intervention were feasible and both highlighted potential
ways in which the therapy received deviated from the treatment as described in the manual. The records
kept by therapists were simpler to use and more complete. However, the lack of therapeutic content in the
video recording of session 10 was not picked up in the therapist records, suggesting that the two methods
may complement each other.
FIDELITY ASSESSMENT RESULTS
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Chapter 5 Health economic results
Feasibility outcomes
The percentage of items of complete data for each key outcome measure is presented in Table 29.
At baseline, the response rate for the standard and pictorial versions of the EQ-5D-5L and resource use
questionnaire was > 90%. There was a lower response rate for the proxy version of the EQ-5D-5L, which was
completed by carers, and for the carers’ EQ-5D-5L about their own health (75.8% and 84.8%, respectively, as
a proportion of those participants who had carers). At the 6-month follow-up, the response rate was slightly
lower for most outcome measures for participants in the intervention group than in the control group. Overall,
at follow-up, the response rate for the standard version of EQ-5D-5L and the resource use questionnaire was
around 80%. Of the 10 participants who did not have standard version EQ-5D-5L data at 6-month follow-up;
eight participants had withdrawn from the study or were lost to follow-up, one participant did not return the
questionnaire and one participant returned the questionnaire but had a response for only four out of the five
domains, meaning that an EQ-5D-5L score could not be calculated. The resource use questionnaire response
rates were analysed by item. At baseline 2% of data were missing and at 6 months 16% of data were
missing. The larger proportion of missing data at 6 months was generally attributable to a small number of
participants not completing any part of the questionnaire, rather than to missing items within otherwise
completed questionnaires.
Within-trial analysis
Quality of life
The standard version of the EQ-5D-5L was used to calculate QALYs as no participants had severe aphasia.
All participants were able to complete the standard version, including the five participants with moderate
aphasia. At the 6-month follow-up, EQ-5D-5L utility scores were slightly higher in the control group than
in the intervention group (Table 30).
As a supplementary analysis, the pairwise correlation between the different utility measures was calculated.
There was a strong correlation (Pearson’s correlation coefficient 0.91) between values of the aphasia accessible
version of the EQ-5D-5L and standard version. The correlation between responses to the EQ-5D-5L completed
by carers on behalf of the study participant (carer proxy) and the standard version completed by the participants
was moderate (Pearson’s correlation coefficient 0.59).
TABLE 29 Response rate by outcome measure
Outcome measure
Time point, % (n/N)
Baseline 6-month follow-up
Treatment arm
Overall
Treatment arm
OverallControl Intervention Control Intervention
EQ-5D-5L (standard version) 100.0 (23/23) 96.0 (24/25) 97.9 87.0 (20/23) 72.0 (18/25) 79.2
EQ-5D-5L (aphasia-friendly version) 95.7 (22/23) 92.0 (23/25) 93.8 82.6 (19/23) 72.0 (18/25) 77.1
EQ-5D-5L (proxy)a 81.3 (13/16) 70.6 (12/17) 75.8 68.8 (11/16) 58.8 (10/17) 63.6
EQ-5D-5L (carer)a 87.5 (14/16) 82.4 (14/17) 84.8 56.3 (9/16) 70.6 (12/17) 63.6
Resource use questionnaire 100.0 (23/23) 96.0 (24/25) 97.9 91.3 (21/23) 76.0 (19/25) 83.3
a Percentages based only on participants with carers.
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Costs
The cost of the intervention was estimated to be £57 per hour.85 This was based on the intervention
being provided on a one-to-one basis by a grade-5 Agenda for Change (AfC) mental health nurse, using
estimates from the PSSRU. PSSRU incorporate training and clinical supervision costs in this estimate and,
therefore, the training and supervision received in the BEADS study was not costed separately. Direct
intervention costs were calculated by multiplying the hourly intervention cost by the average number of
sessions for each individual patient.
There were two participants in the control group and seven in the intervention group with missing cost
data at follow-up. One of these participants also had cost data missing at baseline. As there was the same
level of missing data across resource use categories, data were imputed on the total cost level. The missing
data at 6 months were imputed separately, based on whether or not the participant had achieved a ‘good
response’ as measured by the PHQ-9. Analyses that incorporate imputed data are referred to as ‘full data
set (with imputation)’ analyses. Analyses that do not use imputed data are referred to as ‘complete-case’
analyses.
Average costs at follow-up for the whole trial period (6 months) are shown in Table 31; these figures
contain no imputed data. For all of the categories except societal costs, the average cost per patient in
the intervention group was higher than in the control group (although no differences were statistically
significant, see Table 32). Inpatient costs were incurred by two participants in the intervention group,
compared with no participants in the control group. It is possible that these costs were chance events
rather than being related to the intervention. For outpatient hospital services, two participants in the
intervention group had costs of > £1000, whereas there were no such outliers in the control group.
These costs were associated with psychiatry and psychology outpatient visits. It is unclear whether or
not these costs were related to the intervention.
TABLE 30 The EQ-5D-5L, by treatment arm, at both time points
EQ-5D-5L by treatment arm Mean Standard error 95% CI
EQ-5D-5L at baseline
Control 0.51 0.06 0.40 to 0.63
Intervention 0.50 0.06 0.38 to 0.62
EQ-5D-5L at 6 months
Control 0.60 0.06 0.46 to 0.73
Intervention 0.51 0.07 0.35 to 0.67
TABLE 31 Intervention costs and average costs from resource use questionnaire (complete case)
Treatment arm
Cost (£)
Inpatient
hospital
services
Outpatient
hospital
services
Primary and
community
care
Community day
based services
Intervention
costs Societal
Control 0.0 225.12 1123.02 111.46 0.0 24,133.84
Intervention 466.16 954.78 2175.92 217.96 460.56 19,292.29
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Home help was the main factor that caused the difference between the control and intervention groups
in primary and community care costs. Four participants in the intervention group received home help
compared with three participants in the control group. The intervention group received 295.5 hours more
home help than the control group over the last 3 months of follow-up. There was one participant in the
intervention group who received the equivalent of approximately one visit a day for 3 hours per day, which
was more than that received by any other participant in the trial. See Appendix 14 for the distribution of
costs relevant to the NHS and PSS perspective for the control and intervention groups.
The human capital approach was used to estimate societal costs. The societal component of costs
consisted of work hours lost, carer time, travel expenses, private health-care costs and charity-provided
services. These were added to the costs from the NHS and PSS perspective to form costs for the societal
perspective. Owing to the nature of the population, there were only two participants in the control group
and three participants in the intervention group either working or looking for work. In addition, three
carers were reported to have lost work hours as a result of their caring responsibilities. However, data were
incomplete, with some carers not recording whether or not they worked, and some carers not recording if
they lost any time from work. For this reason, we allocated a cost to all carer time reported for the societal
perspective analysis, whether or not it resulted in time being taken off work. Carer time accounted for
93.3% and 78.0% of societal costs for the control and intervention groups, respectively. See Appendix 15
for the distribution of costs relevant for the societal perspective for the control and intervention groups.
Aggregated costs for the 6 months of the trial are presented in Table 32.
Results from the within-trial analysis
The within-trial analysis was undertaken on both the complete-case and the imputed data sets. Results are
presented in Table 33. Based on the imputed data set, when including all costs relevant to the NHS and
PSS [labelled ‘NHS & PSS perspective (1)’] costs were £1316 higher in the intervention group than the
control group over the course of the study. To illustrate the influence of inpatient hospital stays we
reanalysed the data excluding inpatient costs if the hospital stay was for > 1 night [labelled ‘NHS & PSS
perspective (2)’]. In this analysis the incremental cost associated with the intervention reduced to £980.
The 95% CI for both these estimates includes negative values, indicating that there was no statistically
significant difference in costs between the intervention and control groups.
For all analyses, incremental QALYs were negative, meaning that participants in the intervention group
accrued fewer QALYs over the 6-month trial period than participants in the control group. Again, differences
were not statistically significant. Therefore, based on an NHS and PSS perspective and a within-trial analysis,
the intervention is expected to be dominated by the control, that is, it results in higher costs and lower
QALYs than usual care.
It was estimated that there would be lower costs (by £8281 per patient) in the intervention group than in
the control group, when taking a societal perspective and valuing all carer time regardless of whether it
resulted in the carer taking time off work. This results in an ICER of £539,917 saved per QALY lost based
on the complete-case analysis, and an ICER of £400,048 saved per QALY lost based on the imputed
data analysis. The interpretation of these ICERs is different from the standard interpretation because the
intervention is situated in the south-west quadrant of the cost-effectiveness plane (see Figure 12) – it results
in cost savings but fewer QALYs.
Figures 9 and 10 show the point estimate of the ICER and CIs around this based on the ‘NHS & PSS
perspective (2)’ analysis and the societal analysis, respectively, using the full data set with imputation.
Figures 11 and 12 show the corresponding probabilities of the intervention being cost-effective at
different cost-effectiveness thresholds for these two analyses.
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TABLE 32 Estimated average health-care and societal costs for the 6-month trial period
Treatment arm n Mean (£) Standard error (£) 95% CI (£) Difference (£) Standard error (£) 95% CI
Full data set (with imputation): health-care costs (including intervention costs)
Control 23 1961.18 800.49 234.37 to 3688.01
Intervention 25 3547.46 1072.83 1316.47 to 5778.44 1586.27 1357.62 –1164.24 to 4336.77
Full data set (with imputation): societal costs (including health-care and intervention costs)
Control 23 26,549.36 6078.09 13,801.07 to 39,297.65
Intervention 25 22,991.18 6056.13 10,275.64 to 35,706.72 –3558.18 8724.13 –21,249.47 to 14,133.1
Complete case: health-care costs (including intervention costs)
Control 21 1391.90 318.38 727.77 to 2056.03
Intervention 19 3875.64 1307.22 1129.27 to 6622.01 2483.74 1286.12 –119.88 to 5087.36
Complete case: societal costs (including health-care and intervention costs)
Control 21 25,525.74 6039.68 12,927.19 to 38,124.29
Intervention 19 23,167.92 6470.61 9573.67 to 36,762.18 –2357.817 8842.79 –20,259.11 to 15,543.48
TABLE 33 Results from the within-trial analysis
Cost perspective Incremental costs (£) Standard error (£) 95% CI (£) Incremental QALYs Standard error 95% CI
Complete case (38 participants)
NHS & PSS perspective (1) 1634 1174.0 –667.39 to 3934.63 –0.0107 0.015 –0.04 to 0.02
NHS & PSS perspective (2) 1228 951.9 –638.13 to 3093.27 –0.010 0.015 –0.04 to 0.02
Societal perspective –6479 7727.6 –21,625.08 to 8666.45 –0.012 0.015 –0.04 to 0.02
Full data set (including imputed data; 48 participants)
NHS & PSS perspective (1) 1316 1275.15 –1191.66 to 3823.16 –0.0204 0.021 –0.06 to 0.02
NHS & PSS perspective (2) 980 1245.94 –1469.93 to 3430.61 –0.0205 0.021 –0.06 to 0.02
Societal perspective –8281 7945.87 –23,879.93 to 7318.81 –0.0207 0.021 –0.06 to 0.02
Incremental costs differ from those presented in Table 32 as a result of the covariate adjustment used in the SUR.
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Model-based analysis
Model inputs
Transition probabilities
Transitions from the ‘no response’ health state to the ‘good response’ health state were based on the
response rates observed in the trial. In the intervention group, 68% of participants achieved a 4.78-point
decrease in PHQ-9 from baseline to follow-up and were, therefore, assumed to transit into the ‘good
response’ state. In the control group, 22% of participants achieved this response. Model parameter values
for all parameters included in the model, their CIs and the distribution used to characterise them in PSA
are presented in Appendix 16.
It was not possible to discern relapse rates from the trial and, therefore, these were assumed to be zero in
the base case, but a range of possible relapse rates was considered in sensitivity analysis.
Brønnum-Hansen et al.96 estimated that the annual risk of death from stroke is 18.1% and 10% between
4 weeks to 1 year and after 1 year following stroke, respectively. In the BEADS trial, 60% of participants had
a stroke up to 1 year prior to randomisation, with mean time since stroke for this group being approximately
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FIGURE 11 Cost-effectiveness acceptability curve (controlling for baseline utility and costs) for ‘NHS & PSS
perspective (2)’ analysis, full data set.
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FIGURE 12 Cost-effectiveness acceptability curve (controlling for baseline utility and costs) for the societal
perspective, full data set.
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7 months. Hence, for the first 5 months of the model, the mortality rate was weighted between 18.1%
and 10%, based on the proportion of participants who had a time since stroke of more or less than 1 year.
This mortality rate was applied to both the ‘no response’ and the ‘good response’ health states; hence, we
assume that the intervention does not affect survival. From month 6 up to the start of year 6, the transition
probability for death was based on the 10% annual risk estimated by Brønnum-Hansen et al.96 From year 6
onwards, death from other causes was added to the annual mortality rate based on mortality data from
the Office for National Statistics97 and the age and sex split observed in the BEADS trial.
Quality of life
We calculated utility scores at baseline and at 6 months separately for participants who achieved a ‘good
response’ and those who did not, in order to estimate the increase in utility associated with achieving a
good response using a difference-in-differences approach. We found that achieving a good response was
more beneficial than not responding, such that achieving a good response was associated with an increase
in utility score of 0.066 at 6 months.
It is notable that the increase in utility score in responders was much more substantial in the control group
than in the intervention group (see Appendix 17). However, we assumed that this was due to chance
and in the economic model simply used the utility benefit estimated using all responders in the study,
irrespective of their randomised group.
In the economic model, the utility score for the ‘no response’ health state was 0.52 and the utility score
in the ‘good response’ health state was 0.59 (see the table of parameter values in Appendix 16).
These scores were based on average utility for each response group at 6 months.
Costs
Health state costs were estimated separately for the ‘good response’ and ‘no response’ states. Outlying
costs were observed in the trial analysis; in particular, inpatient hospital costs were observed only in the
intervention group, and these were not deemed to be associated with the intervention. These costs were
for a 17-night inpatient orthopaedics episode and a 10-night inpatient episode for a myocardial infarction.
In order to avoid these costs skewing our model-based analysis, we excluded them from the economic
model. Costs associated with the response and non-response health states used in the economic model
are presented in the table of parameter values in Appendix 16. Costs were slightly higher in the ‘good
response’ health state from the NHS and PSS perspective, but were lower from the societal perspective.
The direct cost of the intervention was estimated to be £460.56, based on an average number of BA
sessions completed in the intervention arm of the trial of 8.08. This cost was added to the intervention
arm of the model only and included in the PSA (see the table of parameter values in Appendix 16).
Probabilistic sensitivity analysis
For the PSA, we assumed that utility in the response group could not fall below the utility of the
non-response group. The difference method was used108 rather than simple (and biased) techniques that
involve resampling or adjustment if the desired ordering is not achieved. It seems reasonable to assume
that a participant with a lower level of depression (i.e. a ‘good response’) would have a higher utility than
a participant with a higher level of depression, all else remaining equal. Without a larger data set of
observations of utility values of responders and non-responders, it is impossible to rule out the possibility
that this assumption does not hold.
Our base-case analysis incorporated a zero relapse rate. We felt that this was likely to lead to misleading
PSA and value-of-information results. Therefore, in a supplementary analysis a hypothetical relapse rate of
10% per month was added to the model. This followed a beta distribution with a standard error of 0.2,
and lower and upper bounds of 0.01 and 0.8, respectively. The standard error was chosen based on an
inflation of the standard error observed for the response rates for each treatment group (0.09 in the
intervention group and 0.08 in the control group).
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Results from the model-based analysis
Deterministic results
Based on an NHS and PSS perspective, the economic model predicted that, over a person’s lifetime, costs
would be £3852 higher in the intervention group than in the control group. It is notable that this represents a
substantial difference compared with the QALY loss estimated using the within-trial analysis. This is because
there was a higher response rate in the experimental group, and the utility score was higher in the ‘good
response’ health state, and is driven by the fact that we assume that the utility of a responder is not dependent
on whether they received the intervention or usual care. This point is revisited in Summary of health economics
findings. A QALY gain of 0.2 was estimated for participants in the intervention group. From these results the
ICER was estimated to be £19,187. Typically, in the UK, interventions are classed as cost-effective if the ICER is
> £20,000 per QALY gained.99 Under a societal perspective, the intervention was estimated to dominate the
control treatment – producing higher QALYs and cost savings. Results are presented in Table 34.
Deterministic sensitivity analysis
Cost-effectiveness analysis results are often more sensitive to the values of certain parameters than others.
A one-way sensitivity analysis allows us to see how changing one parameter and keeping other parameters
constant would influence the ICER. Owing to the relapse rate not being included in our base-case analyses
(as it was not possible to calculate it directly from trial data), the base-case ICERs may be optimistic. Figure 13
demonstrates that when a relapse rate was incorporated within the model, the ICER increases above
£30,000 per QALY gained for relapse rates of > 7% per month, under an NHS and PSS perspective.
From a societal perspective, the intervention continues to dominate for all possible relapse rates, all else
remaining equal.
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FIGURE 13 ICER vs. relapse rate per month, NHS and PSS perspective.
TABLE 34 Results from the deterministic analysis
Cost perspective
Per person treated
Cost (£) QALYs Incremental costs (£) Incremental QALYs ICER (£)
NHS perspective
Control 33,590 3.57
Intervention 37,441 3.77 3852 0.2 19,186.88
Societal perspective
Control 363,127 3.57
Intervention 319,449 3.77 –43,678 0.2 Intervention dominates
HEALTH ECONOMIC RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Probabilistic sensitivity analysis
The results of the deterministic analysis have to be interpreted with caution as they do not account for
parameter uncertainty. PSA assigns distributions to parameters and runs the model many times, each
time selecting a value from the distribution of each parameter. Estimates from each run of the model
are combined and averages are taken to calculate the probabilistic ICER. CEACs are estimated, which
represent the proportion of simulations in which the intervention was associated with an ICER below
a defined cost-effectiveness threshold. We ran the model a total of 10,000 times in a Monte Carlo
simulation. The result of each simulation is presented on the cost-effectiveness plane in Figure 14, for the
analysis that took an NHS and PSS perspective and incorporated imputation. The probabilistic ICER was
£18,979.82 per QALY gained.
Owing to the substantial uncertainty around monthly costs associated with each health state, incremental
costs for each model run varied widely, with approximately 70% of runs estimating that the control group
would have lower costs, and approximately 30% estimating that the intervention group would have lower
costs. CEACs, showing the probability of the intervention being cost-effective at various thresholds for
the NHS and PSS perspective, are plotted in Figure 15. At a threshold of £20,000 per QALY gained, the
intervention had a 51% probability of being cost-effective, and at a threshold of £30,000 the probability
was 60%. Owing to a small number of model runs producing a QALY decrement for the intervention
group, the probability of the intervention being cost-effective does not reach 100%, irrespective of how
high the threshold is. For cost-effectiveness thresholds of > £19,000 per QALY gained, it was estimated
that the intervention would be most likely to be the cost-effective treatment option.
From the societal perspective, the probabilistic analysis estimated that the intervention was dominant – the
vast majority of model runs resulted in cost-effectiveness estimates that lay in the south-east quadrant of
the cost-effectiveness plane (Figure 16). The probability that the intervention was cost-effective at a
threshold of £20,000 per QALY gained was 82.8% (Figure 17).
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FIGURE 14 Model-based analysis: probabilistic results on the cost-effectiveness plane, NHS and PSS perspective.
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FIGURE 16 Model-based analysis: probabilistic results on the cost-effectiveness plane, societal perspective.
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Supplementary analysis
It is important to reiterate that the base-case deterministic and probabilistic results incorporated a relapse
rate of zero, with no uncertainty around this. We conducted a supplementary analysis that incorporated a
hypothetical relapse rate of 10% per month, with a beta distribution with a standard error of 0.2, and lower
and upper bounds of 0.01 and 0.8, respectively. Clearly this is an important assumption. The standard error
represents an inflation of the standard errors associated with the response rate in the experimental and control
groups, which were 0.09 and 0.08, respectively. This resulted in a probabilistic ICER of £21,626.49 per QALY
gained for the NHS and PSS perspective. From the societal perspective the model continued to estimate that
the intervention would dominate, leading to cost savings and QALY gains. The cost-effectiveness plane
scatters and the CEACs for these analyses are presented in Figures 18–21. At a cost-effectiveness threshold of
£20,000 per QALY gained, the probability of the intervention being cost-effective was 42.6% under an NHS
and PSS perspective, and 81.0% under a societal perspective.
Value of information
We conducted our value-of-information analysis based on the supplementary probabilistic analysis that
incorporated a non-zero relapse rate, as it was considered to be unrealistic to assume a zero relapse rate
with no uncertainty. We estimate that the per-patient value of perfect information is £1348.85, given a
cost-effectiveness threshold of £20,000 per QALY gained and taking an NHS and PSS perspective.
We extrapolated the per-patient value-of-information estimates to a population level by estimating the
number of participants that would be likely to receive the treatment over a 10-year time period. It is estimated
that there are 1,202,053 stroke survivors in the UK.109 Approximately 29% of these people will also have
depression.1 To be conservative in our estimation of the population size that could benefit from BA therapy,
we assumed that the intervention would not be suitable for people with severe depression. No published
estimates of the proportion of stroke survivors who had mild, moderate or severe depression were found.
Hence, to estimate this we used the proportion of participants with severe depression in the BEADS trial
(29.2%); thus, 70.8% of stroke survivors with depression were estimated to have mild or moderate depression
and, therefore, to be eligible for the intervention. In total, we estimate that the prevalent population in the UK
that could benefit from the BA intervention is 246,922 [1,202,053 × 0.29 × 0.71].
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FIGURE 17 Cost-effectiveness acceptability curves, societal perspective.
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In addition, it is estimated that approximately 152,145 people in the UK have a stroke each year,110 with
67–75% of these estimated to be first (i.e. not recurrent) strokes. A total of 78% of people experiencing a
stroke are expected to survive for longer than 6 months.111 Again, approximately 29% of these people will
also have depression and we estimate that 70.8% of these would have mild or moderate depression and
be eligible for the intervention. To be conservative, taking the lower bound of the stroke proportion that
represents a first stroke, we estimate that the incidence population in the UK that could benefit from the
intervention is 16,333 per year (152,145 × 0.67 × 0.78 × 0.29 × 0.71).
Pr
o
b
ab
ili
ty
 t
h
at
 t
re
at
m
en
t 
is
th
e 
m
o
st
 c
o
st
-e
ff
ec
ti
ve
 o
p
ti
o
n
0 10 20 30 40 50
Cost-effectiveness threshold (£000 per QALY)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Control
Intervention
Treatment arm
FIGURE 19 Cost-effectiveness acceptability curves, NHS and PSS perspective with relapse rate.
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FIGURE 18 Model-based analysis: probabilistic results on the cost-effectiveness plane, NHS and PSS perspective with
relapse rate.
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In total, we estimate that 410,251 people in the UK could be eligible to receive the intervention over a
10-year time period (246,922 + 10 × 16,333), with, on average, 41,025 treated per year. Based on this,
we estimate a population-level EVPI of £552M.
The EVPI was higher when undertaking the analysis from a societal perspective. The per-patient EVPI was
£1881 at a cost-effectiveness threshold of £20,000 per QALY gained and the population-level EVPI
was £771.8M.
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FIGURE 20 Model-based analysis: probabilistic results on the cost-effectiveness plane, societal perspective with
relapse rate.
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FIGURE 21 Cost-effectiveness acceptability curves, societal perspective with relapse rate.
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Expected value of perfect parameter information
A further analysis was undertaken to gain an insight into which areas would deliver the most value for
future research. The Sheffield Accelerated Value of Information Tool100 was used to estimate the value of
obtaining perfect information for one parameter or a group of parameters. The following parameters were
included in the analysis:
l health-care costs in the ‘response’ state
l health-care costs in the ‘no response’ state
l utility in the ‘response’ state
l utility in the ‘non-response’ state
l probability of good response (control group)
l probability of good response (intervention group)
l relapse rate
l number of BA sessions
l probability of death.
The results of the analysis taken from the NHS and PSS perspective suggest that the parameters that have
the highest value for further research were health costs in both response states (Table 35). For health costs
in the response state, the EVPPI was £926 per person, giving a population EVPPI of £379.8M over 10 years,
for the NHS and PSS perspective. For health costs in the non-response state, the per-person EVPPI was
£891, and for the population was £365.4M over 10 years. The next most important parameter was utility
for a non-response, with an estimated per person EVPPI of £108. A zero value for EVPPI suggests that
whichever value a parameter takes within its defined distribution would not affect the probability of the
intervention being cost-effective at a threshold of £20,000 per QALY gained.
Results of the EVPPI analysis from the societal perspective are presented in Table 36. The EVPPI was zero
for all parameters except societal costs for both response groups.
Given the difficulties associated with collecting accurate data on ‘indirect’ costs (i.e. NHS, PSS and societal
resource use is not directly related to the actual receipt of the intervention), details on these are not always
collected and included in economic evaluations. For this reason, we reran the NHS and PSS perspective
EVPI and EVPPI analyses, including in the economic model only the direct costs associated with the delivery
of the intervention. This resulted in a per-patient EVPI of £50.39, a population-level EVPI of £20M, and
EVPPI results as presented in Appendix 18.
TABLE 35 Results from EVPPI, NHS and PSS perspective
Parameters Per-person EVPPI (£) Standard error (£)
EVPPI for UK over
10 years (£)
Health costs (response) 925.84 21.77 379,800,000
Health costs (no response) 890.61 20.3 365,400,000
Utility (response) 0.0 2.1 0
Utility (no response) 108.42 20.33 44,480,000
Probability of good response (intervention) 13.99 11.44 5,741,000
Probability of good response (control) 0.0 3.32 0
Relapse rate 21.77 22.86 8,932,000
Number of BA sessions 8.24 11.72 3,381,000
Probability of death 0.0 0.0 0
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Summary of health economics findings
The primary objectives of our analysis were to assess the feasibility of collecting data that may be used
in a health economic analysis in the context of the BEADS trial, and to conduct an economic evaluation
and a value-of-information analysis in order to provide information on the potential value of conducting
the definitive trial. Hence, the primary aim of our analysis was not to conclude whether or not the
intervention was likely to represent a cost-effective use of NHS resources, but to conclude whether it is
feasible to collect the data required to make such conclusions based on a full trial, and whether it appears
to represent good value for money to conduct a full trial.
The collection of data required for the economic evaluation was successful in the BEADS trial; it would be
feasible to collect similar data in a full trial. The data collection completion rate was 97.9% at baseline for
the standard EQ-5D questionnaire and for the resource use questionnaire, and was 79.2% and 83.3% for
the EQ-5D and resource use questionnaire, respectively, at the 6-month time point.
Our analyses suggest that there would be a very high value to obtaining further information on key
parameters within the economic mode. This value is likely to far exceed the cost of running a full trial
whether an NHS and PSS perspective is taken (for which the population-level EVPI was estimated to be
£552.6M) or a societal perspective is taken (for which the population-level EVPI was estimated to be
£771.8M) in the economic model. The model parameters that are estimated to be the most valuable on
which to obtain more information are the NHS and PSS costs associated with ‘no response’ and ‘good
response’ health states.
Our aim was not definitively to estimate the cost-effectiveness of the BA therapy. However, our results
suggest that the BA therapy is likely to be of borderline cost-effectiveness from an NHS and PSS perspective,
given a cost-effectiveness threshold of £20,000 per QALY gained, but may be cost-saving from a societal
perspective. However, our analysis is exploratory and the results should be interpreted with care given the
small sample size in the BEADS trial.
It is important to note that the results of our model-based analyses differed substantially from those of the
within-trial analysis. The within-trial analysis estimated QALY losses for the intervention group, whereas the
model-based analyses estimated QALY gains for the intervention. This is because the model was response
based; response rates were higher in the intervention group and utility scores were higher in responders
TABLE 36 Results from EVPPI, societal perspective
Parameters Per-person EVPPI (£) Standard error (£)
EVPPI for UK over
10 years (£)
Health costs (response) 0.0 0.69 0
Health costs (no response) 0.0 0.0 0
Societal costs (response) 734.77 58.69 301,400,000
Societal costs (no response) 420.6 53.15 172,600,000
Utility (response) 0.0 0.0 0
Utility (no response) 0.0 0.0 0
Probability of good response (intervention) 0.0 0.0 0
Probability of good response (control) 0.0 0.59 0
Relapse rate 0.0 6.25 0
Number of BA sessions 0.0 0.0 0
Probability of death 0.0 0.0 0
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and were assumed to be equal irrespective of the treatment that had been received. We feel that this is a
reasonable assumption, but we highlight it here as the reason for the difference between the within-trial
and model-based analyses of QALY gains/losses. In fact, the average increase in utility reported by
responders in the control group was larger than in the experimental group (see Appendix 17). On average,
non-responders in the control group also reported a small utility gain, whereas there was a small decrease
in utility in non-responders in the intervention group. This explains why the within-trial analysis resulted in
a QALY loss for the intervention, whereas the modelled analysis resulted in a QALY gain.
We could have assumed that utility scores for the ‘no response’ and ‘good response’ health states were
treatment arm specific, which would have led to modelled QALY losses for the intervention. However, the
CIs for the utility scores in the ‘no response’ and ‘good response’ health states overlapped for the control
and intervention groups and were based on very low numbers; for example, EQ-5D-5L data at 6 months
were available for only four control group participants who achieved a good response, and six intervention
group non-responders. We therefore decided to calculate health-state utility scores that were not treatment
arm specific, assuming that the utility scores in each response state were not related to treatment received.
We feel that this is a reasonable assumption, but we highlight it here as the reason for the difference
between the within-trial and model-based analyses of QALY gains/losses. This also highlights that there
is considerable uncertainty around the impact of the intervention on QoL, and it is possible that the
intervention could lead to reductions in QoL.
Discussion of health economics findings
Costs were collected on all health-care resource use in the BEADS trial, and the ranges of incurred costs
varied widely between trial participants. Based on the data collected in BEADS, it is highly uncertain
whether a ‘good response’ leads to a reduction or an increase in health-care costs; however, the answer
to this is highly influential for the results of the economic evaluation. This is similarly true when the analysis
takes a societal perspective – the societal costs associated with ‘no response’ and ‘good response’ health
states are highly uncertain and highly influential. Hence, in a definitive trial it would be particularly valuable
to obtain more information on costs.
Given the importance of carer costs in the societal analysis, it is relevant to further consider how these
were estimated. Resource use questionnaires were used to collect data about informal care, and trial
participants were asked the following question at baseline and the end of the trial ‘Over the last 3 months
have you been helped and/or cared for by a relative or friend because of your health?’. If the answer was
‘yes’ participants were asked to record how many hours in the last week the person who helped them
most spent caring for them, and how many hours resulted in the carer not attending work. However,
there were many missing responses for how many hours attending work were lost and, therefore, all carer
time was costed equally. The total cost of carer time over the 6-month trial was estimated by extrapolating
the data for 1 week over the 6-month period and applying an hourly cost based on median hourly
earnings using Office for National Statistics figures (see Appendix 3). Owing to the majority of societal
costs comprising carer costs, we believe that any future trial should aim to improve the collection of data
on carer time. Carer diaries could be incorporated in the trial, or participants could be asked to complete
questionnaires more regularly, to reduce the need to extrapolate information from 1 week over a 6-month
time period.
Although societal costs were much higher than NHS and PSS costs, home help costs were a key driver of
the analysis undertaken from the NHS and PSS perspective. Therefore, for a definitive trial, care should
be taken to collect information on this as accurately as possible. In fact, in our study home help costs
were higher in the intervention group, whereas carer costs were lower; in a definitive trial, any potential
relationship between these resource uses should be further explored.
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Owing to the difficulties associated with obtaining accurate and precise estimates of health state costs
when all NHS and PSS (and societal) resource use is included, it may be argued that value-of-information
analyses that estimate the value of obtaining perfect information on these costs are likely to vastly
overestimate the value of further research because perfect information will never be obtained and high
levels of uncertainty are likely to remain even after a full trial has been completed. For this reason, we
reran our value-of-information analyses excluding all but direct intervention costs from the economic
model. This resulted in a population EVPI over 10 years of £20.67M. This suggests that it would still be
worth conducting a full trial to obtain further information on other parameters such as relapse rate,
utilities and response rates, even if other resource use costs were ignored. These data are best collected
in a RCT.
Although our economic model suggests that the BA therapy is potentially cost-effective, it is important
to reiterate that the within-trial analysis resulted in QALY losses for the intervention. These were highly
uncertain and were not statistically significant, but it is possible that the intervention could reduce QoL.
Limitations of the health economics analysis
It should be noted that there are limitations with value-of-information analyses. The EVPI represent the
value of obtaining perfect information, which is unlikely to occur in reality. It also assumes perfect uptake of
the intervention, which may be unrealistic (although by assuming that people with severe depression would
not receive the intervention we have attempted to estimate the eligible population size conservatively).
Therefore, the EVPI figures may be argued to represent maximum values of obtaining further information.
Conversely, our EVPI estimates account for parameter uncertainty only in our economic model – they do
not account for structural uncertainty. A very simple model structure was used because it was unlikely
to be possible to populate a more elaborate model using data collected in BEADS. For instance, different
categories of response could be modelled, as well as potential future neurological events that would be
expected to have an impact on the long-term effectiveness of the treatment. We believe that a more
elaborate model would not substantially alter the results of our analysis, particularly our supplementary
probabilistic analysis that incorporated a relapse rate to account for long-term effectiveness. However,
a more complex model structure may be appropriate if and when further data become available. Overall,
given that our estimated EVPI values were consistently substantially higher than the likely costs of
undertaking a full trial, it seems reasonable to conclude that conducting such a trial would represent good
value for money.
It may be considered that our assumption of equal mortality rates in the ‘no response’ and ‘good response’
health states is overly conservative, given the evidence of an association between depression and mortality.1,8,9
However, the model states are based on response, not on whether or not a patient still has depression –
a responder could still be classified as having depression. An alternative model structure could use health
states defined around depression instead of response, but this may miss benefits to patients who respond
favourably to the treatment but still have depression.
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Chapter 6 Qualitative research results
In this chapter we begin by providing an overview of the emerging themes and subthemes. At this stage,we have split the themes based on the data derived from the patient- and carer-participant interviews
and the therapist-participant interviews, which are brought together in Chapter 7 to offer a more
comprehensive view of similar issues from a patient, carer and therapist perspective.
The major themes covered in this section focus on patient- and carer-participants’ views of the intervention
and trial procedures, and therapist-participants’ views of and practical aspects of delivering the therapy,
and their views on the trial procedures. Although both groups of participants were asked to comment on
some of the same aspects (e.g. trial procedures), both groups also responded to questions that related to
their unique experiences. For instance, patient-participants commented on their experience of receiving
the intervention, whereas the therapist-participants commented on their experience of the training they
received to deliver the intervention.
The findings from these themes are brought together in a brief summary at the end of this chapter.
In this chapter we attribute quotations to ‘patients’, ‘carers’ or ‘therapists’, to distinguish which participant
group each individual was from. Patient and carer quotations are labelled as A, B or C to denote the study
site anonymously. We had only three therapists in the trial. To protect their identity, we do not attribute
quotations to specific therapists. We use the term ‘they’ so as to not gender the therapist.
Interviews were completed with 16 participants and 10 carers as well as the three study therapists.
See Appendix 19 for a summary of participant characteristics.
Patients’ views of the interventions and trial
Gains and changes
General changes and gains (not therapy related)
None of the control participants reported that they experienced any changes in their lives as a result of
undertaking the study. As might be expected, most patients in the control group explained that they had
only completed questionnaires in the study, thus still could not find a way to deal with their problems:
I: Has being involved in the research study changed anything for [participant] or for yourself at a,
at a greater level?
C: Not really I said because there’s (laughs) all you’re filling it [questionnaires] in isn’t it, nobody’s
highlighted the, oh you answered this and you know, can we help you.
Carer C1/009: control group
However, some control participants found being able to talk to someone about their experiences helpful
and cathartic. Moreover, they reported that answering questionnaires encouraged them to think about
their feelings and experiences. One participant also found the study helpful because it provided useful
information about stroke:
It give me [sic] information that I didn’t understand about strokes and that properly ‘til I came into
your study and it gave me a lot more information about them that I didn’t know.
Patient A6/001: control group
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Therapy-related changes (intervention group only)
Perceived changes in participants’ mood since undertaking therapy
Some intervention participants found it difficult to tell whether or not they felt any changes in their mood
since undertaking the therapy, because their mood was still changing, with several ‘ups and downs’.
However, some participants reported feeling better and less stressed as a result of having the therapy
and engaging in activities, even though they still experienced some ‘bad days’:
Well it was quite uplifting really because [therapist] gave me some good points you know to what to
do because I think I was down in the y’know sometimes I was quite nasty, not intentionally, I didn’t
know I was doing it y’know but [therapist] gave me some positives, positive ideas what do to do like
. . . y’know sometimes I’d be just like I am now and then the next minute me mood’d just gone to
the floor so it was ideas how to get over that and it did and then we found this stroke place didn’t
we which has been good as well so but the therapy has been really good.
Patient B1/087: intervention group
It’s difficult with [patient] because he changes so much with each . . . even though you’re with him
24 hours a day but he is changing so much. Probably sometimes he sinks a little bit more before he
either shouts you to get up in the middle of the night or gets angry, you know.
Carer C7/017: intervention group
Some participants perceived no changes in their moods since undertaking the therapy. One participant provided
conflicting accounts on whether or not they perceived any changes in their mood since undertaking the therapy:
P: It was good, definitely, yeah. Definitely [therapist] made me feel better . . .
I: Do you think you have changed since, after those sessions?
P: Ah well, I don’t know really. I can’t think if I have.
Patient A1/084: intervention group
In one case, the participant reported that the therapy had a positive impact on his mood while it lasted.
However, when it came to an end, he had not been feeling as good as before:
P: I think my mood’s all over the place anyway at the minute. Yeah, I think, yeah, ‘cause it makes me
feel a bit more positively and plan it has a bit more positive impact on my mood, which it had done,
but I think that might be to do with the fact that course came to an end.
I: So you think it improved your mood but then maybe it’s not carried on or it has carried on?
P: It has. It’s only recently I’ve been, I’ve not been as good. I’ve been meaning to ring [psychologist],
to be honest.
Patient C7/017: intervention group
Other perceived benefits of therapy
Participants described benefits in terms of reassurance, engaging in more activities, looking at the bigger
picture and thinking about the future, learning skills to break up tasks into manageable bits, and having
more realistic goals and expectations. The therapy was described as a trigger for planning and setting
realistic goals, and also provided ideas for engaging in activities to occupy the mind and keep participants’
moods up instead of doing nothing:
I think it was, it was the thought that you weren’t being abandoned altogether, that somebody was
there to care for you . . . somebody did come and make various suggestions to do things. So that was
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quite useful . . . I think the thing that gave her ideas of things to do, to occupy her mind, not just to sit
and vegetate but to try and get things done. Which she has done, I mean she’s enjoyed the drawing,
for instance, and she very much, and she’s made a good job of it . . . So it’s give her an idea of
something to do.
Carer A1/084: intervention group
Moreover, some participants reported that the therapy helped them to think about their needs and reflect on
their feelings, and gave them new and positive ideas about things to do. They expressed an understanding
of the relationship between thoughts, mood and engaging in activities:
Um, I don’t feel as if I did anything during the trial that I wouldn’t have been doing anyway. Um, but
it did help me reflect on how activities were affecting my latest mood, certainly . . . I think it was the
reflective process and I think just recording some of the things down to be quite cathartic . . . I think
I learned to accentuate the positive maybe. And what I realised was that it would be very very easy to
get down and depressed if I concentrated more on the things I can’t do now.
Patient A6/002: intervention group
Some participants reported feeling a sense of achievement for being able to do tasks and engage in
activities despite the stroke. They became more aware of their capabilities and realised that they can
still perform certain tasks by setting realistic goals:
[Working voluntarily at the museum] helped me realise just what a gap it was filling in my life. It sort
of grew and it made me feel useful . . . it’s these weekly sessions discussing what I was doing did help
me appreciate what a difference it was starting to make to my life . . . Um, I think it gave me a sense
of achievement to actually physically get out. Um, I think generally where I have a day where
I haven’t gone anywhere or done anything, then I think I’m feeling a bit down by the end of the day
because I feel I’ve wasted the day . . . And I think that’s something that I realised during the sort of
weekly reflections, that that’s the life attitude that really fights off downs. You know, my really giving
myself a pat on the back for what I have done, rather than concentrating on what I feel I can’t do.
Patient A6/002: intervention group
Some participants in the intervention group found that merely talking to the therapist during the sessions
was helpful and cathartic:
I used to get very emotional about it [stroke] and I didn’t like talking about it, I used to bottle it all up.
But I’ve found it helps if you do talk about it . . . It’s like a pressure release valve. It lets a bit of steam off.
Patient C7/001: intervention group
Carers also perceived some benefits of the therapy on their own health and well-being as the positive
changes in participants helped carers to have a break from their caregiving responsibilities and reduced
their burden. Seeing the improvements in participants’ mood also made carers feel happier:
It’s [BA] given me pleasure to think that [patient] enjoys doing things out of it.
Carer A1/084: intervention group
Activities/tasks undertaken (during and after therapy)
Participants talked about a range of tasks and activities undertaken during and after therapy that they
found helpful. For example, participants talked about resuming their creative writing, drawing and
painting, volunteering in a museum, building kit cars and walking, among other things:
[Therapist] suggested projects I might do which some of them I’ve not got round to changing the box
yet and sort of things to do I’ve been doing these paint books you know when I’m sat sort of on me
own y’know . . . I’ve done quite a few erm, yeah they help us concentrate.
Patient B1/087: intervention group
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Therapy-specific experiences (intervention group only)
Understanding the purpose of therapy
Participants had a broad recognition of what the intervention was for and what it could achieve.
There were some initial concerns about what benefit the therapy might offer:
I didn’t know what really to expect. It’s that not knowing bit, isn’t it? But when something like this
[stroke] happens to you, everything’s a big question mark, every day of your life is a question mark.
Whether I can get up in a morning, be motivated to do things.
Patient C7/017: intervention group
In most cases, however, there was a generally positive assessment of the therapy:
Different tasks, really trying to get me back into realising that you can do things . . . this encourages you
to break things down into little bits, rather than the whole thing, which is a better way of doing it.
Patient A1/034: intervention group
Participants felt that therapy was about making them more active to improve their mood by reflecting on
self and activities done, and by making them realise that they needed to break tasks into manageable bits
in order to complete them:
It’s a big hole out of your life, that. So my days will get pretty boring pretty quickly. I suppose with
that, what they were doing with me, was to prevent them things from happening, getting bored and
planning things to do and making sure I went through with them. The tasks, which, I suppose, were
really important. I suppose they were very good with that. That’s the exercise, I think, it did have a
meaning to it. A meaning and an end, if you like. Before that I wasn’t interested in planning nowt,
or doing nowt, on a daily basis.
Patient C7/017: intervention group
Reflections or perceptions of therapy
Perceived mediators of change (helpful aspects of therapy)
The identification of different and meaningful activities to perform aligned with goal-setting was frequently
described and presented as an important aspect of the therapy. However, in general, participants found it
difficult to articulate the mechanisms of change, and they did not explicitly distinguish the effect of BA
therapy from the processes involved in it:
Well [therapist] told me how to do drawing and things like that, I hadn’t even thought of it before
[therapist] came. And it’s done me good really. Trying to do some knitting and crocheting, drawing.
Yeah, fine. I think it’s good the idea, because I hadn’t even thought of it.
Patient A1/084: intervention group
Planning (particularly setting goals that are realistic and manageable) was described as an important aspect
of the therapy:
You try to do things and you struggle because you try to do things, you’re not cutting the picture
down, you’re just trying to look at the whole thing. But this encourages you to break things down into
little bits, rather than the whole thing, which is a better way of doing it . . . I’ve learned how to get
round to doing it with the problem, which is what it’s teaching you. There’s always two ways to get
somewhere, which I think you’ve got to remember.
Patient A1/034: intervention group
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Completing the diary was also found to be one of the most helpful aspects of the therapy because it
allowed the participants to reflect on progress, activities and mood on a regular basis. It also functioned
as a reminder for some participants to do the tasks and achieve their goals:
I made a note of what I did um every day and how I was feeling and we [with therapist] talked through
it. Um, and I did find it useful, interesting, and it sort of um prompted me to reflect on my progress and
my activities . . . I came to look forward to the sessions because it was a chance to sit and reflect and
um, and it gave um, it became an activity in itself um, which helped me to focus what I was doing over
the week. Whereas perhaps if I hadn’t been taking part in this, I would have been taking these activities
for granted . . .
Patient A6/002: intervention group
The mere process of having to talk to someone during the sessions about their feelings and experiences
was found to be helpful by many participants:
The one thing it does is give you, you know that someone’s gonna come round, someone you can
have a friendly chat with as well, which makes a difference.
Patient A1/034: intervention group
The positive characteristics of the therapist (e.g. being ‘friendly’, ‘positive’, trained and encouraging) and
having a good relationship with the patient were alluded to on a number of occasions, suggesting that the
therapist’s manner might be a mediator for the success or acceptability of the therapy:
In the beginning it needs somebody trained to get your mind-set to change and ask the right questions
and get people to think differently.
Carer C7/017: intervention group
There was also a suggestion that continuity (i.e. having the same therapist attend weekly) was important:
Not a stranger because obviously you do get to feel comfortable with the person, with [therapist]
and, you know and you kind of, kind of look forward to it.
Carer B1/087: intervention group
Challenging aspects of therapy
Some participants mentioned that the therapy was useful only while it lasted, so they felt the need for
follow-up sessions to maintain the benefits. Participants highlighted some challenging aspects of the
therapy, even though they found the therapy helpful as a whole:
I’m not 100% certain, I think I did benefit from [therapist’s] weekly visits and going through goal-
setting and things. I suppose that, since [therapist] stopped coming, that’s slipped a bit. And I would
things, sort of think about doing things. I supposed, [therapist] turning up was more of a reminder for
me what I’m doing.
Patient C7/017: intervention group
However, participants understood that the sessions were part of a research project and that it had to end
at some point:
Well, we always realised there was a timescale on it. So, I mean, we were prepared that we knew it
wouldn’t last forever . . .
Carer A1/084: intervention group
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Some participants highlighted that not every stroke patient is affected in the same way and suggested
tailoring the therapy based on individual needs:
It’s difficult because just for myself personally, I think it’s been great but I would think it depends on
the type of person you’re going to see and how it has affected them y’know whether they would
think ‘oh yeah this is fine’ or ‘I can’t be bothered’ y’know that sort of thing but I accepted that
everything that was put to me was positive and I did my best to do it.
Patient B1/087: intervention group
A few participants reported having some trouble with filling out the diary. One participant suggested some
improvements in the mood diary by breaking it into morning/afternoon/evening, as their mood tended to
vary during the day:
His projects that he was supposed to do, I think he found that difficult because [therapist] would give
him a weekly chart like a diary to fill in what he’s been doing in the day and I think he just found that;
even when he were at work he found it difficult to fill in paperwork so it’s nothing new.
Carer C7/017: intervention group
Two participants found the sessions and the tasks repetitive and boring:
The only thing that I found, you know doing all that work with [therapist], a lot of it repeated itself a
lot. It was quite repetitive at times.
Patient C7/017: intervention group
Some of it I thought were [sic] a load of rubbish. On the whole, it was a neutral. Some of it was good,
some of it I found boring, some of it I found helpful and it helped me.
Patient C7/001: intervention group
Format of therapy
Number, frequency and duration of sessions
Most participants thought that the number and duration of sessions were ideal. However, some
participants suggested having follow-up sessions to ‘keep the pot boiling’ and maintain the positive
changes gained in therapy:
Well, it might be worth sometimes to think about some sort of follow-up on a, on a sort of annual
basis, sort of thing? See how things were going . . . it may be useful to keep in touch with things,
I don’t know. You know, to see whether things are still working or not.
Carer A084 A1/084: intervention group
Role of carer in sessions
The carers’ involvement with the sessions was varied. Although some carers reported assisting the therapist,
others stated that they did not get involved with the therapy and supported the patient (if needed) only to
do planning. Some carers reported joining the sessions (despite not taking part in the sessions), whereas
some stated that they had never been to the sessions. However, carers felt happy with the level of their
involvement:
Well, I think it was just assisting whatever [therapist] wanted to do. If [therapist] wanted me to do
something then I would, you know, attempt to do it. You know so it was just a sort of, like a, you
know, assistant. Assisting [therapist] to do whatever they wanted to do with [patient]. Tried not to
interfere more than necessary, really.
Carer A1/084: intervention group
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Therapists’ views of delivering the therapy
Experiences of delivering the therapy
General views and experiences
All three therapists found delivering the therapy to be a positive experience and stated that they would
recommend the intervention to other therapists and patients because of its ‘simplicity’ and usefulness.
They also found implementing the therapy easy and straightforward:
I found it quite easy to implement the therapy . . . I think they [participants] found it really beneficial
and they did just you know writing down just the initial activity diary and just getting them to see
what they do and what they don’t do and how they could incorporate more things and I think that
just really helped so yeah, I’d definitely recommend it.
However, the therapists were also mindful that the therapy would work better for people who had come
to terms with having had a stroke and were ready to put in the amount of time and effort required.
As for this reason, they suggested that the therapy might be more effective if provided as a supplement to
other therapies for adjustment and physiotherapy:
I think it works really well for the people who are kind of at the start following their stroke where they
are ready to kind of put in the amount of time and effort required with behavioural interventions . . .
some people I work with just seemed to be I guess when, when somebody’s got such a low level of
hope and they still kind of haven’t really come to terms with how their stroke has changed them and
how its changed what they can do especially if somebody’s experienced a loss of some kind of role . . .
those people that were really quite resistive to any kind of introduction of activity or identifying activity
they’d just say I can’t do that I can’t do that.
For all three therapists, communicating with participants went well, as they did not have any participants
with extreme difficulties (e.g. severe aphasia or cognitive difficulties). There were only a few participants with
such difficulties but they were all able to understand, follow the conversation and perform the tasks. One
therapist found the communication strategies taught as part of the training to be useful, as most participants
had some degree of impairment in communication owing to stroke, even though it was not severe.
Challenges
The therapists also discussed the challenges they encountered while delivering the therapy. Dealing with
the individual differences was reported to be one of the most challenging parts of delivering the therapy.
Therapists did not rigidly follow the session-by-session plan as not everyone worked at the same speed,
and the physical and cognitive capabilities and personalities of people varied. Some participants were more
resistant to change or sceptical, whereas others were open to take on board new ideas:
I had a couple of people where I had to take it a little slower, needed a little bit more time or a little
bit more time for their writing, again that wasn’t difficult it was just something that I had to be aware
of . . . I think some people are a little bit more resistant to change depending on where they are in
their journey after stroke. Some people are ready to take on board anything that you want to do
others are a little bit more sceptical even though they’ve decided to try it . . . So trying to get people to
understand the rationale and why we were doing it, some people I had to repeat that for a lot more
and really y’know try and keep them on that frame of mind.
In order to deal with the individual differences, therapists tried to be responsive to individual preferences
and tailored the session structure based on individuals’ needs:
I just tried to be responsive to the individuals as I kind of do in my day-to-day therapy and I think
again as I mentioned, going back to the rationale of the therapy and the protocol to try and remind
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them what we were trying to do and why . . . just thinking around the individual needs and exactly
sort of what people were frame of mind that they were in at the time.
Two of the therapists also found the process of identifying meaningful and achievable activities difficult in
some cases owing to the participants’ levels of disability and unrealistic expectations:
I‘d say the hardest things was just working round practicalities of what people could and couldn’t do
now, I think people tended to still get very focussed in their initial goals of ‘I just want to be as I was
in the past’ and so the hardest thing was trying to get people to look at perhaps having to adapt that
and having a different goal slightly or working with that.
Keeping people engaged with the therapy-related tasks was also challenging. One therapist suggested
that this was due to people not being able to come to terms with the stroke and being ready to change.
They also argued that, if they were in a clinical situation, they would withdraw the intervention for such
people (after a collaborative decision). However, as this was a research study they felt the need to keep
pushing to engage people:
Quite a few people that I worked with it seemed like they weren’t quite ready to be increasing their
activity and what they needed more at this stage in their recovery was the talking therapy and work
on acceptance with kind of the stroke and the changes that have happened in their life so there
was some difficulties there in terms of people’s physical capabilities and also engagement with the
intervention because they kind of felt like there wasn’t anything that they could do . . . quite a few
of the people I worked with were telling me that they didn’t really want to plan things out they
didn’t want to plan activity and plan out their lives . . . and I think in a real life clinical situation there
would have been a couple of points where I think I would have had quite a frank conversation with
somebody about their level of engagement with the intervention and where we’d to go from here
and if they really want to carry on.
Improvements needed/suggestions
In order to improve the therapy, two therapists suggested having a standardised interactive therapy
notebook or a folder that might be easier for participants to use and might also facilitate their
engagement with the tasks, as noted in the following quotation from one of the therapists:
I tended to recommend to people or suggest they consider having like I say a bit of a therapy book
because we would obviously have sheets that I could copy for people and things like that and that can
become a bit disparate and people end up with piles of paper all over. So one thing I’d say perhaps
just to consider, and a couple of people did, was to have a therapy book, erm a notebook that they
can make any questions for the session, notes at the end and set the goals in it and kind of almost do
that together and then they can sort of slip their diary in it. And one thing for therapy in the future if
that wanted to be quite standardised across therapists is that could always be something that came
with the therapy so perhaps a bit of a workbook for the clients that BEADS produce so that all the
therapists were doing that in the same way. So even if it was just a notebook with like a couple of
sections or something like that or even just a folder that sheets could go in or just to standardise it if
that’s something to keep quite the same across a large number of people.
Some therapists also argued that delivering the therapy 3 months post stroke was too soon as patients were
still in the process of adjusting to stroke, and behavioural change was not a priority for these participants.
Therefore, they suggested that delivering the therapy 9 or 12 months post stroke might be more beneficial:
I thought that maybe having the therapy 3 months post stroke was a bit too soon, just because people
are still adjusting to what’s happened and having to adapt their homes . . . I felt like it wasn’t so much of
a priority for them to do the BA. They were always wanting to walk or improve their speech.
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Experiences of participants from therapists’ perspectives
Observed changes in participants
Therapists observed that some participants made considerable progress in terms of increased confidence,
engagement in activities and making plans. The level of progress in mood and activity levels varied among
participants. However, even in those participants who progressed less, there was an increase in activity levels:
There was definitely a couple of people that I worked with that were hugely different in what they
were describing, so anecdotal things like confidence increased, going out more, wanting to speak
to other people more.
The people who really engaged with the therapy and kind of did go through this gradual process of
introducing a bit more activity, experiencing lift in their moods, a bit more energy, a bit more motivation
and then it kind of snowballed from there and people being more motivated to engage the following
week because the work they’d carried out had shown benefits for them.
They also observed some secondary benefits of the therapy for participants. Having someone to talk to
during the therapy was thought to reduce participants’ feelings of isolation:
I think having someone who was dedicated to talking to them about how their life had changed and
what they could do to help them and just that acknowledgement was a huge part of it I know that’s
kind of the secondary benefits of any therapy, it’s not the core of BA to be listening to people but that
was huge, and most people commented that the stage that they were at once they’d had all their
discharge support sort of 6 months down the line from the stroke it was very isolating, so they found
that very helpful.
Therapists also observed that those who engaged less with the therapy benefited less than those who
were fully engaged:
. . . then there’d seemed to be some people who don’t carry out the work or they do and don’t get,
they don’t experience as much of a lift in their mood as they were hoping for or they didn’t quite get
from it what they wanted then engagement would drop off and then things kind of snowball in the
other direction if you like.
Observed helpful and unhelpful aspects of therapy to participants
Therapists’ observations of the helpful aspects of the therapy for participants echoed the accounts of
participants and carers. That is, therapists observed that identifying new and meaningful ideas, undertaking
reflective processes during the sessions, having weekly sessions and enabling the participant to talk to the
therapist were the most helpful aspects of the therapy:
More than anything it seemed to be just having the chance to talk things through with someone and
some, mainly a lot of things that came out, just talking and the ideas that it sort of lead them to think
of. So things to do, ways round little problems, getting out the house so all the things that we would
do for the BA activities, people said they’d found that really helpful to do that.
Therapists also emphasised that completing the activity diary helped participants to become aware of the
link between being active and their mood:
I think looking definitely visualising the mood rating and their activity levels really helped mine and
showing them the progress that they were making and how their mood was being marked good
when they were doing certain activities over other activities so I think visualising that and getting
them to see it on paper rather than just telling them about it actually really helps.
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Undertaking the therapy at home and the flexibility of the therapy schedule were also considered helpful:
People really thought it was good that the therapy was available in their own homes, people seemed
to respond really well to that especially when I’d go out to and see them and talk about the study
and explain that the work’s carried out in their own homes, people spoke positively about that and a
couple of people had even kind of before I’d even got to that point indicated they wouldn’t be able to
come out and see me so their preference was to be seen at home.
Practical aspects of delivering the therapy from therapists’ perspectives
Support provided to therapists
Views on the manual
All therapists found the manual to be a helpful resource when delivering the therapy as it provided
guidance during the intervention, broke down the material and gave examples:
The manual was really helpful, some really good hints in it like at the beginning where it gives you a
few more hints about using it with people with difficulties in aphasia again just to remind you, and
broke it down into all the different sessions . . . I think all the sheets at the back were quite helpful
so having a choice of different appendix and things were helpful yeah.
Although two therapists described the structure of the manual as flexible, one therapist found it somewhat
rigid and suggested amending the manual to have a little less structure in how the modules are introduced
to increase flexibility, as the second quotation indicates:
So it’s a very good structure and it was always told to me that it was quite flexible so I never felt that
I was doing that wrong and obviously discussed it in supervision as well but yeah just for myself and
the clients that I had, we didn’t stick very rigidly to that session by session structure . . .
I did find it tricky at times when you kind of reach a road block in one aspect of the therapy like I was
saying before if someone doesn’t want to be kind of formally activity scheduling with some kind of
planner and you’ve tried everything to come up with a way to modify the strategy in a way that’s
acceptable to them but still not getting anywhere and then trying to bring in other strategies like
graded tasks or problem-solving it, the manual in that sense felt a little bit rigid it was kind of I think
problem-solving got introduced in session six or seven of the manual and graded tasks around the
same time but in my head I kind of imagined it being a bit more like a timeline between activity
monitoring, identifying enjoyable activity and activity planning so those are kind of the three stages
and graded tasks and problem-solving are kind of additional strategies that slot in throughout.
One therapist found the manual ‘a bit dense’, but understood that it needed to be comprehensive to cover
people with different needs. They suggested providing a brief overview of each session in the manual to
help therapists as a quick reference:
I did find the manual a bit, a bit dense to use as kind of a brief reference but I understand it needs to
be as comprehensive as possible and it was useful to have the amount of information that was there
but one thing I found really useful was [pause] I flicked through the manual and essentially took out
all the headings for each section within each session and made summary cards for each session which
fit onto a piece of paper about that big a couple of inches long, which I could use just as a reference
. . . As an additional resource I think something like that would have been useful . . .
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Views on the training received
The training received was described by all the therapists as useful in providing a good foundation to BA
therapy. They found it ‘comprehensive’, supportive and responsive as they were able to ask for help and
get answers to their questions:
I’ve found it to be very supportive in all the training and everything that I’ve had . . . the training
helped just kind of make sure I was doing everything in line with the protocol . . . we had plenty of
time to go through different modules and ask questions and sort of get an idea of how the BEADS
wanted us to use the therapy, but without it being . . . and it was nice to meet the other therapists at
that stage, doing the training and talk to people, so I think I found that really helpful and a good
base definitely.
One therapist also commented that the amount of training provided was just about right and that they
had the opportunity to ask for extra support if needed:
I felt very able to ask for help and extra sort of support if I’ve needed it . . . it didn’t feel like it was too
much, overkill or anything like that it was helpful.
The speech and language training was found to be particularly useful as it provided therapists with some
useful tips on communication with people with aphasia:
[The] Speech and Language Therapist . . . gave us training on communicating with people with
aphasia and gave us tools and some resources, that was that was excellent as well that was really
useful as I said I didn’t really work with anyone with very severe communication difficulties but just
the strategies in general were useful with almost everyone I’ve worked with.
Views on the supervision received
The overall supervision received (including supervision from the BEADS team, direct supervision in service and
peer supervision) was also described as useful and supportive. Peer supervision was found to be particularly
helpful as it reduced therapists’ feelings of isolation and provided them with an opportunity to share their
experiences and tips on how to overcome certain issues they encountered:
The supervision was good I think with us being quite all over the country the supervision that we had
with the team, the BEADS team worked well over the phone so it was really, really good to have that
sort of peer supervision here we had conference calls because it was, you’re quite isolated in doing
this role for what you’re doing for the BEADS so it’s very nice to kind of hear and talk to the others
and sort of share experiences and sort of tips and hints of things they’ve overcome so definitely that
was a really good way of doing it . . . I always had the direct supervision within my service from the
sort the PI as well which was fine . . . I felt very supported.
Views on the monitoring of practice
Therapists did not feel like they were being monitored, and felt that there was a good balance between
people keeping an eye on their practice and not making them feel pressured:
It always felt there was a good balance between erm I would have the support where people were
keeping an eye on what I was doing so I couldn’t go too wrong but there wasn’t sort of hovering
over the shoulder and sort of didn’t feel too pressured and I could ask if I needed to so, that
was good.
Therapists also discussed the videotaped sessions and whether they felt that these sessions were different
from unrecorded sessions. All three therapists felt that the videotaped sessions were the same as the
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unrecorded sessions; however, they also admitted being self-conscious at first, but this disappeared after
5–10 minutes. They also reported that they did not observe any differences in participants during the
videotaped sessions:
A little bit self-conscious with kind of the videos . . . it wasn’t a huge, huge problem at all and once
the session got started you kind of forgot it [camera] was there. So it didn’t bother me . . . I was
keeping an eye out for them [participants] maybe not being too different with the camera on from
how I’d seen them in other sessions. So I think the biggest thing was yeah, just trying to make sure
they were OK with that but everyone seemed fine . . .
It was weird having to video yourself but no it was good, most participants were happy to be videoed,
especially when they knew it was just for training purposes and wouldn’t be broadcasted on the news
or something.
Experience of working on trial within therapists’ departments
Therapists had varying experiences of working on the trial within their departments. One therapist was
autonomous, working completely separately from their clinical team. Apart from receiving supervision
and updating the team, they mostly worked independently from home:
I think for me it was completely separate. So I had my supervision from a clinical lead who was the PI
for our site, my team do something very different so apart from I kind of let people know what I was
doing and sort of gave a bit of information, but generally it was just completely autonomous . . .
One therapist felt integrated within a larger clinical team within the department:
My team . . . were brilliant as well, so yeah I really enjoyed it. I had a lot of help from [names person]
. . . everyone was really supportive and always replied to the e-mails and yeah I got a lot of support so
it was really good . . . there was always someone there to help and give you any supervision if you
needed it and . . . so there was always a wealth of knowledge to ask if ever I needed it so yeah,
I couldn’t have asked for better team to be, to be part of.
In contrast, one therapist did not feel integrated within the clinical service and expressed that they were
mostly working in isolation:
I was kind of working in isolation a little bit which isn’t ideal . . . so I didn’t really feel integrated into
the service in anyway and the way that referrals came to me from the service it seemed I wasn’t really
involved in the triage process or really that involved with the other professionals in that team.
Integrating the trial practice into wider service
Barriers
Barriers to integrating the trial practice into wider services included therapists being employed in different
hospital trusts and the difficulty of having to keep reminding people in community teams about the trial:
I think because I had the two different [names settings and place], I think it was difficult to keep
reminding people of the BEADS trial and that it was running.
A couple of issues in terms of software I guess and the systems that we use for note takings
and reports and that was to do with that fact it’s two separate trusts again kind of working
across both.
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Facilitators
Therapists found sharing information, support from psychological services and regular supervision helpful,
and thought that this might facilitate the integration of the trial practice into wider services:
Obviously having the clinical psychologist who was fully supportive and on board . . . so having
someone that was, that knew all the different people and could email them and, and tell them about
the study was really useful for me so that was good.
Regular supervision was really important and helpful . . . I think with a second larger study just keeping
that in mind, the idea of making the therapist feel part of the service by kind of physically locating
them in the same place as the service would be, quite an important thing.
Participants’ views on the trial procedures
Rationale of the study
Participants and carers recognised the importance of the study and there was a sense of them having an
understanding of its rationale:
I think it’s useful information and the only way you can get it is by talking to people like me, that’s
guide through it [sic].
Patient A6/001: control group
You can’t move forward in these situations without these projects and things.
Carer B1/087: intervention group
However, there were a few concerns about what benefit the study and filling out different questionnaires
might offer participants on a personal level:
Well, since this [stroke] has happened I’ve had all sorts chucked at me. Different types of questionnaires.
Varying different types of questionnaires. I thought it was good, it’s got its good points. Erm, but
ultimately what do I achieve from it?
Patient C7/017: intervention group
Motivation and reason to participate
Altruism was one of the most commonly mentioned reasons for participating. Some participants joined the
study as they felt grateful to have been invited. Other participants explained that they thought it was
better than doing nothing and that there was nothing to lose:
I went into this open-minded and I thought, I’ve got nothing to lose, I’m only sat in the house, I’m not
doing anything. If nothing else, it’s somebody to talk to.
Patient C7/001: intervention group
We said yes, you know it’s the least we can do in return for all the care and attention that [patient] had.
Carer C1/047: control group
However, it was evident that some people had specific expectations of the BEADS study. Some wanted to
find out about their problem and what could be done to improve their mood. Others chose to participate
to see if the treatment would work, and some saw the study as an opportunity to talk to others about
their problems:
But err so I’m interested in you know trying to sort out well for ourselves trying to find out what is
it frustration or is it depression that [patient]’s got. Is there anything that we can do about it? . . .
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But yes I am I am in a way desperate or I am keen to try and find a way that we can bring [patient] a
little bit more back to what she was prior to certainly the last two strokes, if not all three strokes.
Carer C1/047: control group
Well I thought, well I’ll see what I can do and try and, try and help like, you know. And see if it help
me to get me head straight a bit.
Patient A4/002: control group
Some participants reported having no expectations regarding the study when they first got involved:
I don’t think we had a thought about whether it was going to help or not. And I, and I don’t think
actually, one way or the other.
Carer A1/124: control group
I didn’t know what to expect, I was just – I’ll do it, I’ll do it, I’m not doing anything else. So yeah,
I thought yeah, I’ll give it a go.
Patient A6/001: control group
For others, it was the hospital or the health professionals who suggested the trial to the patient:
It was from [staff name] at [hospital name], and she came out as sort of a stroke counsellor to try and
help me adjust with you know the stroke. Because it’s difficult. It’s tough when you’ve had a stroke
you know. And she came out and it were [sic] her that suggested it.
Patient A4/002: control group
Understanding the research process
General
From the feedback interviews, we established that, overall, participants and carers thought that the information
provided was clear and easy to follow, and that the study itself was a positive experience in general:
Well as I say the interviews aren’t unpleasant in any way.
Patient C4/005: control group
However, some participants had difficulty with remembering details about the study owing to stroke-related
memory problems:
I can’t remember anything about the study because, apart from everything else, the stroke’s affecting
my memory and I can’t keep them in my mind long, they just disappear after a short while.
Patient A6/001: control group
The follow-ups were highlighted as useful as they provided participants with an opportunity to reflect on
the intervention and the trial:
Been very happy, you know I like the fact that you don’t just leave people, you do follow it up. You
give it a break before you actually come out again, and so it gives you time to settle down and review,
and all that sort of thing.
Carer B1/087: intervention group
Some participants and carers expressed that they would like to know about the findings and receive
feedback about the study:
I know the study’s finished and what’s the final outcome when the final study’s done, all its conclusions?
What’s that? What happens then?
Patient C7/017: intervention group
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For control group participants, the research process was straightforward, involving only the completion of
questionnaires. Most control participants (both participants and carers) reported not feeling involved with
the study and there was a sense of disappointment as a result:
It’s [study] been quite straightforward as far as I’m concerned. No problems whatsoever . . . I’ve had to
do nothing, only attend two visits from people asking me questions. There’s nothing much to say
about it really.
Patient A1/124: control group
Recruitment
When prompted to recall the recruitment process, some participants reported that they could not
remember the finer details of the process. This could be attributed to (1) stroke-related memory problems,
(2) feeling overwhelmed as a result of stroke-related issues happening at the time (e.g. many health
professionals getting in touch, having had the stroke recently) and (3) their involvement having been a
long time ago:
I: How did you come to be involved in the study?
P: I can’t remember haha! It’s that long ago, I can’t, I think we got a phone call or a letter or something.
Or even erm I honestly can’t remember . . . I can’t you see this is where the stroke has affected I can’t . . .
Patient C1/047: control group
In general, participants did not mind being asked to participate in the study and some found the process
of getting involved in the study easy:
I: So how did it feel, being asked to do the study?
P: Ooh I didn’t mind at all. Did I?
Patient A1/084: intervention group
One carer argued that some participants might be discouraged by the use of mental health terms and by
the perceived intrusive nature of the study. However, she was happy to get involved and encouraged the
patient to take part:
I can see why people wouldn’t be, because people are often a bit put off by the words, you know
that are used, the sort of mental health side of it and all that sort of thing. But it was clearly very
appropriate in this situation . . . I guess people might think it’s a bit intrusive or you know, quite a bit,
not personal stuff I don’t remember there being a lot of personal stuff, but it’s, for the actual patient
or you know stroke victim if you like, you know you’re asking how much they can do certain things
and all of this. And it’s another stranger that’s coming into the home and all this sort of thing . . .
But I mean I’m quite, just for me, I’m quite an open person and I will take any help of any sort given
the situation.
Carer B1/087: intervention group
Acceptability of randomisation protocol
In general, intervention group participants felt positive about being allocated to get the therapy and some
thought of this as a ‘privilege’:
Well I think it was, we thought it was a privilege to have the chance to do it rather than be sort
of abandoned.
Carer A1/084: intervention group
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Feelings of disappointment were evident in some control group participants and carers for not having the
intervention, as they understood from recruitment processes that they would be receiving treatment:
I was a little bit disappointed, to be fair, but I was happy to go along with it and see what would
happen, but I was a little bit disappointed. I wanted to be more involved.
Patient B6/001: control group
However, there was also a sense of understanding about why there was the need to have a control group
and a sense of acceptance among participants:
Yeah, I don’t mind that [being in control] because I think it’s useful information and the only way you
can get it is by talking to people like me, that’s going through it.
Patient A6/001: control group
Indeed, some intervention group participants would still have taken part even if randomised to the
control group:
C: But yeah I was fine about it really, either way we would have taken part in it I think wouldn’t we?
P: Yeah, yeah.
C: Because it’s all, it’s all useful and how can you get, you can’t move forward in these situations
without these projects and things. So you can’t lose by it really, we would have gone either way to
be honest.
Carer B1/087: intervention group
However, some uncertainty about the randomisation process was evident; some control participants
thought that they were not taking part in the therapy sessions because ‘they were already doing activities’
or that they did not ‘qualify’ to get the treatment:
I: So your research assistant would have called you to let you know that you were part of the control
group, so you weren’t going to be taking part in these therapy sessions.
P: No. Because I already was doing bits myself, you know. So I was like doing a lot of what they were
going to do, probably, you know.
I: So is that why, is that the reason you think that perhaps you weren’t chosen?
P: I don’t know because I have me books you see, and I sit colouring all day, well most of day!
Patient A4/002: control group
P: Yeah I didn’t get the treatment, I didn’t qualify for the treatment.
Patient C7/013: control group
There was also a perception among some intervention group participants that the questions they answered
were used to ‘qualify’ them to receive the therapy. This demonstrates misunderstanding and perhaps a
lack of clarity in how the trial information has been explained to participants:
Um, I was asked, if I remember right, I was asked certain questions which said whether I, to which one
[group] I would be going to.
Patient A1/034: intervention group
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Participants’ views of the outcome measures
Focus of measures
Overall, participants felt that the focus of the measures was good, ‘pertinent’, ‘pretty thorough’ and
‘interesting’, and they felt that we were asking relevant questions of both the participants and the carers.
Participants and carers were asked to rate the questionnaires on a scale of 1–10 in terms of their content
and focus (1 = for not capturing important aspects of their experiences and 10 = fully capturing important
aspects of their experiences). On average, participant and carers gave 7.15 (SD = 1.85), indicating that the
questionnaires captured important aspects that were relevant to their experiences.
Some participants thought that some of the questions were not relevant to their own personal situation,
but they could see the relevance of such questions for other people who experienced different problems,
and understood that the questions needed to be broad:
. . . so some might not have been quite so relevant for us, but overall you’re covering it all for people
with stroke. So yeah I don’t have a problem with any of it, some more relevant than others, but I
wouldn’t say you should leave anything out because you’ve got to cover it for everybody.
Carer B1/087: intervention group
Some participants mentioned that how they answer the questions might depend on how they feel and cope
on a daily basis and that their answers might be different if they completed the questions at another time:
Sometimes the ones you know, did he feel weak and stuff, not at all this week . . . they do, are
different at the beginning to what they are as you get further on, it depends how they cope with it.
Carer C1/009: control group
Participants felt that the questionnaires were useful as they gave them and the researchers some indication
as to how their mental health was affected by their condition and the intervention itself:
Well yes, yeah. I mean obviously this [questionnaire] gave me some indication as what my mental state
was at the time.
Patient B1/087: intervention group
One participant thought that there were some missing questions regarding fear and confidence that might
be relevant to people affected by stroke:
I know one question which was not on there and I know sometimes I do think it, people who have
had a stroke and got off light, or anybody who’s had a stroke, they are frightened they’re going to
have another one and that’s at the back of their mind . . . because the confidence goes and in the
back of the mind, I might be driving somewhere, have a heart attack because I’ve got AF or could
have another stroke.
Carer C1/009: control group
Ease of understanding/completion
General comments
Most participants and carers had positive views of the questionnaires in terms of ease of completion and
understanding. A number of people found the questions fairly straightforward to complete:
I think he was fine answering the questions. And he found that a lot of the, the questions that were
being asked, or was, well they were asking him when he was in the hospital, I think, we’ve had different
people come, different nurses and things come in. So a lot of the questions were the same as that.
Carer A1/124: control group
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Some participants felt that space was needed to allow them to express their responses in more detail and
they suggested providing more space or asking open-ended questions. In contrast, others mentioned that
they preferred ticking boxes, as this was easier:
It was pretty easy because you’d got the options rather than having to think about what you wanted
to say. About how easy things were, how difficult things were. You got a, you got an option for each
one so, yeah, I would say it was pretty easy.
Patient B6/001: control group
Few participants found completing the questionnaires difficult. One participant found the content of the
questionnaires difficult to grasp because of stroke-related problems, whereas another participant found it
hard to concentrate when questionnaires were lengthy:
Shattered because I had to uh concentrate. And the problem being is, the questionnaires are that long
winded that when your brain’s been affected, you have trouble concentrating, so they could simplify it
just a tad.
Patient A1/034: intervention group
For some participants and carers, it was hard to explain their thoughts and feelings, particularly in a
continually changing context. However, they also suggested that the questionnaires provided them with a
specified amount of time:
C: You know, even though circumstances can change you can only answer with, you know it’s like,
one of them was about me, how was I getting on that particular week. Now that particular week I
wasn’t having a good week. If you’d have asked me a week before that or a fortnight it might have
been oh I’m fine, so they are pretty good.
I: But you, you like that it gave you that defining amount of time?
C: Yeah. Even as though as I said circumstances can change.
Carer C1/009: control group
I: Did you find that [completing questionnaires] easy or quite hard?
C: Hard. Hard to explain your thoughts and feelings.
Carer A6/001: control group
Some participants explained that they needed help with filling in the forms in terms of holding a pen,
concentrating or remembering. One patient stated that she would not complete the questionnaires alone
as she would not have the patience and the ability to concentrate. Thus, participants suggested that, if
they complete the questionnaires together with someone (i.e. by having a conversation), it would boost
the confidence of the patient and completing the questionnaires would be easier.
C: The problem with form filling for [patient] she hasn’t got the almost the patience to do it. So if you
give her something like that and then she’s absolutely bored by the time she’s got to the bottom of
the first page.
I: Hmm, how did you get around that?
C: Talked about it, I asked the question . . .
I: How do you think [patient] would have got on if you hadn’t have been there?
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C: She wouldn’t have done it . . .
P: I’ve always been frightened of forms, filling a form in, in case, in case I do it wrong. In any case so
just looking at it I would have thought I can’t cope with this, and I would have just ignored it, I really
wouldn’t know.
Carer and patient C1/047: control group
Specific outcome measures
In general, participants reported positive views on each specific outcome measure. However, some
participants and carers found it difficult to answer questions about feelings, as how a participant feels
fluctuates all the time depending on the shifting stroke-affected context:
I found it OK. The questionnaire that we had that you know that I filled in for myself at the end, was
OK. Some of the questions were a bit erm, I couldn’t say how he was feeling. You know, you have
to expect that, you want to know how he was feeling on that day. Well, you know, as far as I’m
concerned some days are good days, some days are bad days, so you can’t really make a judgement
on each day, because you don’t know what each, you don’t know what each day is going to pan
out like.
Carer A1/124: control group
Participants expressed some issues with the mood questions. For instance, they felt that asking about
suicidal tendencies was ‘strange’, ‘not appropriate’ and ‘upsetting’, and one participant felt that these
questions were ‘not valid’ as people might not answer them truthfully owing to the stigma associated with
depression and suicidal thoughts. However, there was also a sense of understanding of the purpose of
these questions and that they might be relevant to those who were very depressed:
I found a bit strange I don’t know some people might not, but. It says erm well the question, do you
ever think that, do you ever wish you were dead? Do you think you’d be better off like, you know.
Well that, to me that’s a question, a strange question. ‘Cause I mean I don’t think anything like that,
it’s probably ruddy morbid though . . . I certainly don’t think it’s a relevant question to me . . . I can’t
understand the purpose of a question like that quite honestly. I mean whether it erm, whether the
answer relates to a person, to an individual state of mind or not I don’t know, it may do. Which I
suppose it does in a sense. Because you know people might get all sorts of strange things when they,
through frustration and that. Which erm, which is I do feel a lot sometimes.
Patient A1/124: control group
Several participants found the aphasia-friendly questions with pictures and smiley faces helpful as the
images made the questions more relatable and they enabled participants to better express their feelings:
I feel they sort of, you could put 0–3 but, yeah. They made it, sort of, I felt that YOU could see exactly
how I was feeling . . . I feel that, again, you can see better how I actually feel with the pictures rather
than if it was just like before with the questions. I feel this one you can see a lot more.
Patient B6/001: control group
In contrast, one participant was offended by the simplicity of these questions. This was also echoed by
another intervention participant who declined to complete the aphasia-friendly questionnaire, as he found
these ‘too simplistic’. However, participants recognised that for others more severely affected these
questions were needed:
I didn’t really enjoy it. And then there was one with pictures, and she [researcher] said now can you
point to what’s on these pictures. And I thought well, course I can! There was a bridge, and a ship in
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it, and things, and a fence, and things like that! And I thought of course I can! Then you think after,
it’s probably for them [sic] people that can’t remember, you know, that’s brain’s got a bit, you see.
Patient A4/002: control group
Most participants had difficulty answering the resource use questionnaire as stroke-related memory
problems made it difficult to recall answers:
Quite hard to recall, especially when it’s asking you about the minutes each time. But yeah, if you just
round it up, it’s not too hard.
Patient B6/001: control group
Carers found the caregiving questions to be relevant and they appreciated being considered because they
often felt forgotten:
I was actually quite pleased because in a lot of these types of situations the carers do get forgotten
about, it’s one of those duty things isn’t it. But erm I was pleased to see the carers were at least
considered in the equation really, it wasn’t just about the person that was ill.
Carer B1/087: intervention group
Quantity of questionnaires
Most participants and carers were happy with the number of questionnaires that they had to complete
and stated that the quantity was ‘just about right’:
There wasn’t too many. It was fine, it was, yeah, I would have liked more (laughs) . . . it wasn’t too
short, it wasn’t too long, it seemed to have got all the information.
Patient MB/001: control group
I: What you thought about the number of times and the number of questions we’ve asked you to
complete, whether that’s been OK or whether there’s been too many things?
C: That’s fine, I mean there’s got to be a reason for it hasn’t there? You know, so that’s fine.
Carer C7/013: control group
Four participants thought that there were too many questions:
It took a long while yeah . . . Well, I did get fed up of answering questions [laughs] to be honest, kept
going which is more or which is less, or whatever and things, and I thought not another page you
know! [laughs].
Patient A4/003: control group
Some people questioned why we were being repetitive and wondered if this was a way to ‘trick’ them to
respond in a certain way or to see if they are being ‘honest’ with their answers. The duplication tempted
them to constantly go back and check their answers:
You notice as you filled them in as you’ve gone through them, you notice you’re answering the same
question two or three times over . . . Now whether this is just a trick to sort of get you to put yes on
the first page and no five pages later I don’t know, but they are a lot of questions duplicated . . .
So you can go back and rub all the answers out and make them all agree! Haha! . . . There’s always
temptation isn’t there.
Carer C1/047: control group
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Therapists’ views on the trial procedures
Recruitment
Each therapist experienced different issues with recruitment depending on the setting in which they were
based and their links to recruiting trusts:
I think it was quite difficult in that I couldn’t get hands-on and do things. So we struggled with getting
packs out and recruitment to start with . . . so having permission to go in and work with the team and
the research nurses to send out packs and then contact patients and follow that up would be really
helpful . . . if we could have a few extra staff as it were for the first couple of months to really plough
out that invites, information contact people and then even if that dropped off later because we didn’t
need that support, to kind of almost do it the other way round that would have helped.
They also found that recruitment from voluntary groups was ‘unfruitful’ as the members were already
functioning well or were several years post stroke:
[we] tried a number of approaches for different groups so like the voluntary groups and things like
that, which was completely unfruitful. So that didn’t really work because the groups mainly held
people who were either functioning quite well because they were active in the groups or they were
sort of 15 years post stroke so it was a very long time ago.
One therapist found the process challenging and experienced problems at the start, as the sites had not
been set up as planned. They felt stressed when targets were not met as they believed that it was their
responsibility to recruit the target number of people:
We had a little bit of an issue with recruitment at the start of the study in [names place] and other sites
weren’t quite set up on according to the schedule for the study and that kind of set things back a little
bit . . . the impression I had was that recruitment was and the feeling that I got was that recruitment
was kind of solely my burden almost it was all my responsibility and kind of it was quite stressful at time
when targets weren’t, weren’t being met because of lack of referrals . . . and I think one thing that
helped towards the end of that was getting some more support from the admin team that I was kind of
working with the [name of] admin team which I guess just didn’t figure out was available at the start.
When the therapist was integrated into the wider stroke research team at the trust, they reported that this
went well as they had access to patient data and were able to support all recruitment activity:
I had a lot of help from the stroke co-ordinator . . . she’d given me a database to work from, send out
recruitment packs which really helped to kick-start recruitment for [names site] . . . being able to access
that data and managing all the recruitment myself and sending out the packs and knowing where was
at with everything really helped because I wasn’t having to rely on other people to do it who had their
own jobs to do as well so I think that was a real benefit for [names site] because I was able to look at
the patient records and send out the invitation packs so it was really good.
Two therapists argued that working part-time limited their ability to recruit more people and slowed down
the process, as they did not have sufficient time to exhaust all the available recruitment routes at the same
time as delivering the therapy.
Study procedures
As it was their first research experience, two therapists had initial concerns about following the protocol,
but they both felt that they were able to ask questions and received support from the trial team, which they
found useful:
There was a few things that I had questions on so just to check back on, yeah as I say I’m very clinical
based so a lot of the paperwork it was all new to me quite how much paperwork and forms and
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everything there was. So I was a bit terrified of getting something wrong, but I was, I felt able to ask
questions and anytime something was slightly wrong.
Two therapists found the protocol comprehensive, easy to follow and useful as a reference guide. One
therapist thought that it needed some amendment to allow for flexibility and streamlining in terms of the
processes of screening, baseline assessments, recruitment and consenting:
It [protocol] seemed to work really well, it was nice having that as a reference guide to refer back to,
it was very thorough and so yeah I think that worked well, I can’t think of anything to change.
There were a couple of things in terms of recruitment and the recruitment routes themselves I think
there’s a couple of amendments there to be made to allow for that flexibility but I think just a little bit
more flexibility being inherently more in the protocol would have been useful . . . I think the process
for screening, baselines and recruitment and consent could have been streamlined a little bit I think
that there were some cases I found that it was a little bit disjointed.
One therapist identified that completing therapy treatment sheets and transferring them to the online
system duplicated effort and was time-consuming:
So, for most of the paperwork, like assessment paperwork, you would do it with the client ‘cause you
were doing there and then and then you would transpose it onto the system when you got home
which was fine because you can understand that, but the therapy treatment write-up sheets just felt
like a real duplicate of time because you would write up your notes with the patient, make some
notes as you were going along and then you would do a paper copy and then you would do it on the
computer. So it was almost like ‘cause that was quite time-consuming.
Measures
Therapists thought that all the measures were relevant and comprehensive and fit with the purpose of
the study:
Well I know all the different assessments are capturing different bits of data for various things that
they’re going to be looking at. I think they’re all relevant . . . I think the carer questionnaires were
particularly good, I think the carers that I worked with really liked being involved in the study and that
way being invited to take part as well and have their view . . . They seemed fit for purpose, there wasn’t
anywhere I was thinking that it was I didn’t understand why it was being done or that I was thinking it
wouldn’t be useful there was just that one where there was a doubling up of the aphasia-friendly and
the standard one.
One therapist thought that there were too many questionnaires, but felt that they were not tedious and
were relevant for the purpose of the study. Another therapist did not think that there were too many
measures to complete and noted that, when needed, the assessment session was split:
There was a lot of them [questionnaires], but I could see why they were there. They didn’t feel too
tedious, as I say I never had anyone with great difficulties sort of aphasia or cognitive, they could have
been quite overwhelming if there was, it would have taken time.
I didn’t find that it was too much. I just had one lady who did get tired halfway through so we had
to split the session up . . . I just thought that that was the information that was needed to collect . . .
if participants were struggling I’d read the questions out for them and do and the checking and things
like that.
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One therapist highlighted the doubling up of the aphasia-friendly version and standard version of the
EQ-5D-5L questionnaire at baseline and thought that it would be more efficient and more accurate if
people completed them independently at first and got help from the therapist if needed:
There’s one that there was a standard version and an aphasia-friendly version as part of the baseline
booklet which I always kind of felt that it was a bit of a confounding variable that some of those
baselines were done in person with the therapist as opposed to done by the individual themselves
because a lot of the time the baselines were carried out with me going through them, me reading in
which case the aphasia-friendly version and standard version it kind of, it’s a bit meaningless if it was
me going through them anyway.
Qualitative summary
Most participants’ experiences of being involved in the trial were positive. However, not all participants
understood that they would not receive therapy for their mood problems. In addition, the understanding
of reasons for being randomised to usual care was variable. These findings suggest that more information
should be provided to participants about randomisation before they are consented into the study, possibly
with reminders being given during the course of the trial.
The outcome measures were generally felt to be appropriate in terms of content and length. Some
participants found questions on death and suicide inappropriate, but there was an understanding of their
purpose and their relevance to those who were very depressed. Therefore, outcome assessors may need to
introduce these questions or questionnaires with care. Some participants thought that it would be useful
to include questions about fear and confidence. Some questions were thought to be duplicated across
outcome measures, which is inevitable given that standardised questionnaires were used (with some
overlap of questions). Images to support the understanding of questions were found to be useful by many
participants, but there is a need to be mindful of participants who may find this childish and insulting.
Moreover, some participants had memory issues affecting their ability to complete measures, particularly
the service use questionnaire. Therapists felt that the questionnaires could have been overwhelming if
participants had more significant language and cognitive difficulties.
The therapists’ views of the trial procedures were generally positive. However, they felt that the process
of screening, baseline assessments, recruiting and consenting could be clearer in the protocol. They also
felt that it was important for them to be integrated within the existing clinical teams, when possible, for
ease of recruitment and understanding site-specific processes. Therapists also found completing therapy
forms on paper and on the electronic database a duplication of work that was time-consuming, and they
suggested making this process simpler.
Many patient participants reported benefits of having the BA therapy in terms of their improved use of
strategies, and increased levels of activities and mood. For many, the follow-up appointment was seen
to be useful therapeutically and they suggested that this could be part of the intervention itself. Some
therapists felt that the timing of therapy (3 months post stroke) was too early, as people were still in
the process of adjusting to stroke, and they suggested providing the therapy later (9 or 12 months post
stroke). Therapists also recommended including an interactive therapy notebook to facilitate participants’
engagement with the therapy. Both the training and supervision provided for the therapists were found to
be useful. However, therapists found the manual quite large and suggested providing an overview summary
to refer to as needed.
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Chapter 7 Discussion
Summary of findings
Feasibility was demonstrated across the majority of the selected outcomes and we identified strategies
for improvements in a definitive trial. However, the main issue outstanding is whether or not a sufficient
number of sites that would be capable of delivering the intervention and maintaining participant numbers
over the trial could be recruited.
Feasibility trial
We randomised 49 participants to the trial (one in error) in 27 centre-months of recruitment. Recruitment
was lower than the anticipated sample size of 72, although this calculation was based on 36 centre-
months of recruitment. The highest number of participants was recruited through hospital databases,
whereas recruiting from stroke wards was the least effective method. Nine participants (19%) dropped
out of the study during the 6-month follow-up; seven of these were in the BA arm. Delivery of the
intervention was good, with high attendance (90%).
Participants received a median of 9 and a mean of 8.1 BA therapy sessions (range 0–14 sessions), with
sessions each lasting a mean of 57.3 minutes. Excluding the participants from the BA arm who did not
receive the intervention, 75% of participants received at least eight sessions. A positive effect was found in
the intervention arm for the primary clinical outcome, the PHQ-9 score. We did not test for statistically
significant differences between the groups because this was a feasibility trial but we note that the
95% CI does not include zero. In terms of the secondary outcomes, the intervention had a positive effect
for participants on VAMS ‘Sad’ and the NLQ and for carers on the CSI, although these results are not
considered statistically significant. There was no difference between intervention and control groups on
NEADL. Small negative effects were found for the patient-reported EQ-5D-5L and SADQ.
Fidelity assessment
The therapy record forms, which documented the proportion of time (in 10-minute units) spent on
individual components, indicate that the components of BA described in the manual were delivered to
participants. The distribution of time on the different components over the course of therapy was as
expected. However, there was little use of graded tasks assignments and training in problem-solving
documented. This may be because graded tasks were often used as a between-session task and so were
coded as such. The video recordings of sessions were an important adjunct to the record forms as they
highlighted some aspects not otherwise recorded.
Qualitative
Therapists, participants and carers observed that the most helpful aspects of therapy were identifying new
and meaningful activities, reflection during the sessions, having weekly sessions and having the chance
to talk with someone. Most participants felt that both the number and the duration of sessions were
appropriate, although some participants suggested that follow-up sessions would help to maintain the
gains made. Interestingly, some control participants also found participation in the study helpful as it
provided opportunities to talk about their experiences. However, others were uncertain as to why they
had been randomised to usual care.
The therapists found delivering BA a positive experience and would recommend it to other therapists
because of its simplicity and usefulness. The therapists found the manual and training helpful but
suggested having a summary of each session and an interactive notebook or workbook for participants.
The therapists may also benefit from having a quick reference guide alongside the full treatment manual.
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The therapists also believed that therapy would be more appropriate for those who had come to terms
with their stroke (i.e. those who had a stroke > 3 months ago). The biggest challenge identified was the
variation in individual presentations, although the therapy and manual allowed sessions to be tailored for
individuals’ needs. However, identifying meaningful and achievable activities was difficult for some owing
to their level of disability and unrealistic expectations. The therapists reported different experiences of
recruiting participants to the trial, reflecting local site differences.
Health economics
Behavioural Activation Therapy for Depression after Stroke has shown that it is feasible to collect the
data to conduct a rigorous economic evaluation. Uncertainty is high and influential, such that very high
values of obtaining further information are estimated, irrespective of the perspective of the analysis,
but conducting a full trial would appear to represent good value for money.
Evidence of feasibility and implications for a future definitive trial
Population/recruitment
The primary objective of this multicentre feasibility trial was to assess feasibility of recruitment in the study
population for a definitive trial. A total of 756 participants were screened across all sites, of whom 49 were
recruited, giving a recruitment rate of 1.8 participants per centre per month. Delays in set-up meant that
we had a reduced number of months of recruitment as we still closed the study on the planned date. Had
recruitment been open for 36 months rather than 27 months, at our recruitment rate of 1.8 participants
per centre per month, we would have achieved a sample size of 62. We have identified ways to improve
recruitment in future studies. The delays in site set-up have been outlined in Chapter 3 and were due to
delays in receiving approval for excess treating costs, with the knock-on effect on the appointment of
study therapists in the NHS and the IAPT provider changing close to the time at which the study was due
to open. This suggests that a longer set-up time should be scheduled for a definitive trial, particularly given
the increased number of sites needed.
The sample size for a definitive trial was calculated with two main options, one based on a difference
in PHQ-9 score of 4 points between treatment and control at 6 months and the other based on a
difference in PHQ-9 score of 3 points between treatment and control at 6 months. Both options represent
moderate standardised effect sizes that are appropriate for a trial of this kind. If a definitive trial were to be
powered on the smaller effect size to detect a smaller effect, this would mean that, to have a total sample
size of 580 participants, based on a recruitment rate of 1.5 participants per centre per month, 16 centres
and 24 months of recruitment would be required. However, recruiting 16 centres capable of participating
and delivering the intervention, while maintaining a steady pace of recruitment over 24 months, may be a
potentially significant challenge. Given the variability in psychological support services for people with
stroke, it is not yet clear if 16 centres would be achievable. Data would need to be collected to explore
this aspect further.
The attrition rate, at 19%, was higher than the anticipated 15% and was highest in the BA group. The
reasons given for dropping out were varied and included having insufficient time (for those in the BA group)
and a deterioration of health. However, people did not have to give a reason or may not have given the
real reason for drop-out. The attrition rate was higher than in studies of CBT for post-stroke depression25
and motivational interviewing after stroke.31,35 The sample size was too small to enable subgroup analysis to
explore whether or not particular characteristics were associated with drop-out. One possible factor is that
in BEADS we recruited people at a wider range of time points post stroke.
Recruitment varied across the three sites. Recruitment was most successful at site 1, where the therapist was
based in the hospital with the CRN research nurse, which enabled close working to facilitate recruitment.
This was reflected in the qualitative interviews, in which therapists noted that it was important for them to
be integrated within clinical teams to facilitate recruitment. The therapists were generally positive about the
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trial procedures but suggested that the process of screening, baseline assessments, recruiting and consenting
could be clearer in the protocol.
From our observations in the feasibility trial, the use of IAPT as a main site for recruitment in a definitive
study may not be ideal, particularly if this is separate to the trust delivering wider stroke services. This is
due to the nature of IAPT services, which can be actively sought out by participants, and it was possible
that people would be less likely to refer potential participants owing to the risk of an unfavourable
randomisation outcome. The IAPT site had lower recruitment, possibly as a result of having fewer stroke
patients available to them than the other main sites. This made them heavily reliant on patients identified
from the hospital database at the companion site. This adds to the challenge of recruiting the large
number of sites required for a full trial.
Recruitment varied across the different routes. The highest number of participants (42.9%) was recruited
using hospital databases. Although this requires a large number of potential participants to be contacted,
it may be considered an efficient approach in terms of staff time to send out the invitation packs. This
approach alone may not be sufficient to sustain recruitment over the duration of a definitive trial depending
on the number of patients on the database and how many years previously the details are available (e.g.
if recruiting up to 5 years post stroke). The highest uptake from the number of patients screened was via
community caseload (13/28 participants; 46.4%), which is possibly attributable to the personal approach by
the clinician who had the opportunity to explain the study and answer questions, although this is more
time-consuming than using databases. We did not recruit through GP databases, and this could be explored
as a future option in order to approach people who are later post stroke (e.g. 2–5 years) to reach the large
patient population. We would first need to establish the likely proportion of people on the database who
have had a stroke within the past 5 years and the time and resources needed to send out invitation packs.
A further suggestion for recruiting more patients who are later post stroke (e.g. after 1 year) and therefore
unlikely to be in contact with stroke services would be to increase self-referral. This could be attempted
through advertising the study more widely in the press and through social media.
It is possible that equipoise, or lack of individual equipoise, may have affected recruitment when we were
reliant on clinicians as the gatekeepers notifying potential participants about the study. Interviewing the PIs
and key clinicians from the sites would have provided insight into how they perceived equipoise and to
what extent it influenced how they explained the study to participants. We did get an indication, however,
that there were issues of equipoise at one site early on. At this site objections were raised about the
treatment-as-usual arm not receiving any active intervention, and whether this was ethical. This was
resolved with the explanation that it was unknown whether or not the intervention arm would be shown
to be beneficial. However, additional guidance for clinicians may help them to explain equipoise to
eligible participants.112
Therapists reported that, as a result of their workloads, they could recruit only the number of participants to
whom they could deliver the therapy without undue delay (in the event that participants were randomised
to the intervention arm). At one of our sites, the therapist had to delay randomising participants and this
meant that there were varied periods of delay between baseline assessments and randomisation. In nine
participants this delay was > 30 days. Stratification by site was used but this did not alleviate these delays.
To increase recruitment rate and/or reduce this delay, therapists would potentially need to be employed for
a greater proportion of the week in order to prevent long delays between consent and intervention delivery.
All of the participants with aphasia had mild aphasia, which may indicate that people with more significant
communication support needs may have been missed by the identification and recruitment methods used.
It is possible that staff referring to the study simply did not consider people with significant communication
difficulties. In addition, the written information sent out to potential participants (covering letter, participant
information sheet, reply slip, PHQ-9, VAMS ‘Sad’) may not have provided sufficient support for people with
more significant aphasia to understand the study and demonstrate an interest. For a definitive trial, the
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presence of these difficulties could be one of the factors that help decide whether to send a pack or whether
to arrange a home visit to discuss the study.
The therapists reported not using the CST if they felt that the potential participant seemed to be communicating
well with them. Yet, how well a person appears to understand can be misleading and is subject to the
judgement made by the therapist. If people with more significant communication difficulties are identified
for a future trial, it will be important for therapists to use a tool such as the CST routinely with all
participants. This would ensure consistency and identify any communication difficulties that need to be
supported. It is to be noted that the FAST, which is similar in presentation to the CST, was completed well
as it was part of the CRF. However, FAST indicates only the presence and severity of aphasia, whereas the
CST identifies the levels of communication ability and thus eligibility for the study and also links to support
strategies. These issues could be addressed during staff training in a future study.
Generalisability
The information gained from this feasibility trial was adequate to inform the sample size needed for a
definitive trial. Our inclusion criteria were broad to reflect clinical practice and address the issue of the
generalisability of the results. In order to recruit a sample representative of the wider stroke population,
we identified participants through a range of routes. In most participants (62.5%) the time since stroke
was 3 months to 1 year, although one-quarter of participants were between 1 and 2 years post stroke. We
included people who had their stroke up to 5 years previously because there is evidence that depression is
still common after this time113 and to reflect our original PPI feedback.
The therapists did attend voluntary stroke and aphasia groups in an effort to identify people > 5 years
post stroke but found that they were less likely to need support for low mood and were often more than
5 years post stroke. For a future study there is the potential to access hospital and community databases to
include more people between 2 and 5 years post stroke.
It is an important point that people with aphasia have higher rates of depression than the rest of the
stroke population and it was disappointing that only mildly aphasic participants were recruited. Of the
48 participants recruited, 18 had aphasia, which reflects the incidence rates of aphasia in this population114
(it should be noted that all of these patients were mildly aphasic). This may be a reflection of the recruitment
approaches used. We have already shown in a previous study17 that BA can be delivered to a sample of
participants with aphasia and can improve mood. At baseline, 78.7% of participants were scored as having
mild cognitive impairment on the MoCA, which is in keeping with previous findings that up to 75% of
participants have cognitive impairment after stroke.115
The team discussed the possibility that it is not uncommon for clinical staff to ‘pre-screen’ patients and
not identify those who they believe might struggle with the intervention or they feel they want to protect,
which is common with patients with communication and cognitive difficulties owing to their increased
vulnerability. A possible way to ensure inclusion of a wider range of aphasia severity in a future trial may
be to provide training to the clinical teams about ensuring that all patients identified as eligible are given
the choice about whether or not to participate in the trial, irrespective of a personal clinical viewpoint. In
addition, it may be of benefit to engage more fully and regularly with the speech and language therapists
within each clinical team, as they are best placed to identify people with aphasia.
Half of the people (69/138) who completed the PHQ-9 for screening prior to recruitment scored as
depressed. This is higher than the prevalence of one-third reported in the literature11 and suggests that
our recruitment approaches were able to identify depressed people who were willing to respond to the
invitation for the study. The mean PHQ-9 score of 16.8 points (SD 4.7 points) in the recruited sample at
baseline falls in the category of major depression, moderately severe. In the sample at baseline, 39.6%
of participants scored as having moderate depression, 31.2% were scored as having moderately severe
depression and 29.2% were scored as being severely depressed. We excluded people who were receiving
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medical or psychological treatment for depression when they had their stroke and those currently receiving
psychological intervention. Therefore, we would not expect to have many people with severe depression.
We recognise that all but one participant was from a white British ethnic background. We would therefore
need to improve the representation of the multicultural, multi-ethnic UK population in a definitive trial.
Approaches to improve this representation could involve the selection of a diverse range of study sites as
well as the inclusion of people from different ethnic backgrounds in our PPI group.
For the purposes of this trial, only English speakers were offered the intervention as delivering the
intervention to non-English speakers is not straightforward. This would need to be addressed if the
intervention was shown to be effective with English speakers initially. It is important to explore methods of
broadening this intervention out to non-English speakers, for example by using therapists trained in BA
who speak the same language as the patient, using translators or using family members (this would need
to be explored with caution as translators often do not translate verbatim and, therefore, the content of
the therapy delivered may not always be consistent with that received and so careful fidelity measurement
would be required).
Intervention
The feasibility of the intervention with regard to delivery was very promising as the results demonstrated that
the intervention could be delivered as intended across sites and was acceptable to participants, carers and
therapists. Of the 225 intervention sessions scheduled, 202 sessions were completed (i.e. 90% of sessions
scheduled were delivered). Reasons for missed sessions included changes to participants’ availability (n = 14,
61%), illness (n = 4, 17%) and change of therapists’ availability (n = 3, 13%). Overall, the therapy seemed to
be acceptable to participants, carers and therapists and could be delivered by an AP or IAPT therapist under
supervision from an experienced mental health practitioner. The intervention was manualised to support
delivery of the intervention by the therapists, to facilitate consistency across sites and therapists and to allow
future replication. The therapists did comment in the interviews that the manual was quite large and that
an overview summary to refer to would be helpful. They also recommended that an interactive therapy
notebook/workbook might facilitate participants’ engagement with therapy. Some participants who received
BA suggested that follow-up therapy sessions would be useful to maintain gains. This would be consistent
with the booster sessions offered in the study comparing BA and CBT for depression in primary care.49
The therapy record forms indicate that the components of therapy in the manual were delivered to participants
and that the distribution of time was as expected. The therapy record form may need to be modified to reflect
the content of between-session tasks, as the infrequent coding of problem-solving and graded tasks on the
record form may be because they were covered as between-session tasks. This is supported by the fact that the
therapists and participants did refer to problem-solving and graded tasks (i.e. breaking down a bigger goal or
task into smaller steps), which suggests that these approaches were used.
In the qualitative interviews, therapists felt that the timing of therapy was too early for some participants
as they were still adjusting to stroke, although it is important to note that this was not commented on in
participant interviews. Participants had to be a minimum of 3 months post stroke but could be up to
5 years post stroke, so we did not constrain recruitment to the early months post stroke. The sample size
is not sufficiently large to allow subgroup analysis of whether time post stroke was related to differences
in outcomes. With regard to whether the intervention is sufficiently adaptable for patients who were
perceived to come up with unrealistic goals, we could attempt to address this in a definitive trial by
including more time in the therapists’ training to provide guidance on goal-setting, using examples from
BEADS. We could also seek feedback from our PPI group on how to better explain the purpose of the
therapy to patients and provide examples of goals that may be appropriate.
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Outcomes
Follow-up for a definite trial could be done via telephone (where appropriate), which may improve follow-up
rates. We observed that some participants needed to be reminded by telephone call a few times to complete
and send back outcome assessment packs to the central study team; this could be practically challenging in a
larger study. Postal outcome assessments supported by telephone reminders with the option of resending
questionnaires, completing questionnaires over the telephone or offering a home visit have been used
previously31,35 and Parker and Dewey116 highlighted that administration time was important to maximise
the quantity and quality of information obtained by postal questionnaires. Follow-up home visits could be
offered to all participants; however, this would significantly increase the cost of the study, particularly
considering the number of centres and participants needed for a definitive trial. Text message reminders
could also be used.
Completion rates of individual questionnaires were good and there are no reasons to change the outcome
measures. The outcome measures were generally felt to be appropriate in terms of content and length.
The quality-of-life measures used in the BEADS trial are worthy of further consideration. The standard
EQ-5D questionnaire was included, as was a proxy version completed by carers on the behalf of
participants, an accessible, unvalidated, aphasia-friendly version of the EQ-5D, and the standard version
completed by carers to report their own QoL. Because nearly 98% of participants were able to complete
the standard version of the EQ-5D at baseline, this measure was chosen as the basis for the economic
evaluation, with neither the proxy version nor the accessible version used any further. It is relevant to
note, however, that data completion was slightly worse for proxy measures, and that the agreement
between proxy measures and patient-completed questionnaires was only moderate. Agreement between
patient-completed standard and accessible measures appeared to be much higher, although this does
not represent an appropriate validation of the tool. This reinforces the view that proxy measures should be
avoided when possible, hence the recognised need for accessible preference-based HRQoL measures for
participants who are unable to complete the standard EQ-5D questionnaire.117
Carer QoL was collected marginally less successfully than patient QoL in the BEADS trial. Completion
rates were 84.8% at baseline and 63.6% at the 6-month follow-up time point. QoL of carers has rarely
been taken into account in economic evaluations, but excluding it may underestimate the value of an
intervention owing to health spill-over effects not being incorporated, as the health and well-being of a
carer can be affected by the health of the person for whom they are caring.118 Including these spill-over
effects can affect the cost-effectiveness of an intervention.119,120 There is currently no consensus on how
spill-over effects should be incorporated, but a conceptual framework has been developed to suggest how
they could be.121 The BEADS trial has shown that it is feasible to collect information on the HRQoL of
carers, and this could be incorporated into future analyses to help inform decision-making on the
allocation of scarce health-care resources.
Owing to the small mean difference (and 95% CI) found between the intervention and control groups at
follow-up on the NEADL, this measure could be omitted from a full trial. Overall, the items on the NEADL
may not be sensitive to detect the changes in the types of activities addressed in BA. In the qualitative
interviews the therapists commented that some participants showed an increased confidence during the
therapy. One participant also suggested that questions about fear and confidence were missing from the
measures they completed. A measure of confidence after stroke has recently been published122 and may
be suitable as an outcome measure in a full trial, although, as a new measure, its responsiveness to
change has not yet been determined.
Adverse event reporting
Trials of non-pharmacological health interventions vary widely in their approach to recording AEs and
making attributions in terms of causality. We recommend that the approach taken in any future trial is
appropriate to the level of risk and feasible. Given appropriate resource, we would record AEs but an
option would be to avoid labelling them as ‘adverse’, specifically to avoid the need to assess causality.
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For a definitive trial we would recommend that non-serious AEs are not assessed for relatedness to stroke or
the intervention as these are difficult to attribute to the intervention. As hospital admission details are not easily
accessible for rehabilitation trials and an AE cannot always be assessed for its relatedness to the intervention or
condition, we would propose that events are not recorded as AEs but rather as safety outcomes, which are not
assessed in the same way and for which no action is taken. These safety outcomes could then be reported
regularly to the DMEC for monitoring. We would record and report SAEs.
Strengths and limitations
The feasibility trial
Behavioural Activation Therapy for Depression after Stroke was a multicentre RCT. Allocation concealment
was ensured using internet-based randomisation hosted by Sheffield Clinical Trials Unit. The outcomes
assessors were blind. It was not possible to blind participants or therapists to group allocation. The SAP
was agreed prior to data lock. In addition to the feasibility RCT, we had nested qualitative research, fidelity
assessment and a health economics evaluation. As outlined previously, delays in site set-up meant that the
start of recruitment was delayed. However, we kept the original recruitment end date and so were able
to deliver the trial, intervention and follow-up assessments in the time period originally agreed, albeit
with reduced numbers. Issues with recruitment and recommendations for improvements are detailed in
Chapter 3, Challenges with recruitment and data collection.
Participants were willing to be randomised, although in the interviews some control group participants
seemed to misunderstand why they were randomised to usual care (e.g. they thought that they did not
qualify for the intervention). This suggests that the purpose of randomisation and result of the allocation
needs to be explained more clearly. We were able to recruit a diverse sample in terms of demographic
and clinical characteristics.
The control arm in this trial was treatment as usual; therefore, there was no active control arm or any
attempt to control for attention. We decided against including an attention control group, as there is
already evidence that the benefit from BA to treat depression in other settings is a specific effect of
treatment rather than a non-specific effect of extra attention. In a trial of CBT for post-stroke depression25
it was difficult to deliver an attention placebo intervention that was credible to participants, easy to
facilitate and included none of the active intervention strategies. Further consideration should be given to
including an attention control third arm, but the benefits of this would have to be weighed up against the
difficulties associated with the associated increase in sample size that this would require.
As noted recently by Popp and Schneider,123 there is no ‘gold standard’ for attention placebo controls in
trials of psychosocial interventions. Our main argument against including an attention control group is that
there is already evidence for the effectiveness of BA for treating depression in other settings. In particular,
in a recently updated meta-analysis of RCTs of BA for depression,124 6 of the 25 studies comparing BA to
controls used treatment as usual for the control, 15 used a waitlist control, 3 used a psychological placebo
intervention and 1 study had a waitlist and a placebo as controls. The meta-analysis found that BA was
superior to controls. A smaller effect size was found in studies using a placebo intervention compared with
a waitlist or usual care, but these effect sizes were still statistically significant. There is therefore up-to-date
evidence that BA is an effective treatment for depression in the general population.
In the qualitative process evaluation from the COBRA trial (non-inferiority trial comparing CBT with BA for
depression),49 although common factors, such as being listened to and feeling understood, were valued by
participants, the researchers found that specific aspects associated with the CBT and BA were important
in addition to these factors. In a definitive trial evaluating BA for treating post-stroke depression, it would
therefore be important to use a process evaluation to focus on the mechanisms of change that may be
taking place within BA. For example, in an ongoing cluster RCT of BA by mental health nurses for treating
late-life depression in primary care, BA is being compared with treatment as usual rather than an attention
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control condition and one of the research questions is to explore the mechanisms of change that account
for the effectiveness of BA compared with treatment as usual.125
We do not have detailed information on what usual care was at each of the sites. It was intended that
treatment-as-usual data would be gathered from the resource use inventory but, as this questionnaire
covered all services received, whether treatment was as usual, was sought by participants or paid for, etc.,
it does not provide the specific usual-care information that would be valuable to collect in a definitive trial.
Regarding the disappointment expressed by some participants who were randomised to the control group,
it is worth noting that the attrition rate was lower in the usual-care group than in the BA group. This
suggests that allocation to the usual-care group did not deter people from remaining as participants in
the study and completing the outcome questionnaires. To alleviate the disappointment for participants
allocated to the usual-care group, we would recommend that the training provided to staff who are
explaining the study and taking consent should include additional time spent explaining the concept of
randomisation in lay terms. In addition, we would recommend that the training includes additional time
spent on how to explain the randomisation outcome to participants, in particular to those who have been
allocated to the usual-care group (and who will therefore not be receiving the BA therapy). The materials
for this training (such as example scripts and role-play tasks) would be developed in collaboration with
the PPI group.
Fidelity assessment
We assessed the fidelity of the delivery of the intervention through therapy record forms for every
session and video recordings for a sample of sessions. The video analysis was limited as recordings were
incomplete and did not include all sites. We had intended to select participants and sessions iteratively
using purposive sampling but this was not possible because of practicalities and resources. We had only
one video camera for the study; this meant that each therapist had the camera for only a short period of
time and they could record available sessions only for those patients who consented to this. Technical
issues such as the camera battery running low meant that some sessions were only partially recorded.
Therefore, we cannot be sure that all sessions at all sites were delivered in accordance with the manual;
in a future study it would be logical to review videos during the trial and ensure sufficient funding for all
sites to have a video camera throughout the study. However, in addition to the training and the therapy
manual, weekly clinical supervision by a local clinical psychologist and monthly teleconferences with the
chief investigator and a NHS consultant clinical psychologist were provided. These meetings did not raise
any concerns suggesting that the therapists were not following the manual.
We did not assess the competencies of the therapists in the study (although appropriate clinical supervision
was provided). To our knowledge, a validated competency assessment for BA is not currently available.
We note that Ekers et al.62 developed a fidelity checklist for use in their trial evaluating BA (delivered by
generic mental health workers) for treating depression and there may be scope for this to inform training
and monitoring of therapy in a definitive trial.
Health economics
The BEADS trial has shown that it is feasible to collect the data to conduct a rigorous economic evaluation
– including data to help inform an analysis taking a societal perspective, including indirect costs, and
potentially including spill-over HRQoL effects. The collection of data required for the economic evaluation
was successful and it would be feasible to collect similar data in a full trial. However, it is important to note
that participants reported some difficulty answering the resource use questionnaire owing to issues with
recall; this should be carefully considered when designing the data collection approach in a definitive trial.
In addition, given the importance of carer costs, consideration should be given to collecting information on
carer time over a longer time period, to provide more reliable information for a societal analysis. Resource
use diaries represent an alternative approach, but also have limitations.
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Our analyses suggest that there would be a very high value to obtaining further information on key
parameters within the economic model – this value is likely to far exceed the cost of running a full trial.
It would be most valuable to obtain more information on the NHS, PSS and societal costs associated with
the health states included in the economic model. Often it is difficult to collect such information with
precision even in definitive trials, but there remains substantial value to obtaining further information on
other parameters such as the relapse rate, utilities and response rates, which would be best achieved
through a RCT.
It was not our aim to provide definitive estimates of the cost-effectiveness of the BA treatment. However, our
preliminary analysis of the cost-effectiveness of the intervention suggests that it may represent a dominant
treatment strategy (i.e. cost saving and QALY gaining) from a societal perspective, but is of borderline
cost-effectiveness from a NHS and PSS perspective. However, these results should be interpreted with some
caution, particularly because our within-trial analysis resulted in QALY losses for the BA treatment. Owing to
the higher response rate observed in the intervention group and the assumed higher utility score associated
with good response, our modelled analysis provided an opposite result, but there is clearly considerable
uncertainty around this.
The qualitative research
The nested qualitative research has helped our interpretation of the feasibility results. As well as interviewing
participants who had received the intervention, we interviewed carers and also participants who were
randomised to the control group in order to gain their perspectives. Participants were selected purposively to
represent the centres, range of severity of depression, and stroke survivors with and without aphasia.
Results in the context of other studies of psychological interventions for
post-stroke depression
As outlined in Chapter 1, Current service provision, there is currently limited evidence for the clinical and
cost-effectiveness of psychological therapies for post-stroke depression.38 Previous studies of psychological
interventions have recruited people early after stroke and excluded people with severe communication or
cognitive problems. The CALM study17 found that BA improved mood at 6-month follow-up in stroke
participants with aphasia and low mood. In BEADS we have shown that BA can be delivered to a broader
sample that included people with and without aphasia or cognitive impairment. A reduction in depression
was found in the BA arm, although the purpose of BEADS was to evaluate feasibility and so we did not
aim for it to be powered for efficacy.
Patient and public involvement
The PPI group (two stroke survivors and a carer) was particularly helpful in improving the patient
information materials; this led to us developing a study summary card and a spiral-bound version of the
aphasia-friendly information sheet. The therapists were invited to a PPI meeting as the group wanted
to ask the therapists about their experience of delivering the therapy and working with people with
depression. Both the therapists and the PPI members gave positive feedback about this meeting and we
would recommend this approach in a future study. The PPI group gave feedback on the draft of the plain
English summary and will be asked to feed back on drafts of the final study newsletter for participants.
As we had a separate PPI group and included people with significant aphasia in this group we did not
have a PPI representative on the TSC. With hindsight, it would be beneficial in a definitive trial for a
member of the PPI group also to sit on the TSC to ensure that the PPI representation is integrated into the
overall monitoring of the study.
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Chapter 8 Conclusions
Overall, BEADS has shown that it is feasible for BA to be delivered by an AP or IAPT therapist and thatthe therapy is acceptable to participants, carers and therapists. We were able to recruit participants
but owing to delays in site set-up, the overall recruitment rate was lower than anticipated. We have used
the recruitment rate from BEADS to estimate the number of sites and duration of recruitment that would
be needed for a definitive trial. Although we have identified approaches for improving recruitment, the
issue remains of whether or not 16 study sites could be identified that could deliver the service over
24 months to achieve the sample size estimate required for a definitive trial.
A scoping study is first needed to identify whether or not there are a sufficient number of sites that are
willing and able to recruit participants and deliver the BA intervention for a definitive trial. In selecting
appropriate sites for the study, it would be necessary for the site to have a PI in the stroke service who is able
to commit time to facilitating participant recruitment across the different recruitment routes; this would be
essential, given the number of sites in the study. The site would also have to have an appropriately qualified
clinician who could provide the local clinical supervision to the study therapist. If a site did not already have a
therapist in post to deliver the BA intervention, it would be necessary to secure extra treatment costs to fund
this and also to allow sufficient time in the study set-up to appoint therapists.
Implications for health care
l Half of the people who returned the PHQ-9 at initial screening scored as depressed, which highlights
the prevalence of post-stroke depression and the importance of mood screening after stroke. It is
particularly important to ensure that people with aphasia and/or cognitive impairments are included
within mood screening.
l As the trial was not powered for efficacy, it is not appropriate to draw conclusions on the efficacy of
BA for treating post-stroke depression. However, we have shown that it is feasible to deliver BA to
people with no or mild to moderate aphasia or cognitive impairment.
l We found that, following training, APs and a PWP were able to deliver the BA intervention in this trial.
This provides different potential models for the delivery of BA, namely through stroke services or IAPT
services. As we found recruitment to be more difficult when using the IAPT service as a main site for
recruitment than when using the stroke service sites, this suggests that a referral pathway would need
to be established to link stroke and IAPT services at sites where such a pathway does not exist. We
would need to explore further the competencies required for delivering BA to stroke patients with
depression to identify whether or not the therapy could also be delivered by other clinicians following
appropriate training, such as mental health nurses.
Recommendations for a Phase III trial
The first step is to identify whether or not there are sufficient sites willing and able to deliver the services
needed that could sustain recruitment over the study time frame. Then, if a definitive trial were to be
undertaken, based on our findings, we would recommend the following:
Essential/high priority
l Recruit through stroke services rather than using IAPT as the main site for recruitment.
l Provide at-site support or central monitoring of recruitment.
l Although there were monthly teleconferences between the CI and the therapists, and regular
newsletters to update the sites of key changes and phases of the study, for a definitive trial, regular
teleconferences could be arranged for the site staff and PIs so that they feel more engaged. This may
improve recruitment at sites.
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l Send out regular newsletters to all participants informing them of the study’s progress to help them
feel more engaged in the study. This may increase retention as some participants in the control arm
commented that they did not think they needed to complete the follow-up assessment that they were
sent as they did not realise that they were still involved in the study.
l Amend the therapy record form so that the content of the between-session task is recorded, as some
components of therapy (e.g. graded tasks) may be covered as a between-session task.
l Ensure that study staff and CRN staff resourcing is allocated accordingly for the most effective
recruitment routes (e.g. hospital databases require a large number of letters to be sent out but this is
efficient in terms of sending out a mailing to potential participants).
Moderate priority
l The therapists were in post only until the end of recruitment and so the study manager had to co-ordinate
the reporting of AEs and SAEs, including finding information on the causality, during the follow-up period.
It would be worth considering funding an administrator at the sites during the follow-up period. This would
allow the sites to be more involved in follow-up and in the reporting of AEs and SAEs and would ensure
that related activities, such as dealing with database discrepancies, study completion forms, etc., were dealt
with. Having at-site support for the full duration of the study would also help with collating information
about treatment as usual at the sites and any other issues that arise after the end of the intervention.
l Explore GP databases and social media as other sources to recruit participants, particularly those no
longer receiving rehabilitation.
l Ensure that data on NHS, PSS and societal costs are captured.
l Ensure that sufficient data are collected to allow estimation of a relapse rate.
l Improve the collection of usual-care data. For example, study leads at sites could contact participants
regularly (e.g. every 2 to 3 months) to find out whether they have had any other intervention and
follow up further details with staff who delivered other interventions.
l Ensure that therapists have the capacity to start treatment sessions before randomising participants.
l Consider including a booster session(s) to support the maintenance of therapy gains.
l Consider providing a quick reference guide for the therapists to use alongside the full treatment manual.
l Ensure that the training for researchers includes additional time spent on how to explain the
randomisation outcome to participants, in particular to those who have been allocated to the usual-
care group (and who will therefore not be receiving the BA therapy). The materials for this training
(e.g. example scripts and role-play tasks) should be developed in collaboration with the PPI group.
l Develop a fidelity checklist to be used to inform the training of therapists and the monitoring of the
videos of therapy sessions during the trial.
Recommendations for future research
Several of our recommendations for a Phase III trial include approaches that are also relevant to the
recruitment of participants and the monitoring of treatment fidelity in multicentre trials in stroke rehabilitation
more broadly. In addition to these recommendations, from our experience of BEADS we have identified
further areas for future research:
l identify whether equipoise from clinicians and researchers influences recruitment to RCTs in
stroke rehabilitation
l explore methods for broadening psychological interventions for people who have had a stroke to be
accessible for non-English speakers
l explore the accessibility of psychological interventions for people with severe aphasia and/or
cognitive impairments.
CONCLUSIONS
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Appendix 1 Changes to protocol
TABLE 37 Changes to protocol and details
Changes to protocol Date Approved by
Detail added on notification of GPs following ethics
review by NRES East Midlands – Leicester
Protocol v2.0, 22 Januray 2015 REC 29 Januray 2015
Additional options added to the recruitment process
following early feedback from participating sites, that is,
to include the option of a streamlined recruitment process
whereby the therapist can contact the patient directly by
telephone following consent to contact, and to broaden
the recruitment routes to include potential participants on
acute outpatient caseloads
Protocol v2.1, 19 July 2015 REC 8 July 2015
Additional exclusion criteria to the effect that patients are
not eligible to be recruited to the BEADS trial if they are
currently receiving psychological intervention, that they
will be withdrawn from the intervention arm if it is
subsequently agreed that the patient needs immediate
clinical psychology input and to clarify that usual care can
include psychological input post randomisation
Protocol v2.2, 29 July 2015 REC 7 August 2015
Change in study personnel and contact details
Additional secondary end point of estimating sample size
for a definitive trial
Clarification that two or fewer missing items within the
PHQ-9 questionnaire may be imputed
Protocol v2.3, 26 February 2016 Minor amendment
therefore REC approval
not required. Approval to
implement received from
CRN on 15 April 2016
Change in study personnel (CI and study manager) and
contact details
Protocol v3, 6 May 2016 REC 23 May 2016
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Appendix 2 Video-recording categories
TABLE 38 Video-recording categories
Manual content Code Other content Code
All sessions
Summarise previous session P Social chat SC
Review between-session tasks R Information on organisation of sessions
(e.g. date, venue, time, etc.)
IO
Set agenda and goals for each session AG Travel arrangements T
Agree between-session tasks for the next
session
AN Preparing materials, tasks, etc. PP
Session summary SU Check whether or not participant needs
reminder of the next appointment
(telephone call/text message)
AR
Breaks B
Review events since previous session RE
Session 1 Therapist Activities
Therapist to introduce themselves TI Providing explanation PE
Explain aims of BEADS study AB Providing feedback PF
Explain structure of sessions (i.e.
frequency, time scales, between-visit
tasks etc.)
SS Providing encouragement/reassurance PR
Assessment of current difficulties and
symptoms of depression
DS Summarising S
Discuss communication abilities/
difficulties
CA Paraphrasing PH
Outline BA treatment rationale BA Presenting/discussing BA strategies PS
What else do you want to know? K Address problems with task non-completion AP
Checking understanding U
Session 2
Give opportunities for participant to ask
questions
OQ
Identification of participants’ problems
(problem list)
IP References to between-session activities RA
Agreeing therapy goals (specific,
measurable, time-bound)
TG Reference to problems list PL
Reference to participant goals PG
Session 3 Addressing appropriateness of activities A
Discuss relationship between activity level
and mood
DR Ask participant to rate enjoyment of chosen
activities
AE
Refer to behavioural model of depression BM Asking participant questions QQ
Introduce idea of identifying enjoyable
activities
IA Reference to previous sessions Z
continued
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TABLE 38 Video-recording categories (continued )
Manual content Code Other content Code
Session 4 Participant Activity
Review idea of identifying enjoyable
activities
ER Discussing BA strategies BS
Discuss how enjoyable activities improve
mood
EM Discussing activities D
Identify enjoyable activities E Asking for information AI
Create list of enjoyable activities L Describing problems DP
Identify barriers to engaging in identified
activities
EB Asking questions Q
Check activities are in line with goals CG Information about sessions, venue, group, etc. I
Activity scheduling plan SP Describing mood DM
Feedback on home activities F
Session 5 Feedback on sessions FS
Review whether activities were carried
out (rate success or problem solve for
non-completion)
AO Hospital visit discussion
Speech and language therapy discussion
HD
ST
Identify suitable activities to be
completed as between-session tasks
(new activities/increased frequency of
activities)
SA
Recap idea of activity scheduling RS
Agree which activities to be carried out
for following week
AW
Appendices/Worksheets
Graded task principle discussion/explanation GT
Session 6 Use of graded task principle UG
Review whether activities were carried
out as scheduled
CS Use of/reference to activity diaries/schedules UD
Identify one activity per day to be
scheduled
OA Use of/reference to mood rating scales UM
Identify any potential obstacles to
completing activities and address them
PO Use of/reference to activity lists AL
Use of/reference to activity schedule/activity
monitor
AS
Session 7
Use of/reference to participant specific
communication resources
C
Review relationship between activity
schedule and mood
SM
Identify common problems in planning or
carrying out activities
CP
Problem-solving strategy PK
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TABLE 38 Video-recording categories (continued )
Manual content Code Other content Code
Session 8
Review and rate achievements with
regard to goals set at start of therapy
GA
Addressing a new or unachieved goal N
Discuss behavioural strategies to achieve
goal
DB
Introduce idea of therapy ending TE
Highlight successful behavioural
strategies and progress
H
Session 9
Address reasons for non-completion of
between-session tasks
NC
Discuss therapy ending DE
Highlight successes and achieved goals
and consider continuation of these post
therapy
TC
Identify with participant how behavioural
strategies can be used to address goals
BG
Develop plan to cope with future mood
problems
PM
Session 10
Review problems addressed during
therapy
TP
Summarise successful strategies and skills
used
US
Discuss generalisation of skills to future
situations (relapse prevention)
GS
Questions and answers QA
Remind participants about 6-month
follow-up protocol (indicate date)
RM
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Appendix 3 Resource use costs
TABLE 39 Resource use costs
Resource use Unit cost (£) Reference
Inpatient stay per night (general) 389.10 NHS Reference Costs 2015–1679 (weighted average
of regular day of night admission)
Inpatient stay per night (myocardial
infarction)
442.85 NHS Reference Costs 2015–1679 (weighted average
of EL, EL XS, NEL, NEL XS, NES for EB10A-EB10E)
Inpatient stay per night (orthopaedics) 433.54 NHS Reference Costs 2015–1679 (weighted average
of EL, EL XS, NEL, NEL XS, NES for HE11A-HE83C)
Outpatient attendance 116.92 NHS Reference Costs 2015–1679 (weighted average
of total outpatient attendances data)
Outpatient attendance: psychiatry 171.41 NHS Reference Costs 2015–1679 (total; 715 old age
psychiatry)
Outpatient attendance: clinical
psychology
144.70 NHS Reference Costs 2015–1679 (total; 656 clinical
psychology)
Outpatient attendance: psychotherapy 199.06 NHS Reference Costs 2015–1679 (total; 713
psychotherapy)
Outpatient attendance: liaison mental
health
105.08 NHS Reference Costs 2015–1679 (total; 722 liaison
psychiatry)
Outpatient attendance: accident and
emergency
146.86 NHS Reference Costs 2015–1679 (total; 180 accident
and emergency)
Outpatient attendance (other) 170.60 NHS Reference Costs 2015–1679 (total; 328 stroke
medicine)
127.67 NHS Reference Costs 2015–1679 (total; 320
cardiology)
167.05 NHS Reference Costs 2015–1679 (total; 300 general
medicine)
48.33 NHS Reference Costs 2015–1679 (total; 650
physiotherapy)
116.05 NHS Reference Costs 2015–1679 (total; 652 speech
and language therapy)
79.19 NHS Reference Costs 2015–1679 (total; 662
optometry)
117.01 NHS Reference Costs 2015–1679 (total; 110 trauma
and orthopaedics)
175.60 NHS Reference Costs 2015–1679 (total; 400
neurology)
154.77 NHS Reference Costs 2015–16 (total; 340 respiratory
medicine)
58.33 NHS Reference Costs 2015–1679 (total; 840
audiology)
114.60 NHS Reference Costs 2015–1679 (total; 658 orthotics)
107.52 NHS Reference Costs 2015–1679 [diagnostic imaging
(outpatient); weighted average RD20 A to RD27Z)]
continued
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TABLE 39 Resource use costs (continued )
Resource use Unit cost (£) Reference
GP consultation (at surgery) 3.90 (per minute of
patient contact)
PSSRU 201685 (p. 145)
GP consultation (home visit) 4.90 (per minute,
including travel)
PSSRU 201387 (p. 191)
Practice nurse (at surgery) 43.00 (per hour) PSSRU 201685 (p. 143)
Community nurse 67.00 (per hour) PSSRU 201589 (p. 169)
Community occupational therapist 44.00 (per hour) PSSRU 201685 (p. 159)
Hospital-based physiotherapist 38.00 (per hour) PSSRU 201589 (p. 217)
Hospital-based speech and language
therapist
38.00 (per hour) PSSRU 201589 (p. 219)
Home care worker 24.00 (per hour
face-to-face, weekday)
PSSRU 201685 (p. 160)
NHS counsellor 50.00 (per hour) PSSRU 201488 (p. 51)
NHS psychologist 52.00 (per hour, based
on AfC band 7)
PSSRU 201685 (p. 137)
NHS psychotherapist 52.00 (per hour, based
on AfC band 7)
PSSRU 201685 (p. 137)
Community-based mental health
nurse
75.00 (per hour of
face-to-face contact)
PSSRU 201589 (p. 170)
Social worker/case manager 79.00 (per hour of client
contact)
PSSRU 201685 (p. 156)
CBT therapist 97.00 (per session) PSSRU 201685 (p. 77)
Home care worker 24.00 (per hour) PSSRU 201685 (p. 160)
Podiatrist 32.00 (per hour, based
on AfC band 5)
PSSRU 201685 (p. 137)
Stroke support 25.00 (per hour, based
on higher level clinical
support worker; AfC
band 3)
PSSRU 201685 (p. 137)
Other primary care contact (NHS
community mental health services for
older people)
43.00 (per hour) PSSRU 201685 (p. 167)
Day care for people requiring mental
health support
8.20 (per hour) PSSRU 201685 (p. 38)
Reablement service 43.00 (per hour of client
contact)
PSSRU 201679 (p. 179)
Private and voluntary day care for
people requiring mental health
support
8.00 (per hour) PSSRU 201679 (p. 39)
Lost employment hours/carer time 12.10 (per hour, based
on median hourly
earnings)
Annual survey of hours and earnings, ONS 201697
Behaviour activation 57.00 (per hour of
face-to-face contact)
PSSRU 201685 (p. 40; based on Richards et al.49)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
Appendix 4 A worked example of the audit trail
of the analysis and framework development
P lease note that this is a worked example of the audit trial and some sections/field notes have beenremoved. The detailed trail can be obtained from the authors.
Step 1 (Framework development): The following categories (thematic constructs) were developed based
on a priori issues covered in the interview schedule and extant literature.
1. Participant views
on trial and the
procedures (research
process and
outcomes)
2. Participant views of
the intervention
3. Changes in
participants
a. Therapist views of
delivering the
intervention
b. Therapist views on
practical aspects of
delivering the
intervention
c. Therapist views on
trial and its procedure
(recruitment, methods
and measures)
Step 2 (Familiarisation and revised framework): Gogem Topcu was immersed in the data by reading
and rereading the verbatim transcripts and listening to audio recordings to note salient points, and
recurrent ideas noted under each category. Memos were used to provide a visible audit trail of an
emerging theme or subtheme.
Patient- and carer-participant interviews
1. Participant
views on trial
and the
proceduresa
Understanding
and motivation
Understanding
the research
process
(information
provided,
recruitment
and
randomisation)
2. Participant
views on
outcome
measuresa
Focus of
measures
Ease of
understanding
Quantity of
questionnaires
3. Therapy-
specific
experiences
(intervention
group only)b
Understanding
purpose of
therapy
Reflections or
perceptions of
therapy
(helpful and
challenging
aspects)
Format of
therapy
4. Changes in
participants
General changes
and gains (for
being involved
in the study but
not therapy
related)
Therapy-related
changes
(perceived
changes in
mood, other
perceived
changes,
activities/tasks
undertaken)
5. Stroke-related
changes in lifec
Stroke-related
changes
Other treatment/
support received,
coping strategies
or activities
performed (not
therapy related)
Patient/carer
needs
Other
experiencesd
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Notes: a, After reading the transcripts, Gogem Topcu and Roshan das Nair decided to consider outcomes
as a separate category as they constituted a prominent part of the interview data. This also fit well with
the aims of the project (determining the acceptability of the outcome measures). Therefore, category 1 in
step 1 was divided into two categories and the titles were changed. b, Category name was changed to
better reflect the interview data. c, Another category was created by Gogem Topcu after reading the
interview transcripts as the changes occurred in patients’ lives after stroke were frequently discussed by the
patients. These changes were stroke related and not study or therapy related. Gogem Topcu and Roshan
das Nair agreed to keep this category as it provided context for the interviews. d, This theme was created
to incorporate experiences (e.g. family problems) that did not fit with other themes within this category
but were considered important by some participants in relation to their stroke experiences.
Therapist-participant interviews
a. Therapist views of
delivering the
intervention
Delivering the
therapy
(general views and
experiences,
challenges,
overcoming
difficulties,
improvements
needed)
Therapists’ views on
experiences of
participantsa
b. Therapist views on
practical aspects of
delivering the
intervention
Support provided to
therapists
Experience of
working on trial
within therapist’s
department
Integrating the trial
practice into wider
service
c. Therapist views on
trial and its
procedure
Recruitment
Study procedures
Measures
Notes: a, Experiences of participants from the therapists’ perspective was a recurrent theme. Gogem Topcu
initially considered this as a separate category, but after discussion with Roshan das Nair, they decided to
have this theme under the category ‘Therapist views of delivering the intervention’ as it fit well within this
category in terms of providing a context and further explanation/understanding for their experiences of
delivering the therapy.
Step 3 (Indexing and mapping): Mapping the data onto the constructed thematic framework by
coding and indexing various sections of the data to specific thematic constructs. The indexing process
was iteratively completed by Gogem Topcu, with input from Roshan das Nair, and used the constant
comparison method to check and compare each item with the rest of the data, requiring Gogem Topcu
to go back to previously analysed transcripts as the new themes or subthemes emerged, to check if they
were also evident in these transcripts. This ensured that any additional themes/subthemes were added to
reflect the nuances within the data. Midway through the coding of the transcripts, Roshan das Nair also
examined five transcripts which had been coded by Gogem Topcu, to check the coding of the data
independently. Memos were used to provide a visible audit trail.
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Patient- and carer-participant interviews
1.
 S
tu
d
y 
ex
p
er
ie
n
ce
sa
1.1 Motivation and
reason to participateb
1.1.1 General
1.1.2 Specific to the 
BEADS trial
1.2 Understanding the
study rationaleb
1.3 Understanding the
research process
1.3.1 General
information provided
1.3.2 Recruitment
1.3.3 Randomisation
Notes: a, The name of this category was changed from ‘Participant views on trial and the procedures’ to
‘Study experiences’ to cover all the relevant experiences related to the study (e.g. motivation to participate,
understanding the rationale and understanding the research process). b, The ’Motivation and understanding’
theme that was developed in step 2 was divided into two separate themes ‘Motivation and reason to
participate’ and ‘Understanding the study rationale’ as these represented distinct but inter-related constructs.
Theme 1.1 was further developed into two subthemes (i.e. general and specific to the BEADS trial) to reflect
participant views better, as the motivation and reason to participate were different for each participant.
2.
 O
u
tc
o
m
e 
m
ea
su
re
s
2.1 Focusa
2.1.1 Relevance and
importance – general
2.1.2 Relevance – specific
to outcome measures
2.1.3 Score on 1–10 scale
(capturing experiences)
2.2 Ease of
understandingb
2.2.1 General comments
2.2.2 Specific to outcome
measures
2.3 Number of
questionnaires
2.3.1 Quantity
2.3.2 Repetitionsc
Notes: a, Although some participants made general comments about the focus of the measures, some
participants commented on specific measures. Therefore, we coded these comments under two subthemes.
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Another subtheme was created for participants’ ratings. b, Similarly, when talking about the ease of
understanding, participants made comments either generally or on specific measures. Therefore, data were
coded into two subthemes. c, The subtheme ‘Repetition’ emerged from our reading and interpretation of
the data. Therefore, data were coded into two subthemes. Gogem Topcu went back to previously analysed
transcripts to check if it was also evident in already analysed transcripts.
3.
 T
h
er
ap
y-
sp
ec
ifi
c 
ex
p
er
ie
n
ce
s
(i
n
te
rv
en
ti
o
n
 g
ro
u
p
 o
n
ly
)a
3.1 Understanding
purpose of therapy
3.2 Reflections or
perceptions of therapy
3.2.1 Perceived mediators
of change (helpful aspects
of therapy)b
3.2.2 Challenging aspects
of therapy
3.3 Format of therapyc
3.3.1 Number, frequency
and duration of sessions
3.3.2 Role of carer in
sessions
Notes: a, As this thematic construct was only evident in intervention group participants, we decided to
change the name of the theme to reflect this. b, After discussing this subtheme, Roshan das Nair and
Gogem Topcu agreed to rename it as ‘Perceived mediators of change’ to emphasise that certain aspects
of therapy were perceived by participants as helpful, mediating a change. c, During coding of carer
interviews, a new subtheme, called ‘Role of carer in sessions’, emerged regarding the format of therapy.
Gogem Topcu went back to previously analysed transcripts to check whether it was also evident in those
transcripts already analysed.
4.
 G
ai
n
s 
an
d
 c
h
an
g
es
a
4.1 General changes and
gains (not therapy
related)b
4.2 Therapy-related
changes (intervention
group only)
4.1.1 Changes
attributable to joining
the study
4.1.2 Changes not
attributable to joining
the study
4.2.1 Perceived changes in
patients’ mood since
undertaking therapy
4.2.2 Other perceived
benefits of therapy
4.2.3 Activities/tasks
undertaken (during and
after therapy)
Notes: a, The name of the thematic construct was changed to ‘Gains and changes’ to cover all the themes
and subthemes within this category. b, Some participants attributed changes they experienced to the
study, whereas others discussed changes they experienced in general and did not attribute these changes
to the study. Therefore, we decided to divide this theme into two subthemes.
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5.
 L
if
e 
af
te
r 
st
ro
ke
a
5.1 Stroke-related
changesb
5.1.1 Changes in patient
due to stroke (physical,
mental, social, financial)
5.1.2 Carer-specific
experiences
5.2 Other treatment/
support received, coping
strategies or activities
performed (not therapy
related)c
5.2.1 Helpful
5.2.2 Not helpful
5.3 Patient/carer needs
5.4 Other experiences
Notes: a, The name of the thematic construct was changed to make it clearer and also to be more
comprehensive of the experiences of the participants. b, The theme ‘Stroke-related changes’ was divided
into two subthemes to incorporate carer-specific experiences. c, This theme was also divided into two
subthemes to be able to differentiate and compare helpful and unhelpful support/strategies (not therapy-
related) used by participants.
Therapist–participant interviews
a.
 D
el
iv
er
in
g
 t
h
e 
th
er
ap
ya
a.1 Experiences of
delivering the therapya
a.1.1 General views and
experiences
a.1.2 Challenges
a.1.3 Overcoming
difficulties
a.1.4 Improvements
needed/suggestions
a.2 Experiences of
participants from
therapist’s perspectiveb
a.2.1 Observed changes
a.2.2 Observed helpful
and unhelpful aspects of
therapy to participants
Notes: a, Gogem Topcu revised the names of the thematic construct and the theme a.1, in consultation
with Roshan das Nair, for the purpose of clarity. b, This theme was further divided into two subthemes to
better differentiate therapists’ observations regarding the changes in participants and the helpful/unhelpful
aspects of therapy to participants.
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b
. P
ra
ct
ic
al
 a
sp
ec
ts
b.1 Support provided to
therapistsa
b.1.1 Views on the
manual
b.1.2 Views on the
training received
b.1.3 Views on the
supervision received
b.1.4 Views on the
monitoring practice
b.2 Experiences of
working on trial within
therapist’s department
b.3 Integrating the trial
practice into wider
serviceb
b.3.1 Barriers
b.3.2 Facilitators
Notes: a, This theme was further divided into four subthemes as the interviews focused on four different
types of support provided (i.e. manual, training, supervision, monitoring). b, This theme was further divided
into two subthemes as both barriers to and facilitators of integrating the trial into wider services emerged
from our reading and interpretation of the data.
c.
 V
ie
w
s 
o
n
 t
h
e 
re
se
ar
ch
 p
ro
ce
ss
a
c.1 Recruitment
c.2 Study procedures
c.3 Measures
Notes: a, The name of the thematic construct was revised, in consultation with Roshan das Nair, to make it
more comprehensive and clear.
Step 4 (Charting): After mapping all the data, a matrix was generated by Gogem Topcu in which the data
were charted to summarise each main theme. One matrix per thematic category across participants was
developed, containing summaries of the views and experiences of the participants, and references to
verbatim quotations in the transcripts. This facilitated the process of comparing and contrasting data from
individual participants across themes. Each matrix was reviewed by Roshan das Nair to ensure its rigour and
credibility. Disagreements were resolved by discussion. Memos were used to provide a visible audit trail.
(Please note that the matrices and the corresponding field notes have been removed from this worked
example of the audit trail. The full audit trail can be obtained from the corresponding author.)
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Step 5 (Interpretation): The matrices and the field notes were then used in the interpretation of the
data. The interpretation process was iterative and relied on consultation between Gogem Topcu and
Roshan das Nair regarding the viability and relevance of a theme, to interrogate theoretical constructs,
and to unpack nuances within the data.
(Please note: The field notes regarding the interpretation process have been removed from this worked
example of the audit trail. The full audit trail can be obtained from the corresponding author.)
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Appendix 5 Semistructured interview guide:
participants (version 1)
[P lease note: This is a semistructured topic guide that is designed to be used flexibly with eachparticipant. As such, the questions and prompts (presented as subquestions) asked in each interview
are likely to vary slightly.]
Opening question
1. Please can you tell me about your experience of being involved in the study?
Recruitment and group allocation
2. How did you come to be involved in the study?
a. What did that feel like?
3. How did it feel to be allocated to your study group?
a. How did it feel (not) to be allocated to receive the behavioural activation therapy?
Study procedures
4. What did you think about the information we collected from you at the beginning and end of
the study?
a. How easy (or not) were the questionnaires to complete?
b. What did you think about how many questionnaires you needed to complete?
c. Did the questionnaires ask about things that were relevant for you, in relation to what the study
was about?
d. How would you rate the assessments on a scale of 1–10 (1 did not capture important aspects of my
experience to 10 fully captured the important aspects of my experience)
For intervention participants only
5. How did you find the therapy?
a. What did you find helpful about the therapy? Any particular aspects?
b. What did you find unhelpful about the therapy? Any particular aspects?
c. Were there any particular aspects which were good or bad?
6. How do you think we could improve the therapy in the future?
7. Would you recommend this therapy to other people with low mood after a stroke?
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Impact/perceived benefits
8. Have you experienced any changes since taking part in this study?
a. What are these changes?
b. How do you make sense of these changes?
Other issues
9. Is there anything else you would like to tell me about?
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Appendix 6 Semistructured interview guide:
carers (version 1)
[P lease note: This is a semistructured topic guide that is designed to be used flexibly with eachparticipant. As such, the questions and prompts (presented as subquestions) asked in each interview
are likely to vary slightly.]
Opening questions
1. Please can you tell me about your experience of being involved in the study?
2. Please can you tell me about your (insert appropriate descriptor: spouse/partner/family member/friend)’s
experience of being involved in the study?
Recruitment and group allocation
3. How did you come to be involved in the study?
a. What did that feel like?
4. How did it feel for your (insert appropriate descriptor) to be allocated to their study group?
a. How did it feel for them (not) to be allocated to receive the behavioural activation therapy?
Study procedures
5. What did you think about the information we collected from you at the beginning and end of the study?
a. How easy (or not) were the questionnaires to complete?
b. What did you think about how many questionnaires you needed to complete?
c. Did the questionnaires ask about things that were relevant for you, in relation to what the study
was about?
d. How would you rate the assessments on a scale of 1–10? (1: did not capture important aspects of
my experience to 10: fully captured the important aspects of my experience)
For carers of intervention participants only
6. How much involvement did you have in the therapy?
a. What did you have to do?
b. Were you happy with this level of involvement?
c. What did you find helpful or unhelpful about the therapy? Any particular aspects?
7. How do you think we could improve the therapy for people like your (insert appropriate descriptor) in
the future?
8. Would you recommend this therapy to other people with low mood after a stroke?
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Impact/perceived benefits
9. Have you or your (insert appropriate descriptor) experienced any changes since taking part in
this study?
a. What are these changes?
b. How do you make sense of these changes?
Other issues
10. Is there anything else you would like to tell me about?
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Appendix 7 Semistructured interview guide:
staff (version 1)
[P lease note: This is a semistructured topic guide that is designed to be used flexibly with eachparticipant. As such, the questions and prompts (presented as subquestions) asked in each interview
are likely to vary slightly.]
Opening question
1. Please can you tell me about your experience of being involved in the study?
Intervention delivery
2. Please can you tell me about your experiences of delivering the therapy?
a. How easy/difficult was it to implement the therapy with people who have had a stroke and those
with communication difficulties?
b. What went well?
c. What were the difficulties and how did you overcome them?
d. How did you find the training that you received?
e. How did you find using the manual?
f. How did you find the clinical supervision at site/by the trial therapists?
g. How did you find the monitoring of your practice by the research study??
3. How did participants find the therapy?
a. Were there any particular aspects which were good or bad?
b. Did participants experience any changes/benefits from the therapy?
4. How do you think the therapy could be improved in the future?
5. Would you recommend this therapeutic approach to other psychologists working with people with
post-stroke depression?
Study procedures
6. Please can you tell me about the recruitment process?
a. How could this be improved for a future trial?
7. How did you find the study procedures, i.e. working to the protocol?
a. How could this be improved for a future trial?
8. What did you think about the measures we used at baseline?
a. How would you rate the assessments on a scale of 1–10 (1 did not capture important aspects of the
experience to 10 fully captured the important aspects of the experience).
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Service barriers and facilitators
9. Please can you tell me about your experience of working on the trial within your department?
10. What are the main barriers to integrating the trial practice into the wider service of your department?
11. What are the main facilitators of integrating the trial practice into the wider service of your department?
Other issues
12. Is there anything else you would like to tell me about.
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Appendix 8 Completed COnsolidated criteria for
REporting Qualitative studies checklist
TABLE 40 The COnsolidated criteria for REporting Qualitative studies (COREQ): 32-item checklist
Topic
Number
item Guide questions/description Reported in section
Domain 1: research team and reflexivity
Personal characteristics
Interviewer/facilitator 1 Which author(s) conducted the interview
or focus group?
Chapter 2, The qualitative research,
Interviewer characteristics;
Acknowledgements; Contributions of
authors
Credentials 2 What were the researcher’s credentials
(e.g. PhD, MD)?
Chapter 2, The qualitative research,
Interviewer characteristics
Acknowledgements; Contributions of
authors
Occupation 3 What was their occupation at the time of
the study?
Chapter 2, The qualitative research,
Interviewer characteristics;
Acknowledgements; Contributions of
authors
Gender 4 Was the researcher male or female? Chapter 2, The qualitative research,
Interviewer characteristics;
Acknowledgements; Contributions of
authors
Experience and training 5 What experience or training did the
researcher have?
Chapter 2, The qualitative research,
Interviewer characteristics
Relationship with participants
Relationship established 6 Was a relationship established prior to
study commencement?
Chapter 2, The qualitative research,
Interviewer characteristics
Participant knowledge
of the interviewer
7 What did the participants know about
the researcher? (e.g. personal goals,
reasons for doing the research)
Chapter 2, The qualitative research;
Chapter 2, The qualitative research,
Relationship with participants
Interviewer
characteristics
8 What characteristics were reported about
the inter viewer/facilitator? (e.g. bias,
assumptions, reasons and interests in the
research topic)
Chapter 2, The qualitative research,
Interviewer characteristics
Domain 2: study design
Theoretical framework
Methodological
orientation and theory
9 What methodological orientation was
stated to underpin the study? (e.g.
grounded theory, discourse analysis,
ethnography, phenomenology, content
analysis)
Chapter 2, The qualitative research,
Theoretical and thematic framework
Participant selection
Sampling 10 How were participants selected? (e.g.
purposive, convenience, consecutive,
snowball)
Chapter 2, The qualitative research,
Participant selection
continued
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TABLE 40 The COnsolidated criteria for REporting Qualitative studies (COREQ): 32-item checklist (continued )
Topic
Number
item Guide questions/description Reported in section
Method of approach 11 How were participants approached?
(e.g. face-to-face, telephone, mail, e-mail)
Chapter 2, The qualitative research,
Participant selection; Chapter 2,
The feasibility trial, Participants and
eligibility criteria
Sample size 12 How many participants were in the
study?
Chapter 2, The qualitative research;
Chapter 6
Non-participation 13 How many people refused to participate
or dropped out? Reasons?
Appendix 9
Setting
Setting of data
collection
14 Where was the data collected? (e.g.
home, clinic, workplace)
Chapter 2, The qualitative research
Presence of
non-participants
15 Was anyone else present besides the
participants and researchers?
Chapter 2, The qualitative research
Description of sample 16 What are the important characteristics of
the sample? (e.g. demographic data,
date)
Chapter 6; Appendix 19
Data collection
Interview guide 17 Were questions, prompts, guides
provided by the authors? Was it pilot
tested?
Chapter 2, The qualitative research,
Data collection; Appendices 5–7
Repeat interviews 18 Were repeat interviews carried out?
If yes, how many?
No
Audio/visual recording 19 Did the research use audio or visual
recording to collect the data?
Chapter 2, The qualitative research
Field notes 20 Were field notes made during and/or
after the interview or focus group?
Chapter 2, The qualitative research,
Theoretical and thematic framework;
Chapter 2, The qualitative research,
Data analysis; Appendix 4
Duration 21 What was the duration of the interviews
or focus group?
Chapter 2, The qualitative research
Data saturation 22 Was data saturation discussed? Chapter 2, The qualitative research,
Participant selection
Transcripts returned 23 Were transcripts returned to participants
for comment and/or correction?
No
Domain 3: analysis and findings
Data analysis
Number of data coders 24 How many data coders coded the data? Chapter 2, The qualitative research,
Data analysis; Appendix 4
Description of the
coding tree
25 Did authors provide a description of the
coding tree?
Chapter 6; Appendix 4
Derivation of themes 26 Were themes identified in advance or
derived from the data?
Chapter 2, The qualitative research,
Data analysis; Appendix 4
Software 27 What software, if applicable, was used to
manage the data?
N/A
Participant checking 28 Did participants provide feedback on the
findings?
No
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TABLE 40 The COnsolidated criteria for REporting Qualitative studies (COREQ): 32-item checklist (continued )
Topic
Number
item Guide questions/description Reported in section
Reporting
Quotations presented 29 Were participant quotations presented to
illustrate the themes/findings? Was each
quotation identified? (e.g. participant
number)
Chapter 6
Data and findings
consistent
30 Was there consistency between the data
presented and the findings?
Chapter 7
Clarity of major themes 31 Were major themes clearly presented in
the findings?
Chapter 6; Appendix 4
Clarity of minor themes 32 Is there a description of diverse cases or
discussion of minor themes?
Chapter 6
MD, Doctor of Medicine; N/A, not applicable.
Developed from Tong et al.126
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Appendix 9 Reasons given for drop-out
TABLE 41 Reasons given for drop-out
ID Type of attrition Reason given Treatment arm
Sessions
completed
A1/048 Lost to follow-up Completed other measures but
not PHQ-9
Intervention 9
C7/006 Withdrew from intervention and
lost to follow-up
Physical health/lack of time Intervention 1
C7/009 Withdrew from intervention and
lost to follow-up
Not enough time Intervention 2
C1/040 Withdrew consent No time and personal/family
reasons
Intervention 0
A1/027 Lost to follow-up Unknown Intervention 10
B1/155 Randomised in error Intervention 0
A4/009 Lost to follow-up Out of country caring for a
relative so could not complete
follow-up
Intervention 8
C7/014 Withdrew from intervention and
did not want to be followed up
Health deteriorated following
suicide attempt. Inappropriate to
follow-up
Intervention 5
A1/173 Lost to follow-up Too ill on day and could not
contact again
Control N/A
A1/123 Investigator decision not to
follow up at end of life
At end of life Control N/A
N/A, not applicable.
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Appendix 10 Data collected outside collection
window and delays in randomisation
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Appendix 11 Frequency of content of manual
applicable to all sessions
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TABLE 42 Frequency of content of manual applicable to all sessions
Content
Session, frequency of content, n (%)
Total, frequency of
content, n (%)2 3 4 6 7 10
Manual content
Summarise previous session 4 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 5 (4.6)
Review between-session tasks 2 (5.6) 6 (22.2) 1 (12.5) 1 (7.7) 1 (5.6) 0 (0.0) 8 (7.4)
Set agenda and goals for each session 5 (13.9) 1 (3.7) 0 (0.0) 1 (7.7) 3 (16.7) 0 (0.0) 10 (9.3)
Agree between-session tasks for the next session 3 (8.3) 3 (11.1) 0 (0.0) 1 (7.7) 5 (27.8) 0 (0.0) 12 (11.1)
Session summary 2 (5.6) 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 3 (2.8)
Review events since previous session 3 (8.3) 6 (22.2) 6 (75.0) 7 (53.8) 6 (33.3) 1 (11.1) 29 (26.9)
Other content
Social chat 10 (27.8) 10 (37.0) 0 (0.0) 1 (7.7) 1 (5.6) 8 (88.9) 30 (27.8)
Information on organisation of sessions 3 (8.3) 1 (3.7) 0 (0.0) 2 (15.4) 0 (0.0) 0 (0.0) 6 (5.6)
Travel arrangements 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Preparing materials, tasks, etc. 4 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 5 (4.6)
Check whether or not participant needs reminder of the next appointment 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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Appendix 12 Frequency of content of manual
applicable to specific sessions
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TABLE 43 Frequency of content of manual applicable to specific sessions
Session number
Session, frequency of content, n (%)
Total, frequency of
content, n (%)2 3 4 6 7 10
Session 2
Identification of participant’s problems 14 (41.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 14 (19.2)
Agree therapy goals 20 (58.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 20 (27.4)
Session 3
Discuss relationship between activity level and mood 0 (0.0) 6 (60) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (8.2)
Refer to behavioural model of depression 0 (0.0) 1 (10) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4)
Introduce idea of identifying enjoyable activities 0 (0.0) 3 (30) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (4.1)
Session 4
Review idea of identifying enjoyable activities 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (4.1)
Discuss how enjoyable activities improve mood 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Identify enjoyable activities 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Create list of enjoyable activities 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Identify barriers to engaging in identified activities 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Check activities are in line with goals 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.7)
Activity scheduling plan 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4)
Session 6
Review whether or not activities were carried out as scheduled 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Identify one activity per day to be scheduled 0 (0.0) 0 (0.0) 0 (0.0) 4 (36.4) 0 (0.0) 0 (0.0) 4 (5.5)
Identify any potential obstacles to completing activities and address them 0 (0.0) 0 (0.0) 0 (0.0) 7 (63.6) 0 (0.0) 0 (0.0) 7 (9.6)
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Session number
Session, frequency of content, n (%)
Total, frequency of
content, n (%)2 3 4 6 7 10
Session 7
Review relationship between activity schedule and mood 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (60) 0 (0.0) 6 (8.2)
Identify common problems in planning or carrying out activities 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (40) 0 (0.0) 4 (5.5)
Session 10
Review problems addressed during therapy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Summarise successful strategies and skills used 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discuss generalisation of skills to future situations 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Questions and answers 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100) 2 (2.7)
Remind participants about the 6-month follow-up protocol 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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Appendix 13 Frequency of therapist and
participant activities
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TABLE 44 Frequency of therapist and participant activities
Activities
Session, frequency, n (%)
Total, frequency of
content, n (%)2 3 4 6 7 10
Therapist activities
Providing explanation 9 (13.2) 2 (3.2) 2 (7.4) 1 (5.9) 6 (9.4) 0 (0.0) 20 (7.7)
Providing feedback 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Providing encouragement/reassurance 3 (4.4) 5 (8.1) 2 (7.4) 3 (17.6) 3 (4.7) 0 (0.0) 16 (6.1)
Summarising 5 (7.4) 1 (1.6) 2 (7.4) 2 (11.8) 3 (4.7) 1 (4.3) 14 (5.4)
Paraphrasing 2 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6) 0 (0.0) 3 (1.1)
Presenting/discussing BA strategies 0 (0.0) 9 (14.5) 2 (7.4) 0 (0.0) 6 (9.4) 0 (0.0) 17 (6.5)
Address problems with task non-completion 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Checking understanding 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.3) 1 (0.4)
Giving opportunities for participant to ask questions 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Referring to between-session activities 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6) 0 (0.0) 1 (0.4)
Referring to problems list 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Referring to participant goals 2 (1.3) 6 (9.6) 1 (3.7) 0 (0.0) 2 (3.1) 0 (0.0) 11 (4.2)
Addressing appropriateness of activities 1 (1.5) 2 (3.2) 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.7) 5 (1.9)
Asking participant to rate enjoyment of chosen activities 0 (0.0) 0 (0.0) 2 (7.4) 2 (11.8) 2 (3.1) 2 (8.7) 8 (3.1)
Asking participant questions 4 (5.9) 3 (4.8) 1 (3.7) 0 (0.0) 5 (7.8) 3 (13.0) 16 (6.1)
Referring to previous sessions 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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Activities
Session, frequency, n (%)
Total, frequency of
content, n (%)2 3 4 6 7 10
Participant activities
Discussing BA strategies 0 (0.0) 1 (1.6) 0 (0.0) 0 (0.0) 1 (1.6) 0 (0.0) 2 (0.8)
Discussing activities 14 (20.6) 12 (19.4) 6 (22.2) 0 (0.0) 8 (12.5) 8 (34.8) 48 (18.4)
Asking for information 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Describing problems 20 (12.7) 18 (29.0) 3 (11.1) 5 (29.4) 19 (29.7) 1 (4.3) 66 (25.3)
Asking questions 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Being presented with information about sessions, venue, group, etc. 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Describing mood 2 (1.3) 3 (4.8) 3 (11.1) 1 (5.9) 4 (6.3) 1 (4.3) 14 (5.4)
Feedback on home activities 1 (1.5) 0 (0.0) 1 (3.7) 2 (11.8) 2 (3.1) 1 (4.3) 7 (2.7)
Feedback on sessions 1 (1.5) 0 (0.0) 1 (3.7) 0 (0.0) 0 (0.0) 2 (8.7) 4 (1.5)
Hospital visit discussion 2 (2.9) 0 (0.0) 1 (3.7) 1 (5.9) 1 (1.6) 1 (4.3) 6 (2.3)
Speech and language therapy discussion 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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Appendix 14 Distribution of costs relevant to the
NHS and Personal Social Services perspective
(complete-case analysis)
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Appendix 15 Distribution of costs relevant to the
societal perspective (complete-case analysis)
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Appendix 16 Model parameters and distributions
TABLE 45 Model parameters and distributions
Parameter Base-case value Uncertainty distribution 95% CI
EQ-5D-5L (utility)
Non-response 0.52 Beta(26.22, 24.17) 0.38 to 0.66
Response 0.59 Beta(39.77, 28.08) 0.47 to 0.70
Monthly costs (NHS and PSS perspective)
Non-response £383.61 Gamma(6.12, 62.68) 142.52 to 741.94
Response £473.55 Gamma(7.77, 60.97) 201.48 to 860.37
Monthly costs (societal perspective)
Non-response £4229.19 Gamma(18.68, 226.42) 2534.04 to 6352.24
Response £2968.70 Gamma(10.36, 286.67) 1446.01 to 5032.93
Probability of a good response
Non-response 0.22 Beta(5.00, 18.00) 0.08 to 0.40
Response 0.68 Beta(17.00, 8.00) 0.49 to 0.84
Other parameters
Number of BA sessions 8.08 Gamma(143.05, 0.06) 7.34 to 10.05
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Appendix 17 Change in EuroQoL-5 Dimensions,
five-level version split by response (based on
imputed data)
TABLE 46 Change in EQ-5D-5L version split by response (based on imputed data)
Treatment arm
Number of participants
(for whom utility data
were missing)
Change in EQ-5D-5L
from baseline Standard error 95% CI
Control (no response) 18 (2) 0.04 0.05 –0.07 to 0.16
Intervention (no response) 8 (2) –0.04 0.12 –0.29 to 0.22
Control (response) 5 (1) 0.23 0.18 –0.16 to 0.62
Intervention (response) 17 (6) 0.03 0.08 –0.14 to 0.20
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Appendix 18 Results from expected value of
perfect partial information, excluding all costs except
intervention costs
TABLE 47 Results from expected value of perfect partial information, excluding all costs except intervention costs
Parameter Per-person EVPPI (£) Standard error EVPPI for UK over 10 years (£)
Health costs (response) 0.0 0.0 0
Health costs (no response) 0.0 0.0 0
Societal costs (response) 0.0 0.0 0
Societal costs (no response) 0.0 0.0 0
Utility (response) 0.0 0.05 384
Utility (no response) 0.0 0.0 0
Probability of good response (intervention) 0.02 0.03 6279
Probability of good response (control) 0.07 0.19 29,720
Relapse rate 34.23 4.4 14,040,000
Number of BA sessions 0.0 0.0 0
Probability of death 0.0 0.0 0
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Appendix 19 Participant characteristics for
qualitative feedback interviews
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TABLE 48 Paticipant characteristics for qualitative feedback interviews
Participant
number
Characteristic
Age range
(years) Sex
Lateralisation
stroke
Weakness
side
FAST
score
VAMS ‘Sad’
score (points)
PHQ score
(points) Randomisation
Days since
stroke
Carer’s age
(years)
Carer’s
sex
Carer’s
relationship
to patient
A1/034 50–54 Male Right Left 26 97 21 Intervention 573
A1/053 60–64 Male Right Left 30 47 10 Control 241
A1/084 66–70 Female Left Right 21 24 11 Intervention 181 80 Male Partner
A1/124 80–84 Male Left Right 22 25 13 Control 239 73 Female Partner
A4/002 80–84 Female Left Left 27 22 11 Control 297 85 Male Partner
A6/001 85–99 Female Right Left 25 23 21 Control 1192 88 Male Partner
A6/002 50–54 Male Right Left 30 50 14 Intervention 998
A7/004 70–74 Female Left Right 24 59 12 Control 489 72 Male Partner
B1/087 75–89 Male Unknown Unknown 27 73 14 Intervention 388 58 Female Partner
B6/001 40–44 Female Left Right 30 65 13 Control 950
C1/009 65–69 Male Right Left 30 51 15 Control 1075 Female Partner
C1/047 70–74 Female Right Left 26 49 17 Control 370 69 Male Partner
C4/005 60–64 Male Unknown Unknown 30 21 20 Control 199
C7/001 50–54 Male Left Right 22 3 10 Intervention 199
C7/013 65–69 Male Right Left 27 82 18 Control 207 68 Female Partner
C7/017 50–54 Male Left Left 26 47 21 Intervention 135 48 Female Partner
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